

# re-search for re-start together

Riccione 21-23 Ottobre 2021



13° CONGRESSO NAZIONALE **Italian Conference on AIDS and Antiviral Research**

Presidenza del Congresso:  
**G.V. Calvino, M.R. Capobianchi, A.M. Cattelan, C. Mussini**

Promosso da



e da

**INMI**, Istituto Nazionale per le Malattie Infettive

**ISS**, Istituto Superiore di Sanità

**AMCLI**, Associazione Microbiologi Clinici Italiani

**SIICA**, Società Italiana di Immunologia, Immunologia Clinica e Allergologia

**SIMaST**, Società Interdisciplinare per lo Studio delle Malattie Sessualmente Trasmissibili

**SITA**, Società italiana per la Terapia Antinfettiva

**SIV-ISV**, Società Italiana di Virologia - Italian Society for Virology

**ANLAIDS**, Associazione Nazionale per la lotta all'AIDS

**ARCIGAY**, Associazione LGBT Italiana

**ASA Onlus**, Associazione Solidarietà AIDS Onlus

**EpaC Onlus**, Associazione EpaC Onlus

**LILA**, Lega Italiana per la Lotta contro l'AIDS

**MARIO MIELI**, Circolo di Cultura Omosessuale

**NADIR**, Associazione Nadir Onlus

**NPS Italia Onlus**, Network Persone Sieropositive

**PLUS**, Rete persone LGBT+ sieropositive Aps.

Con il Patrocinio di

Ministero della Salute



Consiglio Nazionale delle Ricerche

Regione Emilia-Romagna



Scientific Programme



*re-search, for re-start*  
*together* Riccione 21-23 Ottobre 2021

## Azioni di contrasto alla pandemia CERTIFICAZIONE VERDE

L'accesso al Centro Congressi di Riccione è consentito  
previa **preliminare registrazione on line** (scheda di iscrizione su MyICAR)  
ed **esclusivamente ai soggetti muniti di certificazione verde COVID-19**,  
salvo i soggetti esclusi dalla campagna vaccinale per età o esenti  
sulla base di idonea certificazione medica.

Il controllo sarà effettuato ad ogni accesso al Centro Congressi.

**All'interno del Centro Congressi è obbligatorio l'uso delle mascherine.**

## Congress Venue

### **Palazzo dei Congressi**

Viale Virgilio, 17 - 47838 Riccione

## Provider and Organizing Secretariat

### **Effetti srl**

Via G.B. Giorgini, 16 - 20151 Milano

Tel. +39 02 3343281

Fax +39 02 38002105

icar2021@effetti.it - @ICARcongress



2

Scientific Programme

13° CONGRESSO NAZIONALE **Italian Conference** on **AIDS** and **Antiviral Research**

re-search, for re-start  
together Riccione 21-23 Ottobre 2021



## Endorsements

Con il Patrocinio di

### INSTITUTIONS

**Ministero della Salute**



### INSTITUTES



### FOUNDATIONS

**Icona**, Fondazione Icona

**Villa Maraini**, Fondazione Villa Maraini

### SCIENTIFIC SOCIETIES

**AIMI**, Associazione Infermieri Malattie Infettive

**AISF**, Associazione Italiana per lo Studio del Fegato

**IAPAC**, International Association of Providers of AIDS care

**SIM**, Società Italiana di Microbiologia

**SISM**, Segretariato Italiano Studenti Medicina

### ASSOCIATIONS

**Arcobaleno AIDS**

**C.I.C.A.**, Coordinamento Italiano delle Case Alloggio per persone con HIV/AIDS

**Differenza Lesbica**

**Gay Center**

**MIT**, Movimento Identità Transessuale





*re-search, for re-start*  
*together* Riccione 21-23 Ottobre 2021

## Scientific Committee

### Chairs

**Giulia Valeria Calvino**, Roma

**Maria Rosaria Capobianchi**, Roma

**Anna Maria Cattelan**, Padova

**Cristina Mussini**, Modena

### Abstract Coordinator

**Franco Maggiolo**, Bergamo

### Scientific Secretariat

**Chiara Agrati**, Roma

**Guido Antonelli**, Roma

**Alessandra Bandera**, Milano

**Marco Borderi**, Bologna

**Andrea Calcagno**, Torino

**Annapaola Callegaro**, Bergamo

**Dario Cattaneo**, Milano

**Francesca Ceccherini-Silberstein**, Roma

**Stefania Cicalini**, Roma

**Antonella Cingolani**, Roma

**Paola Cinque**, Milano

**Nicola Coppola**, Napoli

**Giulio Maria Corbelli**, Bologna

**Andrea Cossarizza**, Modena

**Gabriella d'Ettore**, Roma

**Antonio Di Biagio**, Genova

**Cristina Gervasoni**, Milano

**Enrico Girardi**, Roma

**Giovanni Guaraldi**, Modena

**Miriam Lichtner**, Latina

**Sergio Lo Caputo**, Bari

**Lucia Lopalco**, Milano

**Giordano Madeddu**, Sassari

**Giulia Marchetti**, Milano

**Ada Moznich**, Pordenone

**Silvia Nozza**, Milano

**Giuseppe Nunnari**, Messina

**Massimo Puoti**, Milano

**Stefano Rusconi**, Milano

**Annalisa Saracino**, Bari

**Lolita Sasset**, Padova

**Valentina Svicher**, Roma

### Annual Programme Committee

**Andrea Antinori**, Roma

**Giulia Valeria Calvino**, Roma

**Maria Rosaria Capobianchi**, Roma

**Antonella Castagna**, Milano

**Anna Maria Cattelan**, Padova

**Giulio Maria Corbelli**, Bologna

**Maria Luisa Cosmaro**, Milano

**Antonella d'Arminio Monforte**, Milano

**Cristina Mussini**, Modena

**Carlo Federico Perno**, Roma

### Pre-Conference Courses Secretariat

**Isabella Abbate**, Roma

**Lorenzo Badia**, Bologna

**Isabella Bon**, Bologna

**Gianluca Cuomo**, Modena

**Manuela Gatti**, Lecco

**Roberto Rossotti**, Milano

**Camilla Tincati**, Milano



4

Scientific Programme





## Government Bodies

### ICAR Government

**Massimo Andreoni**, Roma  
**Andrea Antinori**, Roma  
**Massimo Clementi**, Milano  
**Antonella d'Arminio Monforte**, Milano  
(President)  
**Massimo Farinella**, Roma  
**Enrico Girardi**, Roma  
**Franco Maggiolo**, Bergamo  
**Michele Manfredini**, Milano  
**Cristina Mussini**, Modena  
**Massimo Puoti**, Milano  
**Maria Carla Re**, Bologna  
**Marcello Tavio**, Ancona

### SPC

(Scientific Programme Committee)

**Massimo Andreoni**, Roma  
**Andrea Antinori**, Roma  
**Guido Antonelli**, Roma  
**Matteo Bassetti**, Genova  
**Alberto Bignardi**, Bologna  
**Paolo Bonfanti**, Monza MB  
**Stefano Bonora**, Torino  
**Maria Rosaria Capobianchi**, Roma  
**Antonella Castagna**, Milano  
**Francesco Castelli**, Brescia  
**Anna Maria Cattelan**, Padova  
**Benedetto Maurizio Celesia**, Catania  
**Antonella Cingolani**, Roma  
**Massimo Clementi**, Milano

**Giulio Maria Corbelli**, Bologna  
**Andrea Cossarizza**, Modena  
**Antonella d'Arminio Monforte**, Milano  
**Maria Grazia Di Benedetto**, Catania  
**Antonio Di Biagio**, Genova  
**Giovanni Di Perri**, Torino  
**Massimo Di Pietro**, Firenze  
**Margherita Errico**, Milano  
**Vincenzo Esposito**, Napoli  
**Massimo Farinella**, Roma  
**Massimo Galli**, Milano  
**Ivan Gardini**, Vercate MB  
**Enrico Girardi**, Roma  
**Andrea Gori**, Milano  
**Giuseppe Ippolito**, Roma  
**Sergio Lo Caputo**, Bari  
**Paolo Maggi**, Bari  
**Franco Maggiolo**, Bergamo  
**Michele Manfredini**, Milano  
**Bruno Marchini**, Roma  
**Claudio M. Mastroianni**, Roma  
**Giovanni Mazzola**, Palermo  
**Cristina Mussini**, Modena  
**Silvia Nozza**, Milano  
**Giuseppe Nunnari**, Messina  
**Giustino Parruti**, Pescara  
**Carlo Federico Perno**, Roma  
**Massimo Puoti**, Milano  
**Maria Carla Re**, Bologna  
**Giovanni Rezza**, Roma  
**Giuliano Rizzardini**, Milano  
**Stefano Rusconi**, Milano

**Filippo von Schloesser**, Roma  
**Laura Sighinolfi**, Ferrara  
**Guido Silvestri**, Atlanta USA  
**Barbara Suligoj**, Roma  
**Gloria Taliani**, Roma  
**Marcello Tavio**, Ancona  
**Carlo Torti**, Catanzaro  
**Stefano Vella**, Roma  
**Maurizio Zazzi**, Siena

### CsC

(Community sub-Committee)

**Alberto Bignardi**, Bologna  
(ARCIGAY)  
**Giulio Maria Corbelli**, Bologna  
(PLUS)  
**Maria Grazia Di Benedetto**, Catania  
(LILA)  
**Margherita Errico**, Milano  
(NPS Italia Onlus)  
**Massimo Farinella**, Roma  
(Circolo Mario Mieli)  
**Ivan Gardini**, Vercate MB  
(EpaC onlus)  
**Michele Manfredini**, Milano  
(ASA onlus)  
**Bruno Marchini**, Roma  
(ANLAIDS)  
**Filippo von Schloesser**, Roma  
(NADIR onlus)



*re-search, for re-start*  
*together* Riccione 21-23 Ottobre 2021

## Faculty

**Isabella Abbate**, Roma  
**Chiara Agrati**, Roma  
**Silvia Aliverti**, Milano  
**Massimo Andreoni**, Roma  
**Andrea Antinori**, Roma  
**Bertrand Audoin**, Parigi F  
**Lorenzo Badia**, Bologna  
**Patrizia Bagnarelli**, Ancona  
**Francesca Bai**, Milano  
**Alessandra Bandera**, Milano  
**Nir Barzilai**, New York USA  
**Eleonora Maria Beretta**, Monza  
**Giulia Besutti**, Reggio Emilia  
**Alessandra Bianchi**, Milano  
**Mara Biasin**, Milano  
**Alberto Bignardi**, Modena  
**Isabella Bon**, Bologna  
**Paolo Bonanni**, Firenze  
**Stefano Bonora**, Torino  
**Marco Borderi**, Bologna  
**Vanni Borghi**, Modena  
**Amalia Bove**, Roma  
**Michele Breveglieri**, Bologna  
**Maurizia Brunetto**, Pisa  
**Elena Bruzzesi**, Milano  
**Andrea Calcagno**, Torino  
**Annapaola Callegaro**, Bergamo  
**Giulia Valeria Calvino**, Roma  
**Daniele Calzavara**, Milano  
**Maria Rosaria Capobianchi**, Roma  
**Anna Caraglia**, Roma  
**Federica Carli**, Modena  
**Rita Carsetti**, Roma  
**Antonio Cascio**, Palermo  
**Irene Cassaniti**, Pavia  
**Antonella Castagna**, Milano  
**Francesco Castelli**, Brescia  
**Dario Cattaneo**, Milano  
**Anna Maria Cattelan**, Padova  
**Giulio Cavalli**, Milano  
**Francesca Ceccherini - Silberstein**, Roma  
**Benedetto Maurizio Celesia**, Catania  
**Valeria Cento**, Milano  
**Massimo Cernuschi**, Milano  
**Matteo Chiara**, Milano  
**Stefania Cicalini**, Roma

**Antonella Cingolani**, Roma  
**Paola Cinque**, Milano  
**Mario Clerici**, Milano  
**Vincenzo Colangeli**, Bologna  
**Pietro Colletti**, Trapani  
**Anna Colucci**, Roma  
**Nicola Coppola**, Napoli  
**Giulio Maria Corbelli**, Bologna  
**Monica Cornia**, Modena  
**Maria Luisa Cosmaro**, Milano  
**Andrea Cossarizza**, Modena  
**Gianluca Cuomo**, Modena  
**Jessica Cusato**, Torino  
**Antonella d'Arminio Monforte**, Milano  
**Gabriella d'Ettore**, Roma  
**Sara De Biasi**, Modena  
**Andrea De Maria**, Genova  
**Francesco Giuseppe De Rosa**, Torino  
**Anita De Rossi**, Padova  
**Maria Grazia Di Benedetto**, Catania  
**Antonio Di Biagio**, Genova  
**Simona Di Giambenedetto**, Roma  
**Giovanni Di Perri**, Torino  
**Massimo A. Di Pietro**, Firenze  
**Elke Maria Erne**, Bolzano  
**Marco Falcone**, Pisa  
**Iuri Fanti**, Roma  
**Massimo Farinella**, Roma  
**Vito Fiore**, Sassari  
**Antonina Franco**, Siracusa  
**Nicoletta Frattini**, Milano  
**Francesco Gabbrielli**, Roma  
**Roberta Gagliardini**, Roma  
**Massimo Galli**, Milano  
**Manuela Gatti**, Lecco  
**Anna Maria Geretti**, Roma  
**Cristina Gervasoni**, Milano  
**Vania Giacomet**, Milano  
**Maddalena Giannella**, Bologna  
**Nicola Gianotti**, Milano  
**Enrico Girardi**, Roma  
**Andrea Gori**, Milano  
**Paolo Antonio Grossi**, Varese  
**Giovanni Guaraldi**, Modena  
**Chiara Iaria**, Palermo  
**Giancarlo Icardi**, Genova  
**Giuseppe Ippolito**, Roma  
**Pietro Lampertico**, Milano  
**Giuseppe Lapadula**, Monza

**Adriano Lazzarin**, Milano  
**Miriam Lichtner**, Latina  
**Giuseppina Liuzzi**, Roma  
**Sergio Lo Caputo**, Foggia  
**Angela Londero**, Udine  
**Lucia Lopalco**, Milano  
**Monia Luciano**, Padova  
**Giordano Madeddu**, Sassari  
**Paolo Maggi**, Caserta  
**Franco Maggiolo**, Bergamo  
**Ivana Maida**, Sassari  
**Giulia Marchetti**, Milano  
**Marco Massari**, Reggio Emilia  
**Claudio M. Mastroianni**, Roma  
**Sandro Mattioli**, Bologna  
**Giovanni Mazzola**, Caltanissetta  
**Alessio Mazzoni**, Firenze  
**Paolo Meli**, Bergamo  
**Marianna Menozzi**, Modena  
**Marianna Meschiari**, Modena  
**Maria Cristina Moiola**, Milano  
**Monty Montano**, Boston USA  
**Ada Moznich**, Pordenone  
**Cristina Mussini**, Modena  
**Paola Nasta**, Brescia  
**Emanuele Nicastrì**, Roma  
**Silvia Nozza**, Milano  
**Giuseppe Nunnari**, Messina  
**Massimo Oldrini**, Como  
**Saverio Parisi**, Padova  
**Roberto Parrella**, Napoli  
**Giustino Parruti**, Pescara  
**Vito Peragine**, Bari  
**Carlo Federico Perno**, Roma  
**Annalisa Perziano**, Torino  
**Nicola Petrosillo**, Roma  
**Stefania Piconi**, Lecco  
**Stefano Pieralli**, Bologna  
**Tullio Prestileo**, Palermo  
**Massimo Puoti**, Milano  
**Vincenzo Puro**, Roma  
**Maria Eugenia Quiros Roldan**, Brescia  
**Laura Amelia Rachele Rancilio**, Milano  
**Rino Rappuoli**, Siena  
**Diego Ripamonti**, Bergamo  
**Giuliano Rizzardini**, Milano  
**Felipe Rogatto**, Londra UK  
**Barbara Rossetti**, Siena  
**Giada Rossini**, Bologna



6

Scientific Programme

13° CONGRESSO NAZIONALE **Italian Conference** on **AIDS** and **Antiviral Research**



**Roberto Rossotti**, Milano  
**Stefano Rusconi**, Milano  
**Caterina Sagnelli**, Napoli  
**Teresa Antonia Santantonio**, Foggia  
**Maria Santoro**, Roma  
**Annalisa Saracino**, Bari  
**Loredana Sarmati**, Roma  
**Lolita Sasset**, Padova  
**Carolina Scagnolari**, Roma  
**Gabriella Scarlatti**, Milano  
**Simona Schivazappa**, Parma  
**Francesco S. Serino**, Venezia  
**Laura Sighinolfi**, Ferrara

**Guido Silvestri**, Atlanta USA  
**Benedetto Simone**, Zurigo CH  
**Gabriel Siracusano**, Milano  
**Vincenzo Spagnuolo**, Milano  
**Marco Stizoli**, Milano  
**Barbara Suligoj**, Roma  
**Valentina Svicher**, Roma  
**Gloria Taliani**, Roma  
**Lucia Taramasso**, Genova  
**Alessandro Tavelli**, Milano  
**Marcello Tavio**, Ancona  
**Camilla Tincati**, Milano  
**Giusy Tiseo**, Pisa

**Carlo Torti**, Catanzaro  
**Ombretta Turriziani**, Roma  
**Emanuela Vaccher**, Pordenone  
**Francesco Vairo**, Roma  
**Stefano Vella**, Roma  
**Emmanuele Venanzi Rullo**, Messina  
**Gabriella Verucchi**, Bologna  
**Pierluigi Viale**, Bologna  
**Elisa Vicenzi**, Milano  
**Francesca Vichi**, Firenze  
**Filippo von Schloesser**, Roma  
**Maurizio Zazzi**, Siena

## Abstract Reviewers

**Isabella Abbate**, Roma  
**Chiara Agrati**, Roma  
**Guido Antonelli**, Roma  
**Lorenzo Badia**, Bologna  
**Alessandra Bandera**, Milano  
**Teresa Bini**, Milano  
**Isabella Bon**, Bologna  
**Paolo Bonfanti**, Monza  
**Stefano Bonora**, Torino  
**Marco Borderi**, Bologna  
**Vanni Borghi**, Modena  
**Luca Butini**, Ancona  
**Andrea Calcagno**, Torino  
**Annapaola Callegaro**, Bergamo  
**Antonella Castagna**, Milano  
**Dario Cattaneo**, Milano  
**Francesca Ceccherini - Silberstein**, Roma  
**Benedetto Maurizio Celesia**, Catania  
**Massimo Cernuschi**, Milano

**Stefania Cicalini**, Roma  
**Antonella Cingolani**, Roma  
**Paola Cinque**, Milano  
**Nicola Coppola**, Napoli  
**Giulio Maria Corbelli**, Bologna  
**Maria Luisa Cosmaro**, Milano  
**Andrea Cossarizza**, Modena  
**Alessandro Cozzi-Lepri**, London UK  
**Gianluca Cuomo**, Modena  
**Gabriella d'Etto**, Roma  
**Gianpiero D'Offizi**, Roma  
**Antonio Di Biagio**, Genova  
**Margherita Errico**, Milano  
**Carlo Ferrari**, Parma  
**Cristina Gervasoni**, Milano  
**Nicola Gianotti**, Milano  
**Enrico Girardi**, Roma  
**Andrea Gori**, Milano  
**Giovanni Guaraldi**, Modena  
**Giuseppe Lapadula**, Monza  
**Miriam Lichtner**, Latina  
**Sergio Lo Caputo**, Foggia  
**Lucia Lopalco**, Milano  
**Giordano Madeddu**, Sassari

**Paolo Maggi**, Caserta  
**Franco Maggiolo**, Bergamo  
**Giulia Marchetti**, Milano  
**Ada Moznich**, Pordenone  
**Emanuele Nicastrì**, Roma  
**Silvia Nozza**, Milano  
**Giuseppe Nunnari**, Messina  
**Giancarlo Orofino**, Torino  
**Stefania Piconi**, Lecco  
**Tullio Prestileo**, Palermo  
**Massimo Puoti**, Milano  
**Roberto Rossotti**, Milano  
**Stefano Rusconi**, Legnano (MI)  
**Annalisa Saracino**, Bari  
**Loredana Sarmati**, Roma  
**Lolita Sasset**, Padova  
**Laura Sighinolfi**, Ferrara  
**Valentina Svicher**, Roma  
**Gloria Taliani**, Roma  
**Lucia Taramasso**, Genova  
**Camilla Tincati**, Milano  
**Carlo Torti**, Catanzaro  
**Elisa Vicenzi**, Milano  
**Francesca Vichi**, Firenze



*re-search, for re-start  
together* Riccione 21-23 Ottobre 2021



*Giulia Valeria  
Calvino*



*Maria Rosaria  
Capobianchi*



*Anna Maria  
Cattelan*



*Cristina  
Mussini*

## *Dear Colleagues and Friends*

It is our great pleasure to welcome you to the **13th ICAR**, the Italian Conference on AIDS and Antiviral Research.

This year, the Conference claim **“Re-search for re-start together”** highlights the spirit of 2021 edition: the whole scientific community is keen to come back to research activities suspended or slowed down by COVID-19. Now more than ever, through **Scholarships** and **Special Awards**, we choose to encourage and support our young researchers, clinicians, health personnel, the Community of patient associations and volunteers, proposing this **three-days scientific Agorà** to discuss on the crucial issues in the battle against AIDS, COVID-19 as well as other Viral and Bacterial Infections.

At the same time, ICAR 2021 has maintained its commitment to civil society in the prevention of infectious diseases too, by offering **free HIV-HCV Rapid Test** to the local population and by continuing to promote the **RaccontART contest**, now at its 7th edition, that involves high school students.

We are aware that 2020 will be always remembered as a demarcation line: **there will always be a pre-COVID world and a post-COVID world**. Nonetheless, crises can be profound catalysts for change and generate new opportunities to create much more value over time: this last year has clearly demonstrated that only by working together we can effectively face the multidimensional consequences of the pandemic. Moreover, we should all consider this experience as an opportunity to reflect on ways to grow and evolve rather than simply “going back” to what and where we were before.

**Special thanks** go to the Scientific Committee and Secretariat, to the Abstract Coordinator and Reviewers, to our Faculty Members, to the ICAR Governing Board, SIMIT, to the Community of Patient Associations and Volunteers, Institutions, Scientific Societies, Schools and Students, to the Municipality of Riccione, the Emilia-Romagna Region and to our Sponsors who enabled us to involve and host hundreds of participants from all over the Country.

We are greatly honored to welcome you and **re-start together in Riccione!**

# *Welcome to ICAR 2021*

*The Chairs*



*re-search for re-start together*

Riccione 21-23 Ottobre 2021



**13° CONGRESSO NAZIONALE Italian Conference on AIDS and Antiviral Research**

Presidenza del Congresso:  
**G. V. Calvino, M. R. Capobianchi, A. M. Cattelan, C. Mussini**

PROGRAMME  
AT A GLANCE





Giovedì  
21 ottobre



*re-search, for re-start  
together* Riccione 21-23 Ottobre 2021

ORARI	AUDITORIUM CONCORDIA <i>Floor 3</i>	POLISSENA A HALL <i>Floor 4</i>	POLISSENA B HALL <i>Floor 4</i>	ROOM 3 <i>Floor 5</i>
13.30 16.00	SPECIAL SESSION <b>Incontro Scuole RaccontART</b>	PRE-CONFERENCE ADVANCED COURSE <b>Focus on molecular surveillance of epidemic/ pandemic viral infections</b>	PRE-CONFERENCE ADVANCED COURSE <b>New opportunities in HIV and prevention: towards achieving controlled risk</b>	PRE-CONFERENCE ADVANCED COURSE <b>Long-acting therapies in HIV and bacterial infections: the nurse role</b>
<b>AUDITORIUM CONCORDIA</b>				
16.30 17.15	SATELLITE SYMPOSIUM <b>Reflecting on treatment strategies to achieve long-term treatment success in HIV</b>			
17.20 20.00	<b>ICAR 2021</b> <i>Opening Session</i> 17.20 - 17.40 <b>Introducing ICAR 2021: authorities' welcome addresses</b> 17.40 - 18.00 <b>RaccontART contest Awards</b> 18.00 - 18.40 <b>Lecture "40 years of HIV pandemic, 40 years of progress in medicine"</b> 18.40 - 19.10 <b>Mauro Moroni Memorial Lecture "40 years of AIDS: sorrows and successful stories"</b> 19.10 - 19.40 <b>Lecture "The challenging field of vaccine research"</b> 19.40 - 20.00 <b>Closing remarks</b>			
20.00 22.30	<b>ICAR 2021 Welcome Reception</b>			

■ PRE-CONFERENCE COURSES

■ PLENARY SESSION

■ SYMPOSIUM SESSION

■ ORAL POSTER

■ ORAL COMMUNICATIONS SESSION

■ SPONSORED SESSION

■ SPECIAL EVENTS SESSION

■ EXPERT MEETING



12

Programme at a glance

13° CONGRESSO NAZIONALE **Italian Conference** on **AIDS** and **Antiviral Research**





ORARI	AUDITORIUM CONCORDIA Floor 3	POLISSENA A HALL Floor 4	POLISSENA B HALL Floor 4	ROOM 3 Floor 5
09.00 10.00	<b>Keynote Lectures</b>			
10.05 11.05	SYMPOSIUM <b>Antiviral immune control</b>	ORAL COMMUNICATIONS <b>Clinical HIV</b>	ORAL COMMUNICATIONS <b>Epidemiology/ Social sciences I</b>	
11.10 12.10	SPONSORED SYMPOSIUM <b>2DR: Evolving mindset, expanding experience</b>	ORAL COMMUNICATIONS <b>Coinfections and Hepatitis</b>	EXPERT MEETING <b>MDR pathogens in the COVID-19 era: experiences with Cefiderocol</b>	MEET THE COMMUNITY <b>40 years of HIV: reforming law 135/90 to achieve 2030 SDG and AIDS elimination</b>  (11.10 - 13.00)
12.15 13.15	SYMPOSIUM <b>Pharmacology of antiviral drugs and vaccines</b>	ORAL COMMUNICATIONS <b>Clinical HIV &amp; Clinical COVID I</b>	EXPERT MEETING <b>The first of a new generation NNRTI: the opportunity to get to the heart of PLWH</b>	
13.15 14.15	ORAL POSTER <b>Foyer Auditorium Oral Poster</b>			EXPERT MEETING <b>ICONA-PROs in the real-life setting</b>
14.15 15.15	SPONSORED SYMPOSIUM <b>Continuous innovation for long-term treatment success</b>	ORAL COMMUNICATIONS <b>Epidemiology/ Social sciences II</b>	EXPERT MEETING <b>Hyperinflammation and COVID-19: from research to clinical practice</b>	
15.20 16.20	SYMPOSIUM <b>Behavioral and social impact of COVID-19 in PLWH</b>	EXPERT MEETING <b>Monoclonal antibodies and their role in COVID-19 patients: results and perspectives</b>	EXPERT MEETING <b>Roundtable New treatment options for heavily pretreated patients</b>	
16.25 17.25	SYMPOSIUM <b>SARS-CoV-2 infection in persons living with HIV</b>	EXPERT MEETING <b>Vaccines roadmap: the humanity game-changer</b>	ORAL COMMUNICATIONS <b>Antiretroviral Therapy I</b>	ORAL COMMUNICATIONS <b>Epidemiology/ Social sciences III</b>
17.30 18.30	SYMPOSIUM <b>Novel long-acting therapies for the treatment of Multidrug-Resistant (MDR) HIV-1 infection: let's go undetectable again</b>	SYMPOSIUM <b>Co-infections in 2021</b>	ORAL COMMUNICATIONS <b>Clinical HIV &amp; Clinical COVID II</b>	

■ PRE-CONFERENCE COURSES

■ PLENARY SESSION

■ SYMPOSIUM SESSION

■ ORAL POSTER

■ ORAL COMMUNICATIONS SESSION

■ SPONSORED SESSION

■ SPECIAL EVENTS SESSION

■ EXPERT MEETING





Sabato  
23 ottobre



re-search, for re-start  
together Riccione 21-23 Ottobre 2021

ORARI	AUDITORIUM CONCORDIA <i>Floor 3</i>	POLISSENA A HALL <i>Floor 4</i>	POLISSENA B HALL <i>Floor 4</i>	ROOM 3 <i>Floor 5</i>
09.00 10.00	<b>Keynote Lectures</b>			
10.05 11.05	SYMPOSIUM <b>Approaching the Long Acting Therapy in HIV</b>	ORAL COMMUNICATIONS <b>Clinical HIV &amp; Clinical COVID III</b>	EXPERT MEETING <b>Hepatitis D virus in 2021: new challenges in though-to-treat patients</b>	
11.10 12.10	SYMPOSIUM <b>Rethinking antiretroviral therapy: new issues, new approaches</b>	ORAL COMMUNICATIONS <b>Immunopathogenesis I</b>	EXPERT MEETING <b>Remdesivir from the pivotal trials to the real world experiences: are there other open questions?</b>	MEET THE COMMUNITY <b>Sex Check for PrEP</b>
12.15 13.15	SATELLITE SYMPOSIUM <b>How the past shapes the future</b>	ORAL COMMUNICATIONS <b>Comorbidities I</b>	ORAL COMMUNICATIONS <b>Immunopathogenesis II</b>	
13.15 14.15	ORAL POSTER <b>Foyer Auditorium Oral Poster</b>			
14.00 14.45	SYMPOSIUM <b>The Italian Fast-Track Cities Network</b>	ORAL COMMUNICATIONS <b>Antiretroviral Therapy II</b> (14.15-14.45)	ORAL COMMUNICATIONS <b>Comorbidities II</b> (14.15-14.45)	ORAL COMMUNICATIONS <b>Virology and Pharmacology I</b> (14.15-14.45)
14.50 15.50	SYMPOSIUM <b>Long-COVID and HIV: which signatures?</b>	ORAL COMMUNICATIONS <b>Antiretroviral Therapy III</b> (14.50-16.20)	ORAL COMMUNICATIONS <b>Virology and Pharmacology II</b> (14.50-16.20)	ORAL COMMUNICATIONS <b>Epidemiology/ Social sciences IV</b> (14.50-16.20)
16.20 16.40	<b>SIMIT &amp; ICAR-CROI Awards</b>  <b>Closing remarks</b>			

■ PRE-CONFERENCE COURSES

■ PLENARY SESSION

■ SYMPOSIUM SESSION

■ ORAL POSTER

■ ORAL COMMUNICATIONS SESSION

■ SPONSORED SESSION

■ SPECIAL EVENTS SESSION

■ EXPERT MEETING



14

Programme at a glance

13° CONGRESSO NAZIONALE **Italian Conference** on **AIDS** and **Antiviral Research**

*re-search for re-start together*

Riccione **21-23 Ottobre** 2021



**13° CONGRESSO NAZIONALE Italian Conference on AIDS and Antiviral Research**

Presidenza del Congresso:  
**G. V. Calvino, M. R. Capobianchi, A. M. Cattelan, C. Mussini**

PRE-CONFERENCE  
ADVANCED COURSES

Giovedì 21 ottobre



Giovedì  
21 ottobre



re-search, for re-start  
together Riccione 21-23 Ottobre 2021

## PRE-CONFERENCE ADVANCED COURSE 13.30-16.00

## POLISSENA A HALL

### Focus on molecular surveillance of epidemic/pandemic viral infections

Chairs: I. Abbate (Roma), I. Bon (Bologna), C. Tincati (Milano)

Genetic characterisation of viral genomes responsible for epidemic/pandemic episodes has been proven to be a powerful tool to understand outbreak transmission dynamics, spill-over events and to screen the mutations that potentially have an impact on transmissibility, pathogenicity and diagnostics. Sequence data can afford to monitor viral evolution and to timely identify potential markers of increased transmissibility, severity of disease or altered antigenicity. In addition, as the epidemic/pandemic evolves, these data become increasingly important in order to verify the match of the circulating variants with the response to vaccines and the possible emergence of antiviral resistance. By combining information of virus characteristics with clinical and epidemiological data, it is possible to plan public health interventions and to make outbreak control decisions.

- |             |   |                         |
|-------------|---|-------------------------|
| 13.30-14.00 | <b>Epidemic/pandemic viral infections: origin, spread and adaptation of new human viruses</b> | Giada Rossini, Bologna  |
| 14.00-14.30 | <b>Tracing the infection transmission chains</b>  | Francesco Vairo, Roma   |
| 14.30-15.00 | <b>Spatio-temporal distribution of SARS-CoV-2 during COVID-19 pandemic</b>                    | Matteo Chiara, Milano   |
| 15.00-15.30 | <b>SARS-CoV-2 variants and immune evasion</b>   | Camilla Tincati, Milano |
| 15.30-16.00 | <b>Discussion on Course issues</b>  |                         |

## PRE-CONFERENCE ADVANCED COURSE 13.30-16.00

## POLISSENA B HALL

### New opportunities in HIV and prevention: towards achieving controlled risk

Chairs: L. Badia (Bologna), A. Bignardi (Modena), G. Cuomo (Modena), R. Rossotti (Milano)

The first form of treatment for HIV is prevention. The concept of prevention includes the broader concept of an individual's sexual health. Science is making advances toward the goal of preventing HIV and therefore most sexually transmitted infections. The rationale for this course is to investigate the concept of sexual health particularly in "neglected" populations with limited access to health care systems, such as the migrant population. Secondly, scientific advances in HIV prevention will be analyzed with a focus on new strategies for pre-exposure prophylaxis and ongoing trials for an HIV vaccine. Vaccine trials have posed a new key concept, represented by the management of the in-trial patient, the sexually transmitted diseases that occur during the trial and the management of VISP (vaccine-induced seropositivity). Another extremely important way of prevention is the HIV-patient on treatment, and it is crucial in this setting to hear the voice of HIV-positive patients on treatment and with undetectable viral load.

- |             |   |  |
|-------------|---|--|
| 13.30-14.00 | <b>High risk sexual behaviors and HIV/STDs cascade of care in migrants</b>          | Vito Fiore, Sassari                                |
| 14.00-14.30 | <b>New PrEP strategies beyond F/TDF</b>   | Elena Bruzzesi, Milano                             |
| 14.30-15.00 | <b>In-treatment patient's experience</b>  | Nicoletta Frattini, Milano; Marco Stizioli, Milano |
| 15.00-15.30 | <b>Clinical management in ongoing HIV vaccine trials: key points and challenges</b> | Marianna Menozzi, Modena                           |
| 15.30-16.00 | <b>Discussion on Course issues</b>  |  |



16

Pre-Conference Courses

13° CONGRESSO NAZIONALE Italian Conference on AIDS and Antiviral Research



**PRE-CONFERENCE ADVANCED COURSE** 13.30-16.00

**ROOM 3**

**Long-acting therapies in HIV and bacterial infections: the nurse role**

Chair: M. Gatti (Lecco)

*The introducing of long-acting therapy in the clinical practice of Infectious Disease Units will bring positive implications in the management of chronic patients with HIV and bacterial infections. It will be required to reshape the organization of the clinics and consequently a new nursing care model have to be redefined. After forty years of fighting against HIV, the principal aim is the development of antiretroviral therapies capable to reduce the disease progression and slow down clinical manifestations. The use of long-acting therapy can lead to an improvement in therapeutic adherence. This is fundamental in daily clinical practice, especially for the nursing figure who is personally involved not only in the administration of the drug but also in patient's information and education. Moreover, with the use of long-acting therapy in bacterial infections, patients could be treated in outpatient regimens or at home with an improvement in therapeutic efficacy and in the reduction of hospitalizations and healthcare costs.*

13.30-14.00	<b>HIV long-acting therapy: new nursing care model</b>	Eleonora Maria Beretta, Monza
14.00-14.30	<b>Long active drugs are an opportunity to improve adherence to care</b>	Silvia Aliverti, Milano
14.30-15.00	<b>Nursing management of Gram-positive infections</b>	Monia Luciano, Padova
15.00-15.30	<b>Outpatient parenteral antibiotic treatment: the nurse role</b>	Monica Cornia, Modena
15.30-16.00	<b>Discussion on Course issues</b>	



*re-search for re-start together*

Riccione 21-23 Ottobre 2021



**13° CONGRESSO NAZIONALE Italian Conference on AIDS and Antiviral Research**

Presidenza del Congresso:  
**G. V. Calvino, M. R. Capobianchi, A. M. Cattelan, C. Mussini**

# SCIENTIFIC PROGRAMME

21 - 22 - 23 ottobre





Giovedì  
21 ottobre



*re-search, for re-start  
together* Riccione 21-23 Ottobre 2021

## ARTISTIC CONTEST "RaccontART" 13.30-16.00 AUDITORIUM CONCORDIA INCONTRO CON LE SCUOLE FINALISTE

Chairs: A. Caraglia (Roma), F. Ceccherini - Silberstein (Roma), A. Lazzarin (Milano)

### 13.30-13.40 Benvenuto dei Presidenti ICAR

G.V. Calvino (Roma), M.R. Capobianchi (Roma), A.M. Cattelan (Padova), C. Mussini (Modena)

### 13.40-14.00 Introduzione e presentazione della Giuria Artistica e Tecnico-Scientifica

A. Caraglia (Roma), F. Ceccherini - Silberstein (Roma), A. Lazzarin (Milano)

### La Giuria Artistica

- **Elena Capparelli**, Direttrice di RaiPlay e Digital
- **Alessandro Castellano**, Architetto e designer
- **Nefeli Misuraca**, Montatrice e regista di cortometraggi
- **Francesco Suriano**, Scrittore di teatro, sceneggiatore e regista

### La Giuria Tecnico-Scientifica

- **Giulia Valeria Calvino**, ANLAIDS, Roma
- **Maria Rosaria Capobianchi**, Saint Camillus International University of Health Sciences, Roma
- **Anna Caraglia**, Direzione prevenzione sanitaria - Ministero della Salute, Roma
- **Anna Maria Cattelan**, Azienda Ospedaliera di Padova, Padova
- **Francesca Ceccherini-Silberstein**, Università degli Studi di Roma Tor Vergata
- **Antonella Cingolani**, Fondazione Policlinico Universitario Agostino Gemelli, Roma
- **Paola Cinque**, IRCCS Ospedale San Raffaele, Università Vita-Salute, Milano
- **Maria Luisa Cosmaro**, LILA, Milano
- **Giovanni Del Bene**, ANLAIDS, Milano
- **Antonio Di Biagio**, Ospedale Policlinico San Martino, Genova
- **Margherita Errico**, NPS Italia, Milano
- **Massimo Farinella**, Circolo di Cultura Omosessuale Mario Mieli, Roma
- **Donatella Mainieri** ANLAIDS, Milano
- **Sandro Mattioli**, Plus aps, Bologna
- **Paolo Meli**, Associazione Comunità Emmaus, Bergamo
- **Cristina Mussini**, Azienda Ospedaliero-Universitaria Policlinico, Modena
- **Silvia Nozza**, IRCCS Ospedale San Raffaele, Università Vita-Salute, Milano
- **Laura Sighinolfi**, Azienda Ospedaliero-Universitaria, Ferrara



20

Scientific Programme

13° CONGRESSO NAZIONALE Italian Conference on AIDS and Antiviral Research



14.10-15.45 **Presentazione delle Opere finaliste al Concorso a cura degli Istituti Scolastici**

### Gli Istituti Scolastici e le opere finaliste:

#### I.I.S. Ettore Majorana - San Lazzaro di Savena (BO)

- **Volami nel cuore** - Sofia Mazzotti

#### I.S. Puecher Olivetti - Rho (MI)

- **A che prezzo** - Serena De Luca, Gabriele Natali
- **È cambiato qualcosa in me** - Roberto Melziade, Gabriele Natali
- **HIV e pregiudizio** - Serena De Luca, Noemi Indelicato, Gabriele Natali, Giosuè Pantano, Lucrezia Russo, Giorgia Viola
- **Meglio sieropositivo che...Negativo!!!** - Lucrezia Russo
- **Uguali ma diversi** - Serena De Luca, Roberto Melziade, Gabriele Natali, Lucrezia Russo

#### Liceo Artistico Giuseppe Terragni - Centro Studi Casnati - Como

- **Be Careful, Fight Your Demons** - Sveva Ceresola
- **HIV** - Elena Di Pierri
- **Hope** - Davide Santillo
- **Indelebile** - Gennifer Bulanti
- **Preclusioni Di Fumo** - Sara Longoni, Irene Valli
- **Prevent Covid** - Giorgia Colombo
- **Prevention Is Better Than Cure** - Esteban Frigerio

#### Liceo Artistico Simone Weil - Treviglio (BG)

- **Inutile girarci intorno** - Manuel Morelli, Nicole Milan
- **La sicurezza di amare** - Claudia Modugno
- **Lotta & prevenzione** - Emma Mandelli, Matteo Bocciarelli
- **Rapporti Sociali** - Giulia Gastoldi
- **Rifiorire** - Alice Pessina

#### Liceo Linguistico Giovanni Pascoli - Firenze

- **Be safe... With Protection 2021** - Leonardo Settimelli
- **Come ci si lava le mani re-remix for children** - Lucrezia Bindelli, Margherita Silli
- **Mangia, Prega, Ama** - Alice Tassi

15.45-16.00 **Conclusioni**

A. Caraglia (Roma), F. Ceccherini - Silberstein (Roma), A. Lazzarin (Milano)





Giovedì  
21 ottobre



re-search, for re-start  
together Riccione 21-23 Ottobre 2021

## SATELLITE SYMPOSIUM 16.30-17.15

Con la sponsorizzazione non condizionante di Gilead Sciences

### Reflecting on treatment strategies to achieve long-term treatment success in HIV

Chairs: A.M. Cattelan (Padova), C. Mussini (Modena)

Discussant: A. Gori (Milano)

To explore how current treatment strategies, an evolving ART landscape and renewed focus on evolving patient needs will drive changes in treatment goals and expectations among PLWH. The meeting will open with a short plenary presentation reviewing how current treatment strategies are able to meet goals and patient needs in the management of both treatment-naïve and treatment-experienced PLWH, with focus on late-presenters, rapid ART initiation and switching strategies for optimizing ART to achieve treatment success. This will be followed by an eye to the future with the innovative HIV pipeline. Finally, a panel-led discussion will facilitate the discussion around the benefits and potential drawbacks of individualized approaches to reach long-term treatment success.

## AUDITORIUM CONCORDIA

16.30-16.35 **Introduction**

Anna Maria Cattelan, Padova; Cristina Mussini, Modena

16.35-16.45 **Current treatment strategies to meet evolving needs in HIV naïve patients**

Antonella d'Arminio Monforte, Milano

16.45-16.55 **Current treatment strategies and long term safety in HIV switching patients**

Giovanni Di Perri, Torino

16.55-17.05 **How Long acting and future drugs will address individual patient needs**

Antonella Castagna, Milano

17.05-17.15 **Round table with Faculty panel.**

**Reflecting upon today for change tomorrow: addressing issues to improve outcomes across the diverse patient populations**

Discussant: Andrea Gori, Milano



22

Scientific Programme

13° CONGRESSO NAZIONALE Italian Conference on AIDS and Antiviral Research



## ICAR 2021 OPENING SESSION

## AUDITORIUM CONCORDIA

### Introducing ICAR 2021 17.20-17.30

G.V. Calvino (Roma), M.R. Capobianchi (Roma), A.M. Cattelan (Padova), C. Mussini (Modena)

### Authorities' Welcome addresses 17.30-17.40

### RaccontART contest Awards 17.40-18.00

Chairs: A. Caraglia (Roma), F. Ceccherini - Silberstein (Roma), A. Lazzarin (Milano)

### Keynote Lectures 18.00-19.40

#### 18.00-18.40 **40 years of HIV pandemic, 40 years of progress in medicine**

Chairs: G.V. Calvino (Roma), M. Galli (Milano)

Speakers: Giuseppe Ippolito (Roma) and Massimo Oldrini (Como)

#### 18.40-19.10 **Mauro Moroni Memorial Lecture "40 years of AIDS: sorrows and successful stories"**

Chairs: A. Antinori (Roma), M.L. Cosmaro (Milano)

Speaker: Antonella d'Arminio Monforte (Milano)

#### 19.10-19.40 **The challenging field of vaccine research**

Chairs: F. Ceccherini-Silberstein (Roma), A. Cossarizza (Modena)

Speaker: Rino Rappuoli (Siena)

### Closing remarks 19.40-20.00

G.V. Calvino (Roma), M.R. Capobianchi (Roma), A.M. Cattelan (Padova), C. Mussini (Modena)

## ICAR 2021 Welcome Reception 20.00-22.30

## FOYER AUDITORIUM





Venerdì  
22 ottobre



re-search, for re-start  
together

Riccione 21-23 Ottobre 2021

## KEYNOTE LECTURES 09.00-10.00

Chairs: A. De Maria (Genova), A. Moznich (Pordenone)

09.00-09.30 **Community services for vulnerable groups at the forefront during the COVID-19 pandemic.**

**How to ensure sustainability?**

Daniele Calzavara, Milano

09.30-10.00 **Immune system biology to fight COVID-19**

Sara De Biasi, Modena

## AUDITORIUM CONCORDIA

## SYMPOSIUM 10.05-11.05

### Antiviral immune control

Chair: L. Lopalco (Milano)

*The delicate balance between protective and pathogenetic processes during viral infections represents a key topic to be addressed in order to identify protective signature and viral/host targets for new treatments. In SARS-CoV-2 infection, the wide range of clinical presentations of COVID-19, ranging from asymptomatic to severe pneumonia, strongly supports a main role of host factors in defining the outcome of the infection. Accordingly, several studies described underlying immune-based pathogenic mechanisms characterized by a profound lymphopenia, an exacerbated inflammatory responses and a dysregulated innate and adaptive immune response. Early events after infection (Type-I IFN-s, innate immune cells activation, inflammatory storm) can represent the first critical step able to drive the generation of a sterilizing and long lasting immunity.*

10.05-10.10 **Introduction**

10.10-10.20 **Maintaining immunological memory in COVID-19 patients: the role of vaccination**

Alessio Mazzoni, Firenze

10.20-10.30 **Interferon pathways in controlling HIV and COVID infections**

Carolina Scagnolari, Roma

10.30-10.40 **Exploring humoral immunity in COVID patients**

Gabriel Siracusano, Milano

10.40-10.50 **Persistence of an intact HIV reservoir in CD4 T cell subtypes**

Emmanuele Venanzi Rullo, Messina

10.50-11.05 **Discussion on Symposium issues**

## AUDITORIUM CONCORDIA

## ORAL COMMUNICATIONS 10.05-11.05

### Clinical HIV

Chair: C. Sagnelli (Napoli)

10.05-10.20 **Redesigning pregnancy in PLWH 2021**

Francesca Vichi, Firenze

## POLISSENA A HALL

**OC 1 10.20-10.30 Coinfection with Hepatitis B Virus and/or Hepatitis C Virus is a risk factor for HIV virological rebound in course of antiretroviral therapy**

V. Malagnino<sup>1</sup>, A. Cozzi-Lepri<sup>10</sup>, V. Svicher<sup>2</sup>, E. Girardi<sup>3</sup>, C.F. Perno<sup>4</sup>, A. Saracino<sup>5</sup>, G. Cuomo<sup>6</sup>, S. Rusconi<sup>7</sup>, M. Puoti<sup>8</sup>, A. d'Arminio Monforte<sup>9</sup>, M. Andreoni<sup>1</sup>, L. Sarmati<sup>1</sup> for the ICONA Foundation Study Group

<sup>1</sup>Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy, <sup>2</sup>Department of Experimental Medicine, University of Tor Vergata, Rome, <sup>3</sup>Department of Epidemiology and Pre-Clinical Research, National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy, <sup>4</sup>IRCCS Bambino Gesù Children's Hospital, Rome, Italy, <sup>5</sup>Infectious Diseases, Università degli Studi "Aldo Moro" di Bari, Italy, <sup>6</sup>Clinic of Infectious Diseases, Azienda Ospedaliero-Universitaria Di Modena, Modena, Italy, <sup>7</sup>Infectious Diseases Unit, Legnano General Hospital, ASST Ovest Milanese, Università degli studi Di Milano, Legnano, <sup>8</sup>Department of Infectious Diseases, Grande Ospedale Metropolitano Niguarda, Milan, Italy, <sup>9</sup>ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy, <sup>10</sup>University College London, London, UK

**OC 2 10.32-10.42 Transitions in frailty phenotype states and its association with frailty index: A multi-state Markov model study**

J. Milic<sup>1,2</sup>, S. Renzetti<sup>3</sup>, S. Barbieri<sup>1</sup>, E. Aprile<sup>4</sup>, M. Belli<sup>4</sup>, M. Venuta<sup>4</sup>, M. Menozzi<sup>4</sup>, A. Santoro<sup>4</sup>, C. Mussini<sup>4</sup>, S. Calza<sup>3</sup>, G. Guaraldi<sup>1,2,4</sup>

<sup>1</sup>Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy, <sup>2</sup>Modena HIV Metabolic Clinic (MHMC), University of Modena and Reggio Emilia, Italy, <sup>3</sup>Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy, <sup>4</sup>Department of Infectious Diseases, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy

**OC 3 10.44-10.54 Intrapartum use of zidovudine in HIV pregnant women in Italy. Is it still being used in the era of U=U?**

L. Taramasso<sup>1</sup>, F. Bovis<sup>2</sup>, A. di Biagio<sup>3</sup>, F. Mignone<sup>4</sup>, C. Giaquinto<sup>5</sup>, C. Tagliabue<sup>6</sup>, V. Giacometti<sup>7</sup>, O. Genovese<sup>8</sup>, E. Chiappini<sup>9</sup>, S.



24

Scientific Programme

13° CONGRESSO NAZIONALE Italian Conference on AIDS and Antiviral Research



Salomè<sup>10</sup>, R. Badolato<sup>11</sup>, I. Carloni<sup>12</sup>, M. Cellini<sup>13</sup>, I. Dodì<sup>14</sup>, G. Bossi<sup>15</sup>, A. Allodi<sup>16</sup>, S. Bernardi<sup>17</sup>, R. Consolini<sup>18</sup>, M. Dedoni<sup>19</sup>, G. Banderali<sup>20</sup>, A. Mazza<sup>21</sup>, M. De Martino<sup>22</sup>, C. Lisi<sup>23</sup>, P.A. Tovo<sup>24</sup>, M. Bassetti<sup>3</sup>, C. Gabiano<sup>24</sup>, L. Galli<sup>9</sup>, on behalf of The Italian Register for HIV Infection in Children

<sup>1</sup>Infectious Diseases Clinic, Policlinico San Martino Hospital-IRCCS, Genoa, Italy, <sup>2</sup>Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy, <sup>3</sup>Infectious Diseases Clinic, Department of Health Sciences, University of Genoa, San Martino Hospital-IRCCS, Genoa, Italy, <sup>4</sup>AOU Città della Salute e della Scienza di Torino, Italy, <sup>5</sup>University of Padova, Italy, <sup>6</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, UOSD Pediatria Alta Intensità di Cura, Milan, Italy, <sup>7</sup>Department of Biomedical and Clinical Sciences L Sacco, Unit of Paediatric Infectious Disease, University of Milan, Milan, Italy, <sup>8</sup>Policlinico Gemelli di Roma, Italy, <sup>9</sup>Paediatric Infectious Diseases Unit, Department of Health Sciences, Anna Meyer Children University Hospital, Florence, Italy, <sup>10</sup>Division of Neonatology, Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy, <sup>11</sup>Pediatrics Clinic, University of Brescia and ASST-Spedali Civili di Brescia, Brescia, Italy, <sup>12</sup>Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, Italy, <sup>13</sup>U.O. Oncoematologia Pediatrica Azienda Ospedaliero-Universitaria di Modena, Modena, Italy, <sup>14</sup>Pediatria Generale e d'Urgenza, Ospedale dei Bambini Pietro Barilla, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy, <sup>15</sup>UOC Pediatria, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, <sup>16</sup>Unit of Obstetrics and Gynaecology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, <sup>17</sup>Ospedale Pediatrico Bambino Gesù Malattie Infettive e Immunoinfettivologia DPUO, Roma, Italy, <sup>18</sup>Ospedale Santa Chiara, Università di Pisa, Italy, <sup>19</sup>Pediatric Clinic, Cagliari University, Italy, <sup>20</sup>Department of Paediatrics, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy, <sup>21</sup>Paediatric Unit, S. Chiara Hospital, Trento, Italy, <sup>22</sup>Department of Pediatrics, University of Florence, Florence, Italy, <sup>23</sup>Department of Statistics, University of Florence, Florence, Italy, <sup>24</sup>Department of Pediatrics, University of Turin, Turin, Italy

## ORAL COMMUNICATIONS 10.05-11.05 Epidemiology / Social Sciences I

## POLISSENA B HALL

Chair: L. Sighinolfi (Ferrara)

- OC 4 10.05-10.15 Long-term follow-up in a community-based PrEP cohort: controlled increase in risk exposure**  
P. Vinti<sup>1,2</sup>, A. Tavelli<sup>1,3</sup>, A. De Bona<sup>1,3</sup>, R. Rossotti<sup>1,4</sup>, D. Calzavara<sup>1</sup>, R. Repossi<sup>1,2</sup>, A. Bianchi<sup>1,2</sup>, S. Bossolasco<sup>1,5</sup>, D. Tesoro<sup>1,3</sup>, A. Foschi<sup>1,6</sup>, D. Canetti<sup>1,5</sup>, A. Antonino<sup>1,2</sup>, F. Rossi<sup>1,2</sup>, M. Massa<sup>1</sup>, C. Ferrara<sup>1,2</sup>, E. Suardi<sup>1,3</sup>, D. Zagato<sup>2</sup>, A. d'Arminio Monforte<sup>1,3</sup>, M. Cernuschi<sup>1,2,5</sup> on behalf of the Milano Check Point Group  
<sup>1</sup>Milano Check Point, Milano, <sup>2</sup>ASA Onlus, Milano, <sup>3</sup>ASST Santi Paolo e Carlo, Milano, <sup>4</sup>ASST Grande Ospedale Metropolitano Niguarda, Milano, <sup>5</sup>IRCCS Ospedale San Raffaele, Milano, <sup>6</sup>ASST Fatebenefratelli Sacco, Milano
- OC 5 10.17-10.27 Chemsex use in a HIV pre-exposure prophylaxis (PrEP) program based in Milan**  
C. Muccini<sup>1,2</sup>, A. Tavelli<sup>1,3</sup>, R. Rossotti<sup>1,4</sup>, A. De Bona<sup>1,3</sup>, D. Calzavara<sup>1</sup>, P. Vinti<sup>1</sup>, M. Lanza<sup>1</sup>, A. D'Arminio Monforte<sup>1,3</sup>, M. Cernuschi<sup>1,2</sup> on behalf of the Milano Checkpoint Group  
<sup>1</sup>Milano Checkpoint, Milano, <sup>2</sup>IRCCS San Raffaele Scientific Institute, Milano, <sup>3</sup>ASST Santi Paolo e Carlo, Milano, <sup>4</sup>ASST Niguarda Hospital, Milano
- OC 6 10.29-10.39 Between loss to follow-up and persistence of risky sexual behaviors: how the COVID-19 pandemic impacted access to PrEP**  
E. Baccà, M. Menozzi, G. Cuomo, M. Digaetano, L. Gozzi, C. Mussini  
Azienda Ospedaliero Universitaria di Modena, Università di Modena e Reggio Emilia
- OC 7 10.41-10.51 Impact of COVID pandemic on sexual habits and pre-exposure prophylaxis retention in care in a community-based service**  
R. Rossotti<sup>1,2</sup>, A. Tavelli<sup>2</sup>, D. Calzavara<sup>2</sup>, A. De Bona<sup>2,3</sup>, P. Vinti<sup>2</sup>, C. Muccini<sup>2,4</sup>, D. Tesoro<sup>2,3</sup>, S. Bossolasco<sup>2,4</sup>, M. Cernuschi<sup>2,4</sup>, A. d'Arminio Monforte<sup>2,3</sup>  
<sup>1</sup>ASST Grande Ospedale Metropolitano Niguarda, Milan, <sup>2</sup>Milano Checkpoint, Milan, <sup>3</sup>ASST Santi Carlo e Paolo, Milan, <sup>4</sup>IRCCS San Raffaele Scientific Institute, Milan
- OC 8 10.53-11.03 School-based sexuality education in Italy 2016-2020: a highly heterogeneous scenario**  
A. Chinelli<sup>1</sup>, M. Farinella<sup>2</sup>, L. Rancilio<sup>3</sup>, M. C. Salfa<sup>4</sup>, A. Cellini<sup>5</sup>, P. Meli<sup>6</sup>, R. Galipò<sup>7</sup>, A. Camposeragna<sup>8</sup>, M. Oldrini<sup>9</sup>, L. Colaprico<sup>10</sup>, L. Ceccarelli<sup>11</sup>, A.T. Palamara<sup>12</sup>, A. Caraglia<sup>13</sup>, B. Suligoj<sup>14</sup>, L. Tavošchi<sup>15</sup>  
<sup>1</sup>Università di Pisa, Pisa, <sup>2</sup>Circolo di Cultura Omosessuale Mario Mieli, Roma, <sup>3</sup>Caritas Ambrosiana, Milano, <sup>4</sup>Istituto Superiore di Sanità, Roma, <sup>5</sup>Università La Sapienza, Roma, <sup>6</sup>Coordinamento Italiano Case Alloggio/AIDS (CICA), Bergamo, <sup>7</sup>Associazione Nazionale per la Lotta contro l'AIDS (ANLAIDS), Roma, <sup>8</sup>Coordinamento Nazionale Comunità di Accoglienza (CNCA), Roma, <sup>9</sup>Lega Italiana per la Lotta contro l'AIDS (LILA), Roma, <sup>10</sup>Croce Rossa Italiana (CRI), Roma, <sup>11</sup>Università di Pisa, Pisa, <sup>12</sup>Università La Sapienza, Roma, <sup>13</sup>Ministero della Salute, Roma, <sup>14</sup>Istituto Superiore di Sanità, Roma, <sup>15</sup>Università di Pisa, Pisa







Venerdì  
22 ottobre



re-search, for re-start  
together Riccione 21-23 Ottobre 2021

## SPONSORED SYMPOSIUM 11.10-12.10

Con il supporto di ViiV Healthcare

### 2DR: Evolving mindset, expanding experience

Chairs: A. Di Biagio (Genova), S. Lo Caputo (Foggia)

The life expectancy of people living with HIV (PLWHIV) is now close to the one of HIV negative people. This important milestone has been achieved thanks to the continuous evolution of antiretroviral therapy (ART), the basis of which continuous improvement placed on providing optimal therapeutic options for long-term management. In this context, ART therapy has evolved in the direction of 2-drug regimens (2DR), which, initially considered a new concept, today represent a reality in the embedded phase. In particular, dolutegravir (DTG)-based regimens are an important therapeutic option, both in the initial phase of treatment and in the switch from ARV. Starting from these assumptions, the session will focus on the evolution of the mindset in therapy management thanks to the solid evidence from the clinical studies available for DTG / 3TC and DTG / RPV. This evolution is associated with a growth of experience in clinical practice with the expansion of the use of DTG-based 2DRs in both HIV + naïve and virologically suppressed patients. Regarding these aspects, the most recent data available for regimens containing dolutegravir and lamivudine (DTG / 3TC; DTG + 3TC) and dolutegravir and rilpivirine (DTG / RPV) will be investigated.

- |             |  |   |
|-------------|--|---|
| 11.10-11.15 | <b>Introduction</b>  | Antonio Di Biagio, Genova; Sergio Lo Caputo, Foggia |
| 11.15-11.35 | <b>Evolving mindset with 2DR: the latest results to better identify the right patient at the right time</b>                    | Diego Ripamonti, Bergamo                            |
| 11.35-11.55 | <b>Expanding experience with 2DR: the latest learnings from the real-life use of DTG/3TC in HIV+ naïve and switch patients</b> | Simona Di Giambenedetto, Roma                       |
| 11.55-12.10 | <b>Discussion on Symposium issues</b>  |   |

## AUDITORIUM CONCORDIA

## ORAL COMMUNICATIONS 11.10-12.10

### Coinfections and Hepatitis

Chairs: F. Maggiolo (Bergamo), P. Colletti (Trapani)

- |             |  |                         |
|-------------|--|-------------------------|
| 11.10-11.25 | <b>New anti-HBV drugs: virological and immunological bases</b> | Valentina Svicher, Roma |
|-------------|--|-------------------------|

## POLISSENA A HALL

### OC 9 11.25-11.35 Enrichment of positively charged amino acids in HBsAg C-terminus correlates with HBV-induced liver cancer, hampers HBsAg secretion and alters its structural stability

L. Piermatteo<sup>1</sup>, L. Carloti<sup>1</sup>, G. Leoni<sup>1</sup>, L. Duca<sup>1</sup>, P. Saccomandi<sup>1</sup>, G. Cappiello<sup>2</sup>, P. Trimoulet<sup>3</sup>, H. Fleury<sup>3</sup>, S. Francioso<sup>4</sup>, I. Lenci<sup>4</sup>, M. Andreoni<sup>5</sup>, M. Angelico<sup>4</sup>, A. Minutolo<sup>1</sup>, C. Matteucci<sup>1</sup>, L. Sarmati<sup>5</sup>, F. Ceccherini-Silberstein<sup>1</sup>, V. Svicher<sup>1</sup>, R. Salpini<sup>1</sup>

<sup>1</sup>Tor Vergata University, Department of Experimental Medicine, Rome, Italy, <sup>2</sup>Microbiology and Virology Unit, "Sandro Pertini" Hospital, Rome, Italy, <sup>3</sup>Hôpital Pellegrin tripode, Laboratoire de Virologie, Bordeaux, France, <sup>4</sup>Tor Vergata University Hospital, Hepatology Unit, Rome, Italy, <sup>5</sup>Tor Vergata University Hospital, Infectious Diseases Unit, Rome, Italy

### OC 10 11.37-11.47 HBcrAg strongly correlates with higher HDV replicative activity and with enhanced liver inflammation and damage: implications for HBcrAg as a biomarker of disease progression in the setting of HDV co-infection

R. Salpini<sup>1</sup>, L. Piermatteo<sup>1</sup>, U.S. Gill<sup>2</sup>, A. Battisti<sup>1,2</sup>, M. Alkhatib<sup>1</sup>, S. D'Anna<sup>1</sup>, R. Scutari<sup>1</sup>, E. Andreassi<sup>1</sup>, K.M.A. Ho<sup>2</sup>, F. Ceccherini-Silberstein<sup>1</sup>, C. Usai<sup>2</sup>, P.T.F. Kennedy<sup>2</sup>, V. Svicher<sup>1</sup>

<sup>1</sup>University of Rome Tor Vergata, Department of Experimental Medicine, Rome, Italy, <sup>2</sup>Barts Liver Centre, Immunobiology, Blizard Institute, Barts and The London SMD, QMUL, London, United Kingdom

### OC 11 11.49-11.59 Endocrine pathways of non-alcoholic fatty liver disease in people living with HIV

J. Milic<sup>1,2</sup>, L. Gozzi<sup>1,2</sup>, S. Renzetti<sup>3</sup>, S. Calza<sup>3</sup>, D. Ferrari<sup>1</sup>, S. Barbieri<sup>1</sup>, A. Cervo<sup>4</sup>, G. Franceschi<sup>4</sup>, V. Iadiserchia<sup>4</sup>, C. Diazzi<sup>5,6</sup>, V. Rochira<sup>5,6</sup>, C. Mussini<sup>1,4</sup>, G. Sebastiani<sup>7</sup>, G. Guaraldi<sup>1,2,4</sup>

<sup>1</sup>Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy, <sup>2</sup>Modena HIV Metabolic Clinic (MHMC), University of Modena and Reggio Emilia, Italy, <sup>3</sup>Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy, <sup>4</sup>Department of Infectious Diseases, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy, <sup>5</sup>Department of Endocrinology, Ospedale Civile di Baggiovara, Modena, Italy, <sup>6</sup>Department of Biomedical, Metabolic and Neuroscience Sciences, University of Modena and Reggio Emilia, Modena, Italy, <sup>7</sup>McGill University, Montreal, Quebec, Canada



26

Scientific Programme

13<sup>o</sup> CONGRESSO NAZIONALE Italian Conference on AIDS and Antiviral Research



**EXPERT MEETING** 11.10-12.10

**POLISSENA B HALL**

Con la sponsorizzazione non condizionante di Shionogi

**MDR pathogens in the COVID-19 era: experiences with Cefiderocol**

Chair: P. Viale (Bologna)

Antimicrobial resistance (AMR) is a growing global problem to which the ongoing COVID-19 pandemic may further contribute. Every year, drug-resistant microbes are responsible for an estimated 700,000 deaths and future projections for the impact of unresolved AMR are as high as 10 million deaths per year by 2050.

One of the most significant threats in global health is the carbapenem-resistant gram-negative bacteria and lack of efficient antibiotics. The World Health Organization designated carbapenem-resistant Enterobacteriaceae, *Pseudomonas aeruginosa*, and *Acinetobacter baumannii* as high-priority pathogens, which urgently need new antimicrobial development. The Expert Meeting aims to provide information on real life cases treated with Cefiderocol, a recent new option for patients with multidrug-resistant Gram-negative bacterial infections.

11.10 - 11.25	<b>From in vitro activity to clinical efficacy</b>	Pierluigi Viale, Bologna
11.25 - 11.35	<b>Real-life experiences with Cefiderocol in Pseudomonas infections</b>	Marianna Meschiari, Modena
11.35 - 11.45	<b>Real-life experiences with Cefiderocol in Acinetobacter baumannii infections</b>	Giusy Tiseo, Pisa
11.45-11.55	<b>Cefiderocol place in therapy</b>	Maddalena Giannella, Bologna
11.55-12.05	<b>Questions &amp; Answers</b>	
12.05-12.10	<b>Take-home messages</b>	Pierluigi Viale, Bologna

**ROUND TABLE** 11.10-13.00

**ROOM 3**

**Meet the Community: "40 years of HIV: reforming law 135/90 to achieve 2030 SDG and AIDS elimination"**

Chairs: G.V. Calvino (Roma), L. A. Rancilio (Milano)

Participants: M. Farinella (Roma), M. Galli (Milano), E. Girardi (Roma), S. Pieralli (Bologna)

**SYMPOSIUM** 12.15-13.15

**AUDITORIUM CONCORDIA**

**Pharmacology of antiviral drugs and vaccines**

Chairs: G. Scarlatti (Milano), M. Zazzi (Siena)

At global level, the change in viral dynamics is severe enough to require a corresponding interest in discussing some of the issues directly related to the pandemic controls, i.e. the variability of the viruses and the microbiological aspects of vaccination. As far as the "pharmacology" issue is concerned, it is interesting noting that several antiretroviral drugs are substrates of enzymes belonging to the cytochrome P450 superfamily, which are polymorphically expressed, and consistent evidences are available in literature showing that genetic variation in these enzymes can predict the likelihood of anti-HIV treatment success, toxicity and/or the potential for drug-drug interactions. Preliminary evidences are also available showing that allelic variants of genes involved in the pharmacodynamics of antiretroviral drugs can impact on the clinical outcome of people living with HIV.

12.15-12.30	<b>Pharmacogenetics of drug response in antiviral therapies</b>	Jessica Cusato, Torino
12.30-12.45	<b>Variability and evolution of viruses: biological and clinical aspects</b>	Carlo Federico Perno, Roma
12.45-13.00	<b>Vaccines against viruses: the microbiological point of view</b>	Irene Cassaniti, Pavia
13.00-13.15	<b>The influence of inflammation on antiviral drugs disposition and efficacy</b>	Giulia Marchetti, Milano





Venerdì  
22 ottobre



re-search, for re-start  
together

Riccione 21-23 Ottobre 2021

## ORAL COMMUNICATIONS 12.15-13.15

## POLISSENA A HALL

### Clinical HIV & Clinical Covid I

Chairs: G. Lapadula (Monza), M.C. Moiola (Milano)

#### 12.15-12.30 Therapeutic approaches with monoclonal antibodies in HIV and SARS-CoV-2 infections

Anna Maria Cattelan, Padova

#### OC 12 12.30-12.40 Higher risk of MABs clinical failure associated to bamlanivimab/etesevimab exposure and to infection by SARS-CoV-2 P.1 /Gamma variant of concern in a real life setting

V. Mazzotta<sup>1</sup>, S. Lanini<sup>1</sup>, S. Rosati<sup>1</sup>, P. Lorenzini<sup>1</sup>, E. Lalle<sup>2</sup>, C. Cimaglia<sup>3</sup>, I. Mastroiosa<sup>1</sup>, A. Corpolongo<sup>1</sup>, B. Bartolini<sup>2</sup>, A. Vergori<sup>1</sup>, G. Maffongelli<sup>1</sup>, S. Vita<sup>1</sup>, M. Fusto<sup>1</sup>, E. Girardi<sup>3</sup>, C. Castilletti<sup>2</sup>, F. Vaia<sup>4</sup>, E. Nicastri<sup>1</sup>, A. Antinori<sup>1</sup>

<sup>1</sup>Clinical Department, <sup>2</sup>Laboratory of Virology, <sup>3</sup>Clinical Epidemiology, <sup>4</sup>Medical Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy

#### OC 13 12.42-12.52 Bamlanivimab and Etesevimab administered in an outpatient setting for SARS-CoV-2 infection

D.F. Bavaro<sup>1</sup>, L. Diella<sup>1</sup>, A.G. Solimando<sup>2</sup>, S. Cicco<sup>2</sup>, E. Buonamico<sup>3</sup>, C. Stasi<sup>4</sup>, M. Ciannarella<sup>4</sup>, M. Marrone<sup>5</sup>, F. Carpagnano<sup>6</sup>, O. Resta<sup>3</sup>, G.E. Carpagnano<sup>3</sup>, V.O. Palmieri<sup>4</sup>, A. Vacca<sup>2</sup>, M. Dell'Aera<sup>6</sup>, A. Dell'Erba<sup>5</sup>, G. Migliore<sup>8</sup>, M. Arico<sup>9</sup>, A. Saracino<sup>1</sup>

<sup>1</sup>Clinic of Infectious Diseases, Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro", Bari, Italy, <sup>2</sup>Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine "G. Baccelli" University Hospital Policlinico, Bari, Italy, <sup>3</sup>Department of Basic Medical Science, Institute of Respiratory Disease, Neuroscience, and Sense Organs, University of Bari "Aldo Moro", Bari, Italy, <sup>4</sup>Clinica Medica "A. Murri", Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Bari, Italy, <sup>5</sup>Interdisciplinary Department of Medicine, University of Bari – Section of Legal Medicine, Bari General Hospital, Bari, Italy, <sup>6</sup>Direttore Farmacia Ospedaliera AOU Policlinico di Bari – Bari, Italy, <sup>7</sup>Section of Health Management, Policlinico Hospital, Bari, Italy, <sup>8</sup>General Direction, Policlinico Hospital, Bari, Italy, <sup>9</sup>Strategic Direction, Policlinico Hospital, Bari, Italy

#### OC 14 12.54-13.04 Real life use of monoclonal antibodies and their impact on SARS-CoV-2 clearance kinetics: a single centre experience

M. Mazzitelli<sup>1,2</sup>, D. Leoni<sup>1</sup>, M. Canova<sup>1</sup>, P. Furlan<sup>3</sup>, S. Cocchio<sup>3</sup>, E. Franchin<sup>4</sup>, B. Deris<sup>3</sup>, A.M. Cattelan<sup>1</sup>

<sup>1</sup>Infectious and Tropical Diseases Unit, Padua Hospital, Padua, Italy, <sup>2</sup>Department of Medical and Surgical Sciences, Magna Graecia University of Catanzaro, Catanzaro, Italy, <sup>3</sup>Department of Medicine and Public Health, Padua University Hospital, Padua, Italy, <sup>4</sup>Microbiology and Virology Unit, Padua University Hospital, Padua, Italy

## EXPERT MEETING 12.15-13.15

## POLISSENA B HALL

Con la sponsorizzazione non condizionante di MSD Italia

### The first of a new generation NNRTI: the opportunity to get to the heart of PLWH

Chair: M. Andreoni (Roma)

PLWH may be predisposed to higher risk of Cardiometabolic Disorders such as dyslipidemia, cardiovascular disease and diabetes. In fact, metabolic syndrome affects up to 52% of PLWH. EACS guidelines suggest an ARV modification in case of CVD risk. Here, we review the efficacy and safety profile of the new generation of NNRTI, with a focus on Cardiometabolic Disorders.

12.15 - 12.20 Introduction

Massimo Andreoni, Roma

12.20 - 12.35 The first of a new generation NNRTI: the opportunity to get to the heart of PLWH

Andrea Antinori, Roma

12.35 - 13.05 Discussion

13.05 - 13.15 Take-home messages and conclusions

Massimo Andreoni, Roma



28

Scientific Programme

13° CONGRESSO NAZIONALE Italian Conference on AIDS and Antiviral Research



## ORAL POSTER 13.15-14.15

## FOYER AUDITORIUM

### Antiretroviral Therapy I

Chairs: F. Bai (Milano), V. Colangeli (Bologna)

- OP 1 13.15-13.20 Real-life Experience with Dolutegravir-Based Two-Drug Regimens**  
R. Pincino<sup>1</sup>, A. Falletta<sup>1</sup>, S. Bianchi<sup>1</sup>, S. Mora<sup>3</sup>, M. Giacomini<sup>3</sup>, L. Taramasso<sup>2</sup>, M. Bassetti<sup>1,2</sup>, A. Di Biagio<sup>1,2</sup>  
<sup>1</sup>Infectious Diseases Clinic, University of Genoa, <sup>2</sup>Department of Infectious Diseases, San Martino Hospital, Genoa, <sup>3</sup>Department of Informatics, Bioengineering, Robotics and System Engineering, University of Genoa
- OP 2 13.22-13.27 Comparison of efficacy and tolerability of Dolutegravir / Rilpivirine or Dolutegravir / Lamivudine in experienced HIV-1 positive patients switched from a three-drug regimen based on Non-Nucleoside Reverse Transcriptase Inhibitors in a single center in Italy**  
F. Lagi<sup>1,2</sup>, M. Romanelli<sup>1</sup>, S. Tekle Kiros<sup>1</sup>, F. Ducci<sup>1</sup>, A. Bartoloni<sup>1,2</sup>, G. Sterrantino<sup>1</sup>  
<sup>1</sup>Department of Experimental and Clinical Medicine, University of Florence, Florence Italy, <sup>2</sup>Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy
- OP 3 13.29-13.34 Efficacy and safety of switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in virologically-suppressed HIV patients (EBONY Study)**  
S. Cicalini, P. Lorenzini, E. Grilli, S. Ottou, M.M. Plazzi, F. De Zottis, M. Camici, M. Fusto, R. Gagliardini, R. Bellagamba, A. Antinori  
National Institute for Infectious Diseases "Lazzaro Spallanzani", IRCCS, Rome
- OP 4 13.36-13.41 Efficacy and tolerability of a switch to bictegravir/emtricitabine/tenofovir alafenamide in virally suppressed PLWH**  
D. Canetti<sup>1</sup>, A. Poli<sup>1</sup>, L. Galli<sup>1</sup>, S. Nozza<sup>1</sup>, V. Spagnuolo<sup>1,2</sup>, C. Muccini<sup>1,2</sup>, M. Mastrangelo<sup>2</sup>, E. Bruzzesi<sup>2</sup>, M. Ranzenigo<sup>2</sup>, M. Chiurlo<sup>2</sup>, A. Castagna<sup>1,2</sup>, N. Gianotti<sup>1</sup>  
<sup>1</sup>Unit of Infectious and Tropical Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, <sup>2</sup>Vita-Salute San Raffaele University, Milan, Italy
- OP 5 13.43-13.48 Efficacy, safety and feasibility of a rapid antiretroviral therapy starting B/F/TAF in advanced hiv disease (Rainbow study)**  
M. Camici, R. Gagliardini, P. Lorenzini, S. Ottou, A. Mondì, M.M. Plazzi, C. Pinnetti, A. Vergori, E. Grilli, F. De Zottis, I. Mastroianni, V. Mazzotta, J. Paulicelli, R. Bellagamba, S. Cicalini, A. Antinori  
National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome
- OP 6 13.50-13.55 Effectiveness, safety and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people living with HIV (PLWH) in routine clinical practice: 6-month results of the Italian BICSTaR cohort**  
A. d'Arminio Monforte<sup>1</sup>, S. Rusconi<sup>2</sup>, D. Canetti<sup>3</sup>, G. Di Perri<sup>4</sup>, E. Quiros-Roldan<sup>5</sup>, A. Giacometti<sup>6</sup>, A. Antinori<sup>7</sup>, M. Andreoni<sup>8</sup>, A. Saracino<sup>9</sup>, L. Albini<sup>10</sup>, R. Caldera<sup>10</sup>, G. Forcina<sup>10</sup>, V. Esposito<sup>11</sup>  
<sup>1</sup>Clinic of Infectious Diseases, Department of Health Sciences, University of Milan, "ASST Santi Paolo e Carlo", Milan, Italy, <sup>2</sup>Infectious Diseases Unit, ASST is Ovest Milanese - University of Milan, Milan, Italy, <sup>3</sup>Clinic of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, <sup>4</sup>Department of Medical Sciences, Infectious Diseases, University of Turin, Italy, <sup>5</sup>Division of Infectious and Tropical Medicine, ASST Spedali Civili, Brescia Italy, <sup>6</sup>Infectious Diseases Clinic, Department of Biological Sciences and Public Health, Marche Polytechnic University, Ancona, Italy, <sup>7</sup>HIV/AIDS Department, National Institute of Infectious Diseases, L. Spallanzani, IRCCS, Rome, Italy, <sup>8</sup>Infectious Diseases Clinic, University Hospital "Tor Vergata", Rome, Italy, <sup>9</sup>Division of Infectious Diseases, Bari University Hospital, University of Bari, Italy, <sup>10</sup>Gilead Sciences Srl, Milan, Italy, <sup>11</sup>Infectious Diseases and Gender Medicine Unit D. Cotugno Hospital-A.O. dei Colli Naples, Italy

13.57-14.15 Discussion

## ORAL POSTER 13.15-14.15

## FOYER AUDITORIUM

### Comorbidities / Miscellaneous

Chair: F. Carli (Modena)

- OP 7 13.15-13.20 MARAND-X: clinical trial on the use of less neurotoxic antiretrovirals in HAND**  
A. Lazzaro<sup>1</sup>, A. Barco<sup>2</sup>, G. Stroffolini<sup>2</sup>, V. Pirriatore<sup>2</sup>, D. Vai<sup>3</sup>, G. Guastamacchia<sup>3</sup>, C. Giacone<sup>3</sup>, M. Nigra<sup>4</sup>, G. Noce<sup>5</sup>, V. Ghisetti<sup>6</sup>, M.C. Tetttoni<sup>2</sup>, M. Trunfi<sup>2</sup>, A. Trentalange<sup>2</sup>, S. Bonora<sup>2</sup>, G. Di Perri<sup>2</sup>, A. Calcagno<sup>2</sup>  
<sup>1</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, Rome, Italy, <sup>2</sup>Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy, <sup>3</sup>Unit of Neurology, Maria Vittoria Hospital, ASL "Città di Torino", Turin, Italy, <sup>4</sup>Biochemistry and Immunology Laboratory, Maria Vittoria Hospital, ASL "Città di Torino", Turin, Italy, <sup>5</sup>IRCCS SDN, Napoli, Italy, <sup>6</sup>Microbiology and Molecular Biology Laboratory, Amedeo di Savoia Hospital, ASL "Città di Torino", Turin, Italy





Venerdì  
22 ottobre



re-search, for re-start  
together

Riccione 21-23 Ottobre 2021

- OP 8** 13.22-13.27 **Management of diabetes mellitus in people living with HIV and diabetes: a single-center experience**  
D. Cattaneo, C. Resnati, A. Gidaro, A. Rossi, A. Merlo, T. Formenti, P. Meraviglia, S. Antinori, C. Gervasoni  
ASST Fatebenefratelli Sacco University Hospital, Milano, Italy
- OP 9** 13.29-13.34 **The interplay between resilience and health related quality of Life in PLWH during the COVID era: a comparison of a geriatric cohort with a cohort of PLWH younger than 65 years**  
G. Guaraldi<sup>1</sup>, J. Milic<sup>1</sup>, M. Ferrara<sup>2</sup>, L. Micai<sup>2</sup>, S. Barbieri<sup>1</sup>, E. Aprile<sup>1</sup>, M. Belli<sup>1</sup>, M. Venuta<sup>1</sup>, S. Arsuffi<sup>3</sup>, C. Fornari<sup>3</sup>, E. Focà<sup>3</sup>, G. Di Perri<sup>2</sup>, S. Bonora<sup>2</sup>, S. Calza<sup>4</sup>, C. Mussini<sup>1</sup>, A. Calcagno<sup>2</sup>  
<sup>1</sup>University of Modena and Reggio Emilia, Modena, Italy, <sup>2</sup>Department of Infectious Diseases, University of Torino, <sup>3</sup>Unit of Infectious and Tropical Diseases, University of Brescia, <sup>4</sup>Department of Molecular and Translational Medicine, University of Brescia, Italy, Brescia, Italy
- OP 10** 13.36-13.41 **Efficacy and Tolerability of Doravirine + Raltegravir combination regimen as therapy of switch in ART experienced PLWHIV: the DOR-INI experience**  
M. Poliseno<sup>1</sup>, S.R. Bruno<sup>1</sup>, S. Ferrara<sup>1</sup>, C. Gallo<sup>2</sup>, L. Montemurro<sup>1</sup>, M.L. D'Errico<sup>1</sup>, M. Rizzo<sup>1</sup>, T.A. Santantonio<sup>1</sup>, S. Lo Caputo<sup>1</sup>  
<sup>1</sup>Department of Clinical and Experimental Medicine, Unit of Infectious Diseases, Policlinico "Riuniti", Foggia, Italy, <sup>2</sup>Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy
- OP 11** 13.43-13.48 **Trends of polypharmacy and 2DR antiretroviral use: a 15-year observational matched-cohort study**  
J. Milic<sup>1,2</sup>, S. Cantergiani<sup>3</sup>, S. Barbieri<sup>1</sup>, F. Carli<sup>2,4</sup>, G. Cuomo<sup>2,4</sup>, D. Yaacoub<sup>4</sup>, G. Burastero<sup>4</sup>, M. Faltoni<sup>4</sup>, G. Franceschi<sup>4</sup>, S. Volpi<sup>4</sup>, V. Iadernia<sup>4</sup>, C. Mussini<sup>1,4</sup>, G. Guaraldi<sup>1,2,4</sup>  
<sup>1</sup>Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Italy, <sup>2</sup>Modena HIV Metabolic Clinic (MHMC), University of Modena and Reggio Emilia, Italy, <sup>3</sup>University of Modena and Reggio Emilia, Modena, Italy, <sup>4</sup>Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico di Modena, Modena, Italy
- OP 12** 13.50-13.55 **Rapid, drug-resistance-driven, start of antiretroviral therapy: an open-label, prospective, proof-of-concept, clinical study (TWO DAY Study)**  
N. Gianotti<sup>1</sup>, L. Galli<sup>1</sup>, L. Della Torre<sup>1</sup>, G. Annicchiarico<sup>1</sup>, S. Aliverti<sup>1</sup>, S. Nozza<sup>1</sup>, F. Badalucco<sup>1,2</sup>, G. Mori<sup>1,2</sup>, I. Mainardi<sup>1,2</sup>, R. Monardo<sup>1,2</sup>, G. Ponta<sup>1,2</sup>, A. Castagna<sup>1,2</sup>  
<sup>1</sup>San Raffaele Scientific Institute, Infectious Diseases, Milano, Italy, <sup>2</sup>Università Vita-Salute San Raffaele, Infectious and Tropical Diseases, Milano, Italy

13.57-14.15 **Discussion**

**ORAL POSTER** 13.15-14.15

**HIV & Covid I**

Chair: P. Maggi (Caserta)

- OP 13** 13.15-13.20 **UV irradiation and SARS-CoV-2: a focus on UVA/UVB/UVC -inactivation on viral replication**  
S. Strizzi<sup>1,2</sup>, A. Introini<sup>1</sup>, A. Bianco<sup>3</sup>, O. Utyro<sup>1</sup>, S. Musollino<sup>1</sup>, D. Trabattoni<sup>1</sup>, G. Pareschi<sup>3</sup>, M. Biasin<sup>1</sup>, M. Clerici<sup>1</sup>  
<sup>1</sup>DIBIC University of Milan, <sup>2</sup>University of Sassari, <sup>3</sup>INAF- Brera Astronomical Observatory Merate
- OP 14** 13.22-13.27 **Determinants and characteristics of progressor and non progressor SARS COV-2 infected patients**  
P. Zuccalà, E. Chichi, R. Marocco, B. Kertusha, T. Tieghi, L. Fondaco, M. Del Borgo, A. Gasperin, A. Parente, D. Caianiello, A. Cifra, G. Gabrielli, G. Brignone, A. Spagnolo, M. Lichtner  
Hospital "S.Maria Goretti", UOC Infectious Diseases, Latina and "Sapienza" University of Rome, Polo Pontino
- OP 15** 13.29-13.34 **Metabolic associated fatty liver disease is highly prevalent in the post-acute COVID syndrome**  
J. Milic<sup>1</sup>, S. Barbieri<sup>1</sup>, L. Gozzi<sup>1</sup>, A. Brigo<sup>2</sup>, B. Beghé<sup>3</sup>, A. Verduri<sup>3</sup>, E. Bacca<sup>4</sup>, V. Iadernia<sup>4</sup>, G. Cuomo<sup>4</sup>, G. Dolci<sup>4</sup>, D. Yaacoub<sup>4</sup>, E. Aprile<sup>4</sup>, M. Belli<sup>4</sup>, M. Venuta<sup>4</sup>, M. Meschiaro<sup>4</sup>, G. Sebastiani<sup>6,7</sup>, E. Clini<sup>3</sup>, C. Mussini<sup>1,3</sup>, A. Lonardo<sup>5</sup>, P. Raggi<sup>8</sup>, G. Guaraldi<sup>1,4</sup>  
<sup>1</sup>Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Italy, <sup>2</sup>University of Modena and Reggio Emilia, Modena, Italy, <sup>3</sup>Respiratory Unit, Azienda Ospedaliero-Universitaria, Policlinico di Modena, Modena, Italy, <sup>4</sup>Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico di Modena, Modena, Italy, <sup>5</sup>Department of Internal Medicine, Azienda Ospedaliero-Universitaria, Ospedale Civile di Baggiovara, Modena, Italy, <sup>6</sup>Division of Experimental Medicine, McGill University, Montreal, QC, Canada, <sup>7</sup>Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, QC, Canada, <sup>8</sup>Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
- OP 16** 13.36-13.41 **Assessment of well-being, resilience and intrinsic capacity in patients with post-acute COVID-19 syndrome**  
J. Milic<sup>1</sup>, T. Marchio<sup>2</sup>, S. Barbieri<sup>1</sup>, F. Mediolì<sup>3</sup>, J. Conti<sup>3</sup>, S. Esperti<sup>3</sup>, A. Mazzocchi<sup>3</sup>, M. Del Monte<sup>3</sup>, I. Baldisserotto<sup>3</sup>, M.D. Di Trapani<sup>3</sup>, A. Dessilani<sup>3</sup>, C. Mussini<sup>1,3</sup>, G. Guaraldi<sup>1,3</sup>  
<sup>1</sup>Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Italy, <sup>2</sup>University of Modena and Reggio Emilia, Modena, Italy, <sup>3</sup>Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico di Modena, Modena, Italy



30

Scientific Programme

13<sup>o</sup> CONGRESSO NAZIONALE Italian Conference on AIDS and Antiviral Research



**OP 17 13.43-13.48 Achieving virological control in pan-resistant HIV-1 infection**

D. Canetti<sup>1</sup>, C. Muccini<sup>1,2</sup>, V. Spagnuolo<sup>2</sup>, L. Galli<sup>1</sup>, A. Poli<sup>1</sup>, N. Gianotti<sup>1</sup>, M. Feasi<sup>3</sup>, A. Castagna<sup>1,2</sup>

<sup>1</sup>Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, <sup>2</sup>Vita-Salute San Raffaele University, Milan, Italy, <sup>3</sup>Ente Ospedaliero Ospedali Galliera, Genoa, Italy

**OP 18 13.50-13.55 Resilience and frailty in people living with HIV during the COVID era: two complementary constructs associated with health-related quality of life**

G. Guaraldi<sup>1,2,3</sup>, J. Milic<sup>1,2</sup>, S. Barbieri<sup>1</sup>, T. Marchiò<sup>4</sup>, A. Caselgrandi<sup>4</sup>, E. Aprile<sup>3</sup>, M. Belli<sup>3</sup>, M. Venuta<sup>3</sup>, C. Mussini<sup>1,3</sup>

<sup>1</sup>Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Italy, <sup>2</sup>Modena HIV Metabolic Clinic (MHMC), University of Modena and Reggio Emilia, Italy, <sup>3</sup>Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy, <sup>4</sup>University of Modena and Reggio Emilia, Italy

13.57-14.15 **Discussion**

**ORAL POSTER 13.15-14.15**

**FOYER AUDITORIUM**

**Coinfections and Hepatitis**

Chairs: P. Colletti (Trapani), I. Maida (Sassari), G. Mazzola (Caltanissetta)

**OP 19 13.15-13.20 Impact of polypharmacy and aging on the risk of multiple drug-drug interactions (DDIs) in HCV patients treated with pangenotypic direct-acting antivirals (pDAA)**

A. Mangia<sup>1</sup>, P. Toniutto<sup>2</sup>, N. Coppola<sup>3</sup>, D.D. Ancona<sup>4</sup>, M. Andretta<sup>5</sup>, F. Bartolini<sup>6</sup>, F. Ferrante<sup>7</sup>, A. Lupi<sup>8</sup>, S. Palcic<sup>9</sup>, F.V. Rizzi<sup>10</sup>, D. Re<sup>11</sup>, G.A. Nieto<sup>12</sup>, C. Hernandez<sup>12</sup>, V. Perrone<sup>13</sup>, L. Degli Esposti<sup>13</sup>, S. Fagioli<sup>14</sup>

<sup>1</sup>IRCCS- Ospedale Casa Sollievo Della Sofferenza, <sup>2</sup>Hepatology and Liver Transplantation Unit, Azienda Ospedaliero Universitaria, Udine, <sup>3</sup>Infectious Diseases Unit, University of Campania L. Vanvitelli, Naples, Italy, <sup>4</sup>Direttore Del Dipartimento Farmaceutico Della ASL BAT, <sup>5</sup>Uoc Assistenza Farmaceutica Territoriale, Azienda Ulss 8 Berica, <sup>6</sup>Direttore Dipartimento Farmaceutico-Usl Umbria 2, <sup>7</sup>Direttore Dipartimento Della diagnostica Ed Assistenza Farmaceutica - ASL Frosinone, Frosinone, Italia, <sup>8</sup>Direttore Di Struttura complessa Di Cardiologia - ASL Vco - Omega (VB), <sup>9</sup>Dirigente Della Farmaceutica Territoriale- Azienda Sanitaria Universitaria Integrata Giuliano-Isontina (ASUGI), <sup>10</sup>Dirigente Responsabile Uos Farmacovigilanza e Monitoraggio Spesa Farmaceutica- ASL BAT, <sup>11</sup>Servizio Farmaceutico Territoriale ASL Teramo, <sup>12</sup>Gilead Sciences, <sup>13</sup>Clicon S.r.l., Health Economics and Outcomes Research, <sup>14</sup>Gastroenterology and Transplant Hepatology, Papa Giovanni XXIII Hospital, Bergamo, Italy

**OP 20 13.22-13.27 HBeAg levels vary across the different phases of HBV infection, and can be predictive of therapeutic outcome in the setting of immunosuppression-driven HBV reactivation**

L. Piermatteo<sup>1</sup>, M. Alkhatib<sup>1</sup>, A. Bertoli<sup>1</sup>, D. Stella<sup>1</sup>, E. Basile<sup>2</sup>, A. Iuvara<sup>2</sup>, M. De Cristofaro<sup>3</sup>, G. Cappiello<sup>3</sup>, C. Cerva<sup>4</sup>, V. Malagnino<sup>4</sup>, C. Minichini<sup>5</sup>, M. Pisaturo<sup>5</sup>, M. Starace<sup>5</sup>, N. Coppola<sup>5</sup>, C. Fontana<sup>2</sup>, M. Angelico<sup>6</sup>, M. Andreoni<sup>4</sup>, L. Sarmati<sup>4</sup>, S. Grelli<sup>1,2</sup>, F. Ceccherini-Silberstein<sup>1</sup>, V. Svicher<sup>1</sup>, R. Salpini<sup>1</sup>

<sup>1</sup>University of Rome "Tor Vergata", Department of Experimental Medicine, Rome, Italy, <sup>2</sup>University Hospital of Rome "Tor Vergata", Microbiology and Virology Unit, Rome, Italy, <sup>3</sup>"Sandro Pertini" Hospital, Microbiology Unit, Rome, Italy, <sup>4</sup>University Hospital of Rome "Tor Vergata", Infectious Disease Unit, Rome, Italy, <sup>5</sup>University of Campania "Luigi Vanvitelli", Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, Naples, Italy, <sup>6</sup>University Hospital of Rome "Tor Vergata", Hepatology Unit, Rome, Italy

**OP 21 13.29-13.34 HCV knowledge and awareness among injecting drug users in the direct acting antivirals era**

A. Boschini<sup>1</sup>, P. Piselli<sup>2</sup>, C. Smacchia<sup>3</sup>, R. Paletti<sup>1</sup>, M. Begnini<sup>1</sup>, P. Ottogalli<sup>1</sup>, C. Cimaglia<sup>2</sup>, M.P. Parracino<sup>2</sup>, E. Girardi<sup>2</sup>

<sup>1</sup>Comunità San Patrignano, Rimini, <sup>2</sup>INMI "L. Spallanzani" IRCCS, Rome, <sup>3</sup>Servizio Dipendenza Patologiche Verona

**OP 22 13.36-13.41 A pilot intervention for HCV elimination among MSM in Rome: an update on more than 1200 screened individuals**

P. Piselli<sup>1</sup>, M. Giuliani<sup>2</sup>, M. Farinella<sup>3</sup>, C. Cimaglia<sup>1</sup>, A. Latini<sup>2</sup>, F. Carduccelli<sup>3</sup>, C. Ancona<sup>2</sup>, O. Bruzzi<sup>1</sup>, G. De Carli<sup>1</sup>, R. Esvan<sup>1</sup>, F. Gili<sup>1</sup>, M. Marra<sup>3</sup>, N. Orchi<sup>1</sup>, E. Piscitelli<sup>1</sup>, S. Pittalis<sup>1</sup>, A.R. Garbuglia<sup>1</sup>, A. Amendola<sup>1</sup>, S. Meschi<sup>1</sup>, S. Cicalini<sup>1</sup>, M. De Palo<sup>1</sup>, M. Zaccarelli<sup>1</sup>, E. Grilli<sup>1</sup>, G. Scarfò<sup>1</sup>, A. Puleio<sup>1</sup>, A. Antinori<sup>1</sup>, M.R. Capobianchi<sup>1</sup>, A. Cristaudo<sup>2</sup>, G. D'Offizi<sup>1</sup>, V. Puro<sup>1</sup>, E. Girardi<sup>1</sup>

<sup>1</sup>INMI "L. Spallanzani" IRCCS, Rome, <sup>2</sup>STI/HIV Unit, San Galliciano Dermatological Institute, IRCCS, Rome, <sup>3</sup>Circolo di Cultura Omosessuale "Mario Mieli", Rome, Italy

**OP 23 13.43-13.48 Humoral response to mRNA SARS-CoV-2 vaccine in cirrhotic patients without prior exposure to the virus**

C. Sorace, E. Biliotti, U. Visco, R. Lionetti, M. Montalbano, M. Depalo, A. Rianda, C. Taibi, C. Castillette, P. Galli, G. D'Offizi

INMI L.Spallanzani, Roma, Italia

**OP 24 13.50-13.55 Syphilis reinfection in people living with HIV (PLWH): a monocentric retrospective study**

G. Tiecco<sup>1</sup>, V. Marchese<sup>2</sup>, S. Storti<sup>1</sup>, M. Degli Antoni<sup>1</sup>, S. Amadasi<sup>2</sup>, M. Gulletta<sup>2</sup>, S. Calza<sup>3</sup>, F. Viola<sup>1</sup>, E. Focà<sup>1</sup>, F. Castelli<sup>1</sup>, E. Quirós-Roldán<sup>1</sup>

<sup>1</sup>Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali di Brescia, Italy, <sup>2</sup>Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali di Brescia, Italy, <sup>3</sup>Department of Molecular and Translational Medicine, University of Brescia, Italy

13.57-14.15 **Discussion**







Venerdì  
22 ottobre



re-search, for re-start  
together Riccione 21-23 Ottobre 2021

**ORAL POSTER** 13.15-14.15

**FOYER AUDITORIUM**

## Immunopathogenesis I

Chair: G. Liuzzi (Roma)

- OP 25** 13.15-13.20 **Decreased neutralization of the B.1.525 (Nigerian) SARS-CoV-2 variant by sera of previously infected and uninfected vaccinated individuals**  
*L. Vicenti<sup>1</sup>, F. Dragoni<sup>1</sup>, A. Boccutto<sup>1</sup>, A. Bergna<sup>2</sup>, C. Della Ventura<sup>2</sup>, F. Giammarino<sup>1</sup>, F. Saladini<sup>1</sup>, L. Pezzati<sup>3</sup>, G. Zehender<sup>2</sup>, M. Zazzi<sup>1</sup>, A. Lai<sup>2</sup>*  
<sup>1</sup>Department of Medical Biotechnologies, University of Siena, Siena, Italy, <sup>2</sup>Department of Biomedical and Clinical Sciences L. Sacco, University of Milan, Milan, Italy, <sup>3</sup>Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, Italy
- OP 26** 13.22-13.27 **Severity of COVID-19 patients predicted by serum sphingolipids signature**  
*E. Torretta<sup>1</sup>, M. Garziano<sup>2,3</sup>, M. Polisenò<sup>4</sup>, D. Capitanio<sup>5</sup>, M. Biasin<sup>3</sup>, T.A. Santantonio<sup>4</sup>, M. Clerici<sup>2,6</sup>, S. Lo Caputo<sup>4</sup>, D. Trabattoni<sup>3</sup>, C. Gelfi<sup>1,5</sup>*  
<sup>1</sup>IRCCS Orthopedic Institute Galeazzi, Milan, Italy, <sup>2</sup>Department of Pathophysiology and Transplantation, Milan, Italy, <sup>3</sup>Department of Biomedical and Clinical Sciences "L. Sacco", Milan, Italy, <sup>4</sup>Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy, <sup>5</sup>Department of Biomedical Sciences for Health, University of Milan, Segrate, Italy, <sup>6</sup>Don C. Gnocchi Foundation, IRCCS, Milano, Italy
- OP 27** 13.29-13.34 **Expansion of myeloid derived suppressor cells contribute to platelet activation by L-Arginine deprivation during SARS-CoV-2 infection**  
*A. Sacchi, G. Grassi, S. Notari, S. Gili, V. Bordoni, E. Tartaglia, R. Casetti, E. Cimini, D. Mariotti, G. Garotto, A. Beccacece, L. Marchioni, M. Bibas, E. Nicastri, G. Ippolito, C. Agrati*  
National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy
- OP 28** 13.36-13.41 **Cysteamine is an approved drug with antiviral and immunomodulatory properties promising for COVID-19 treatment**  
*T. Alonzi<sup>1</sup>, A. Aiello<sup>1</sup>, L. Petrone<sup>1</sup>, S. Najafi Fard<sup>1</sup>, M. D'Eletto<sup>2</sup>, L. Falasca<sup>1</sup>, R. Nardacci<sup>1</sup>, F. Rossini<sup>2</sup>, G. Delogu<sup>3,4</sup>, C. Castilletti<sup>1</sup>, M.R. Capobianchi<sup>1</sup>, G. Ippolito<sup>1</sup>, M. Piacentini<sup>1,2</sup>, D. Goletti<sup>1</sup>*  
<sup>1</sup>Istituto Nazionale per le Malattie Infettive "L. Spallanzani" IRCCS, <sup>2</sup>Department of Biology, University of Rome "Tor Vergata", <sup>3</sup>Institute of Microbiology, Università Cattolica del Sacro Cuore, Fondazione Policlinico Gemelli, <sup>4</sup>Water Olbia Hospital
- OP 29** 13.43-13.48 **High CD169 monocyte/lymphocyte ratio reflects the immuno-phenotyping disruption and predicts oxygen need in COVID-19 patients**  
*M. Fanelli<sup>1</sup>, V. Petrone<sup>1</sup>, A. Minutolo<sup>1</sup>, C. Maracchioni<sup>1</sup>, M. Iannetta<sup>2,3</sup>, M. Giudice<sup>1</sup>, I.A. Belkacem<sup>4,5</sup>, M. Zordan<sup>2,3</sup>, P. Vitale<sup>3</sup>, P. Sinibaldi Vallebona<sup>1,6</sup>, L. Sarmati<sup>2,3</sup>, M. Andreoni<sup>2,3</sup>, F. Malergue<sup>5</sup>, G. Rasi<sup>1</sup>, P. Di Francesco<sup>1</sup>, E. Balestrieri<sup>1</sup>, C. Matteucci<sup>1</sup>, S. Grelli<sup>1</sup>*  
<sup>1</sup>Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy, <sup>2</sup>Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy, <sup>3</sup>Infectious Diseases Clinic, Policlinic of Tor Vergata, Rome, Italy, <sup>4</sup>Aix Marseille Université, CNRS, INSERM, CIML, Centre d'Immunologie de Marseille-Luminy, Marseille, France, <sup>5</sup>Department of Research and Development, Beckman Coulter Life Sciences-ImmunoTech, Marseille, France, <sup>6</sup>Institute of Translational Pharmacology, National Research Council, Rome, Italy, <sup>7</sup>Virology Unit, Policlinic of Tor Vergata, Rome, Italy
- OP 30** 13.50-13.55 **Effect of SARS-CoV-2 sequences on immune response in A549-ACE2 lung cells**  
*G. Cappelletti<sup>1</sup>, S. Strizzi<sup>1</sup>, M. Saresella<sup>3</sup>, S. Musollino<sup>1</sup>, C. Fenizia<sup>1,2</sup>, D. Trabattoni<sup>1</sup>, M. Clerici<sup>2,3</sup>, R. Cagliani<sup>4</sup>, D. Forni<sup>4</sup>, M. Sironi<sup>4</sup>, M. Biasin<sup>1</sup>*  
<sup>1</sup>Dipartimento di Scienze Biomediche e Cliniche "L. Sacco", Milan, Italy, <sup>2</sup>Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Milan, Italy, <sup>3</sup>IRCCS Fondazione Don Carlo Gnocchi, Milan, Italy, <sup>4</sup>IRCCS Eugenio Medea, Milan, Italy

13.57-14.15 **Discussion**

**ORAL POSTER** 13.15-14.15

**FOYER AUDITORIUM**

## Epidemiology / Social Sciences I

Chair: A. Bianchi (Milano)

- OP 31** 13.15-13.20 **SARS-CoV-2 evolutionary dynamics in the first phase of the epidemic in Italy**  
*A. Lai<sup>1</sup>, A. Bergna<sup>1</sup>, S. Toppo<sup>2,3</sup>, M. Morganti<sup>4</sup>, S. Menzo<sup>5</sup>, V. Ghisetti<sup>6</sup>, B. Bruzzone<sup>7</sup>, M. Codeluppi<sup>8</sup>, V. Fiore<sup>9</sup>, E. Venanzi Rullo<sup>10</sup>, G. Antonelli<sup>11</sup>, L. Sarmati<sup>12</sup>, G. Brindicci<sup>13</sup>, A. Callegaro<sup>14</sup>, C. Sagnelli<sup>15</sup>, D. Francisci<sup>16</sup>, I. Vicenti<sup>17</sup>, A. Miola<sup>18</sup>, G. Tonon<sup>19,20</sup>, D. Cirillo<sup>21</sup>, I. Menozzi<sup>4</sup>, S. Caucchi<sup>5</sup>, F. Cerutti<sup>6</sup>, A. Orsi<sup>22</sup>, R. Schiavo<sup>23</sup>, S. Babudieri<sup>9</sup>, G. Nunnari<sup>10</sup>, C.M. Mastroianni<sup>24</sup>, M. Andreoni<sup>12</sup>, L. Monno<sup>13</sup>, D. Guarneri<sup>14</sup>, N. Coppola<sup>15</sup>, A. Crisanti<sup>25,26</sup>, M. Galli<sup>1</sup>, G. Zehender<sup>1</sup> and SCIRE- SARS-CoV-2 Italian Research Enterpri-*



32

Scientific Programme

13<sup>o</sup> CONGRESSO NAZIONALE Italian Conference on AIDS and Antiviral Research



### se-collaborative group

<sup>1</sup>Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy, <sup>2</sup>Department of Molecular Medicine University of Padova, Padua, Italy, <sup>3</sup>CIRI Biotech Center University of Padova, Padua, Italy, <sup>4</sup>Risk Analyses and Genomic Epidemiology Unit, Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna, Parma, Italy, <sup>5</sup>Department of Biomedical Sciences and Public Health, Virology Unit, Polytechnic University of Marche, Ancona, Italy, <sup>6</sup>Laboratory of Microbiology and Virology, Amedeo di Savoia, ASL Città di Torino, Torino, Italy, <sup>7</sup>Hygiene Unit, IRCCS AOU San Martino-IST, Genoa, Italy, <sup>8</sup>UOC of Infectious Diseases, Department of Oncology and Hematology, Guglielmo da Saliceto Hospital, AUSL Piacenza, Italy, <sup>9</sup>Infectious and Tropical Disease Clinic, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy, <sup>10</sup>Unit of Infectious Diseases, Department of Experimental and Clinical Medicine, University of Messina, Messina, Italy, <sup>11</sup>Department of Molecular Medicine, University Hospital Policlinico Umberto I, Sapienza University of Rome, Rome, Italy, <sup>12</sup>Infectious Diseases, Tor Vergata University, Rome, Italy, <sup>13</sup>Infectious Diseases Unit, University of Bari, Bari, Italy, <sup>14</sup>Microbiology and Virology Laboratory, ASST Papa Giovanni XXIII, Bergamo, Italy, <sup>15</sup>Department of Mental Health and Public Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy, <sup>16</sup>Department of Medicine and Surgery, Clinic of Infectious Diseases, "Santa Maria della Misericordia" Hospital, University of Perugia, Perugia, Italy, <sup>17</sup>Department of Medical Biotechnologies, University of Siena, Siena, Italy, <sup>18</sup>Intesa San Paolo Innovation Center-AI LAB, Turin, Italy, <sup>19</sup>Center for Omics Sciences, IRCCS Ospedale San Raffaele, Milan, Italy, <sup>20</sup>Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy, <sup>21</sup>Division of Immunology, Transplantation and Infectious Disease, IRCCS Ospedale San Raffaele, Milan, Italy, <sup>22</sup>Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, <sup>23</sup>UOC of Microbiology, Department of Clinical Pathology, Guglielmo da Saliceto Hospital, AUSL Piacenza, Italy, <sup>24</sup>Department of Public Health and Infectious Diseases, University Hospital Policlinico Umberto I, Sapienza University of Rome, Rome, Italy, <sup>25</sup>Microbiology and Virology Diagnostic Unit Padua University Hospital, Padua, Italy, <sup>26</sup>Department of Life Science Imperial College London South Kensington Campus Imperial College Road SW7 AZ London, United Kingdom, UK

### OP 32 13.22-13.27 Characterization of SARS-CoV-2 variants circulating in Central Italy by deep-sequencing of full-length S gene

M.C. Bellocchi<sup>1</sup>, R. Scutari<sup>1</sup>, L. Carioti<sup>1</sup>, M. Iannetta<sup>2</sup>, L. Piermatteo<sup>1</sup>, M. Botticelli<sup>1</sup>, M. Alkhatib<sup>1</sup>, S. Tedde<sup>2</sup>, L. Duca<sup>1</sup>, V. Malagnino<sup>2</sup>, A. Crea<sup>2</sup>, L. Ansaldo<sup>2</sup>, E. Teti<sup>2</sup>, L. Coppola<sup>2</sup>, S. D'Anna<sup>1</sup>, A. Bertoli<sup>1</sup>, A. Di Lorenzo<sup>2</sup>, P. Paba<sup>2</sup>, P. Saccomandi<sup>1</sup>, R. Salpini<sup>1</sup>, V. Svicher<sup>1</sup>, L. Sarmati<sup>2</sup>, M. Andreoni<sup>2</sup>, F. Ceccherini-Silberstein<sup>1</sup> for the PTV-ID-COVID Group

<sup>1</sup>University of Rome Tor Vergata, Rome, Italy, <sup>2</sup>University Hospital of Rome "Tor Vergata", Rome, Italy

### OP 33 13.29-13.34 Impact of COVID pandemic and anti-SARS-CoV-2 immunization on vaccination against sexually transmitted infections

R. Rossotti<sup>1,2</sup>, C. Baiguera<sup>1</sup>, M.C. Moiola<sup>1</sup>, D. Calzavara<sup>2</sup>, C. Rogati<sup>1</sup>, P. Vinti<sup>2</sup>, L. Brunelli<sup>1</sup>, L. Rezzonico<sup>1</sup>, M. Cernuschi<sup>2,3</sup>, M. Puoti<sup>1</sup>

<sup>1</sup>ASST Grande Ospedale Metropolitano Niguarda, Milan, <sup>2</sup>Milano Checkpoint, Milan, <sup>3</sup>IRCCS San Raffaele Scientific Institute, Milan

### OP 34 13.36-13.41 Influenza vaccine: knowledge and beliefs among adherent PLWH during the first seasonal campaign of the COVID-19 era

V. Marchese, S. Storti, G. Tiecco, M. Degli Antoni, F. Viola, C. Morganti, F. Castelli, E. Focà, E. Quiros-Roldan

Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali di Brescia

### OP 35 13.43-13.48 Results of a SARS-CoV-2 worker screening in the Marche Nord companies to prevent virus infection in the workplace

C. Orlandi<sup>1</sup>, D. Betti<sup>1</sup>, B. Borghi<sup>2</sup>, A. Baroni<sup>2</sup>, M. Papalini<sup>2</sup>, M. Magnani<sup>1</sup>, A. Casabianca<sup>1</sup>

<sup>1</sup>Department of Biomolecular Sciences, University of Urbino "Carlo Bo", <sup>2</sup>Confindustria Pesaro Urbino

### OP 36 13.50-13.55 A mixed method of follow-up with total patient care provided continuum with saving of hospital checks during the COVID-19 pandemic

P. Fusco<sup>1</sup>, M. Mazzitelli<sup>1,2</sup>, F. Serapide<sup>1,3</sup>, V. Scaglione<sup>1,3</sup>, R. Lionello<sup>1,3</sup>, C. Davoli<sup>1</sup>, M.T. Tassone<sup>1</sup>, V. La Gamba<sup>1</sup>, E.M. Trecarichi<sup>1,3</sup>, C. Costa<sup>3</sup>, C. Torti<sup>1,3</sup>

<sup>1</sup>University "Magna Graecia", Catanzaro, <sup>2</sup>Unit of Infectious Diseases, "Azienda Ospedale Università Padova", Padova, <sup>3</sup>Unit of Infectious Diseases, "Mater Domini" Hospital, Catanzaro

13.57-14.15 Discussion

## ORAL POSTER 13.15-14.15

### Epidemiology / Social Sciences II

Chairs: M. Breveglieri (Bologna), T.S. Prestileo (Palermo)

## FOYER AUDITORIUM

### OP 37 13.15-13.20 HIV-related internalized stigma and patient health engagement (PHE) model in an Italian cohort of people living with HIV

V. Massaroni<sup>1</sup>, V. Delle Donne<sup>1</sup>, N. Ciccarello<sup>2</sup>, F. Lombardi<sup>3</sup>, S. Lamonica<sup>3</sup>, A. Borghetti<sup>3</sup>, A. Ciccullo<sup>4</sup>, S. Di Giambenedetto<sup>1,3</sup>

<sup>1</sup>Infectious Diseases Institute, Department of Safety and Bioethics, Catholic University of Sacred Heart, Rome, Italy, <sup>2</sup>Department of Psychology, Catholic University, Milan, Italy, <sup>3</sup>UOC Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, <sup>4</sup>UOC Infectious Diseases, Ospedale S. Salvatore, L'Aquila, Italy

### OP 38 13.22-13.27 Talking about stigma and HIV prevention, the artists' contribution

G. Dessì, V. Mascia, B. Mocci

Lila Cagliari OdV, Cagliari





Venerdì  
22 ottobre



re-search, for re-start  
together

Riccione 21-23 Ottobre 2021

**OP 39 13.29-13.34 A visual scale to evaluate the quality of life in PLWHA. Fourth-90, utopia or reality?**

F. Paciosi<sup>1</sup>, C. Palotto<sup>2</sup>, A. Lanzi<sup>1</sup>, C. Papalini<sup>2</sup>, M.B. Pasticci<sup>3</sup>, D. Francisci<sup>1</sup>

<sup>1</sup>Infectious Diseases Clinic, Department of Medicine and Surgery, University of Perugia, Perugia, Italy, <sup>2</sup>Infectious Diseases Clinic, General Hospital of Perugia, Perugia, Italy, <sup>3</sup>Infectious Diseases Clinic, Department of Medicine and Surgery, University of Perugia, Terni, Italy

**OP 40 13.36-13.41 Health-related quality of life (HRQoL) from HIV patients' perspective: comparison of patients-reported outcome (PRO) measures among people living with HIV (PLWH) and other chronic clinical conditions**

C. Seguiti<sup>1,2</sup>, P.F. Salvo<sup>1</sup>, E. Di Stasio<sup>3,4</sup>, S. La Monica<sup>2</sup>, A.L. Fedele<sup>5</sup>, S. Manfrida<sup>6</sup>, N. Ciccarelli<sup>7</sup>, B. Corvari<sup>6</sup>, C. De Luca<sup>3</sup>, L. Tartaglione<sup>8</sup>, D. Pitocco<sup>8</sup>, R. Cauda<sup>1,2</sup>, A. Cingolani<sup>1,2</sup>

<sup>1</sup>Malattie Infettive, Università Cattolica S. Cuore, Roma, <sup>2</sup>UOC Malattie Infettive, Fondazione Policlinico A. Gemelli IRCCS, Roma, <sup>3</sup>UOC Chimica, Biochimica e Biologia Molecolare Clinica, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma, <sup>4</sup>Dipartimento di Scienze biotecnologiche di base, cliniche intensivologiche e perioperatorie, Università Cattolica del Sacro Cuore, Roma, <sup>5</sup>Divisione Reumatologia, Fondazione Policlinico A. Gemelli IRCCS, Roma, <sup>6</sup>Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Pol. A. Gemelli IRCCS, Roma, <sup>7</sup>Dipartimento di Psicologia, Università Cattolica, Milano, <sup>8</sup>UOS Diabetologia, Fondazione Policlinico A. Gemelli IRCCS, Roma

**OP 41 13.43-13.48 Using technology to support vulnerable PLWHIV at the time of coronavirus**

S. Patrucco<sup>1</sup>, P. Altini<sup>1</sup>, G.L. Ciperò<sup>1</sup>, C. Di Chio<sup>1</sup>, S. Maneo<sup>1</sup>, G. Orofino<sup>2</sup>, A. Perziano<sup>1</sup>

<sup>1</sup>ARCOBALENO Aids ODV Torino, <sup>2</sup>Ospedale Amedeo di Savoia Torino - ARCOBALENO Aids ODV Torino

**OP 42 13.50-13.55 Impact of SARS-CoV-2 pandemic on quality of life in people with HIV**

M. Fois, A. De Vito, B. Zauli, A. Colpani, M.C. Meloni, F. Seddone, S. Babudieri, G. Madeddu

Unit of Infectious Diseases, Department of Medical, Surgical, and Experimental Sciences, University of Sassari, Sassari, Italy

13.57-14.15 **Discussion**

**EXPERT MEETING 13.15-14.15**

**ROOM 3**

Con la sponsorizzazione non condizionante di Gilead Sciences

**ICONA-PROs in the real-life setting**

Chairs: A. Cingolani (Roma), A. d'Arminio Monforte (Milano)

As infection with the Human Immunodeficiency Virus (HIV) has evolved into a chronic disease there is a strong rationale for evaluating the impact of antiretroviral therapies on broader aspects of patient's lives, including psychological, symptoms, functioning, well-being, satisfaction, etc. and the impact on the patient. Therefore, perceived health-related quality of life (HRQoL) became a prominent and important patient-reported outcomes (PROs) measure in HIV care, defined as any report of the status that comes directly from the patient without interpretation by a clinician or anyone else. This is particularly true in a cohort setting such as ICONA which decided to launch a new project devoted to HRQoL and PROs including the QoL APP, created to better respond to requests of effective digital tool to collect measures of patient-reported outcomes.

13.15 - 13.20 **Introduction**

Antonella Cingolani, Roma; Antonella d'Arminio Monforte, Milano

13.20 - 13.30 **The ICONA QoL Project: rationale, objectives**

Antonella d'Arminio Monforte, Milano

13.30 - 13.40 **Measure the HIV Quality of Life through patient-reported outcomes (PROs)**

Antonella Cingolani, Roma

13.40-14.00 **Digital technologies to support the patient: the new ICONA QoL APP**

Iuri Fanti, Roma; Alessandro Tavelli, Milano

14.00 - 14.15 **Questions & Answers**



34

Scientific Programme

13<sup>o</sup> CONGRESSO NAZIONALE Italian Conference on AIDS and Antiviral Research



## SPONSORED SYMPOSIUM 14.15-15.15

## AUDITORIUM CONCORDIA

Con la sponsorizzazione di Gilead Sciences

### Continuous innovation for long-term treatment success

Chair: S. Rusconi (Milano)

The advent of antiretroviral therapy (ART), once-daily single tablet regimens (STRs) combining efficacy and long-term safety in a simpler and simpler way, represents some of the most significant milestones that have helped bring radical change in the outlook for people living with HIV. However, there are still some clinical and virological needs in the achievement of the long-term treatment success. The Symposium is designed both to rethink the determinants of long-term treatment success and take a look to the present and future therapeutic options. It's a matter of quality or quantity?

14.15 - 14.20	<b>Introduction</b>	Stefano Rusconi, Milano
14.20 - 14.40	<b>Driving Innovation</b>	Felipe Rogatto, Londra UK
14.40 - 14.50	<b>Clinical and virological debate: what is meant by long-term treatment success from a virological point of view?</b>	Carlo Federico Perno, Roma
14.50 - 15.00	<b>Clinical and virological debate: what is meant by long-term treatment success from a clinical point of view?</b>	Massimo Andreoni, Roma
15.00 - 15.10	<b>Today's choices for the long treatment success</b>	Sergio Lo Caputo, Foggia
15.10 - 15.15	<b>Take-home messages</b>	Stefano Rusconi, Milano

## ORAL COMMUNICATIONS 14.15-15.15

## POLISSENA A HALL

### Epidemiology / Social Sciences II

Chairs: A. Cascio (Palermo), A. Colucci (Roma)

#### OC 15 14.15-14.25 Correlates of treatment and disease burden in PLWH in Italy

A. Cingolani<sup>1</sup>, A. Tavelli<sup>2</sup>, F. Maggiolo<sup>3</sup>, V. Calvino<sup>4</sup>, A. Di Biagio<sup>5</sup>, A.M. Cattelan<sup>6</sup>, L. Sighinolfi<sup>7</sup>, G. Marchetti<sup>8</sup>, S. Nozza<sup>9</sup>, R. Rossotti<sup>10</sup>, A. d'Arminio Monforte<sup>8</sup>, A. Antinori<sup>11</sup>, on behalf of Icona Network

<sup>1</sup>Fondazione Policlinico Universitario A. Gemelli - Università Cattolica Del Sacro Cuore, Roma, <sup>2</sup>Fondazione Icona, Milano, <sup>3</sup>ASST Papa Giovanni XXIII, Bergamo, <sup>4</sup>ANLAIDS Onlus, Roma, <sup>5</sup>Ospedale San Martino, Genova, <sup>6</sup>Azienda Ospedaliera Padova, <sup>7</sup>Azienda Ospedaliera Ferrara, <sup>8</sup>Università di Milano, ASST Santi Paolo e Carlo, Milano, <sup>9</sup>HSR San Raffaele IRCCS, Milano, <sup>10</sup>ASST Niguarda "Ca Granda", Milano, <sup>11</sup>IRCCS L. Spallanzani INMI, Roma

#### OC 16 14.27-14.37 The fourth "95" is at reach

F. Maggiolo<sup>1</sup>, R. Teocchi<sup>1</sup>, P. Meli<sup>2</sup>, D. Valenti<sup>3</sup>, F. Radici<sup>4</sup>, I. Mercurio<sup>5</sup>, A.P. Callegaro<sup>1</sup>

<sup>1</sup>ASST Papa Giovanni XXIII, <sup>2</sup>Comunità Emmaus & Caritas Bergamasca, <sup>3</sup>Associazione FROM, <sup>4</sup>Arcigay Bergamo Cives, <sup>5</sup>CRI-Comitato di Bergamo, Bergamo

#### OC 17 14.39-14.49 Narratives of HIV-positive patients in the DIAMANTE study

A. Antinori<sup>1</sup>, D. Ripamonti<sup>2</sup>, V. Esposito<sup>3</sup>, S. Rusconi<sup>4,5</sup>, A. Cascio<sup>6</sup>, E. Manzillo<sup>7</sup>, M. Andreoni<sup>8</sup>, G. Orofino<sup>9</sup>, A. Cappuccio<sup>10</sup>, L. Reale<sup>10</sup>, M.G. Marini<sup>10</sup>, D. Mancusi<sup>11</sup>, A. Uglietti<sup>11</sup>, M. Portaro<sup>11</sup>, R. Termini<sup>11</sup>

<sup>1</sup>National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS HIV/AIDS Department Roma, Italy, <sup>2</sup>Infectious Diseases Clinic, Papa Giovanni XXIII Hospital, Bergamo, Italy, <sup>3</sup>Infectious Diseases and Gender Medicine Unit, D. Cotugno Hospital - AO dei Colli - Naples, Italy, <sup>4</sup>Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Milan, Italy, <sup>5</sup>Infectious Diseases Unit, Legnano Hospital ASST Ovest Milanese, <sup>6</sup>Infectious Diseases Clinic, AOU Policlinico "P. Giaccone", Palermo, Italy, <sup>7</sup>Infectious Disease and Infectious Emergencies, Azienda Ospedaliera dei Colli, Naples, Italy, <sup>8</sup>Infectious Diseases Clinic, Fondazione Policlinico Tor Vergata University Hospital, Rome, Italy, <sup>9</sup>Amedeo di Savoia Hospital Unit of Infectious Diseases Torino, Italy, <sup>10</sup>ISTUD Foundation, Milan, Italy, <sup>11</sup>Medical Affairs Department, Infectious Diseases and Vaccines, Janssen-Cilag SpA, Cologno Monzese, Italy

#### OC 18 14.51-15.01 A telephone-based multidimensional interview in elderly people living with HIV from the GEPPCO cohort

M. Ferrara<sup>1</sup>, J. Milic<sup>2</sup>, L. Micai<sup>1</sup>, S. Barbieri<sup>2</sup>, E. Aprile<sup>2</sup>, M. Belli<sup>2</sup>, M. Venuta<sup>2</sup>, S. Arsuffi<sup>3</sup>, C. Fornari<sup>3</sup>, E. Focà<sup>3</sup>, G. Di Perri<sup>1</sup>, S. Bonora<sup>1</sup>, G. Guaraldi<sup>2</sup>, A. Calcagno<sup>1</sup>

<sup>1</sup>Department of Infectious Diseases, University of Torino and "Amedeo di Savoia" Hospital, Turin, Italy, <sup>2</sup>Infectious Diseases Clinic, Department of Medical Specialties, University of Modena and Reggio Emilia, Modena, Italy, <sup>3</sup>Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy for the GEPPCO Cohort





Venerdì  
22 ottobre



re-search, for re-start  
together Riccione 21-23 Ottobre 2021

**EXPERT MEETING** 14.15-15.15

**POLISSENA B HALL**

**Hyperinflammation and COVID-19: from research to clinical practice**

Chairs: A. Cossarizza (Modena), A. Gori (Milano)

*The natural history of COVID-19 includes an initial stage of viral replication that can be followed by a second stage of immunopathology driven by a hyperinflammatory response to SARS-CoV-2 infection. This is characterized by excessive release of pro-inflammatory cytokines (i.e. IL-1, IL-6, IL-8, TNF, GM-CSF, and IFN-g). This increasing evidence has prompted the investigation of immunomodulatory therapies in order to 1) attenuate the exaggerated immune response of the host; 2) identify the most appropriate immunomodulating strategies; 3) the optimal timing of such interventions, and achieve the more robust clinical benefits in patients with COVID-19.*

14.15 -14.20 **Introduction**

14.20 -14.35 **COVID-19 and IL-1, targeting the inflammatory cascade**

Giulio Cavalli, Milano

14.35 -14.50 **Tracing the pathway to the SAVE-MORE study results**

Emanuele Nicastrì, Roma

14.50 -15.05 **On the way to real-world experiences**

Alessandra Bandera, Milano

15.05 -15.15 **Questions & Answers**

**SYMPOSIUM** 15.20-16.20

**AUDITORIUM CONCORDIA**

**Behavioral and social impact of COVID-19 in PLWH**

Chairs: P. Meli (Bergamo), A. Saracino (Bari)

*COVID-19 has heavily impacted the lives of PLHIV for a number of different reasons, ranging from the difficulty in accessing infectious disease units and keeping in contact with their doctors, to changes in relational and behavioural habits - traumas to which people with HIV have been exposed in the past. Prolonged periods of lockdown, social distancing, forced isolation and being in the condition to transmit a virus to others again have evoked old fears. COVID-19 has also highlighted and increased health inequalities: vulnerable people have to struggle to take care of basic needs such as food and shelter, while little has been done to ensure equity and address the health and socioeconomic disparities of vulnerable communities. This symposium tries to shed some light on these different aspects.*

15.20 - 15.25 **Introduction**

15.25 - 15.40 **Health inequalities in the COVID-19 era**

Vito Peragine, Bari

15.40 - 15.55 **Mental health in the COVID era**

Amalia Bove, Roma; Annalisa Perziano, Torino

15.55 - 16.10 **Role of digital technologies (telemedicine): pro and cons**

Francesco Gabbrielli, Roma; Filippo von Schloesser, Roma

16.10 - 16.20 **Discussion on Symposium issues**



36

Scientific Programme

13° CONGRESSO NAZIONALE **Italian Conference** on **AIDS** and **Antiviral Research**



**EXPERT MEETING** 15.20-16.20

**POLISSENA A HALL**

**Monoclonal antibodies and their role in COVID-19 patients: results and perspectives**

Chair: M.S. Clerici (Milano)

The development of therapeutic monoclonal antibodies is currently at the front line of fighting against the COVID-19 pandemic. However, the emergence and proliferation of SARS-CoV-2 variants conferring resistance to some antibodies is deeply concerning. Furthermore, as additional variants of concern will likely continue to emerge, there is a high unmet medical need for therapeutics that, alone or in combination, can remain effective as the virus evolves. The Expert Meeting will present the state of the art of virological research against COVID-19 with a look at the promising clinical data emerging from the use of monoclonal antibodies and the most recent clinical experiences in the field.

15.20 -15.25 **Introduction**

15.25 -15.35 **From viral pathophysiology to symptoms: rational, candidates, results of early treatment of COVID-19**

Stefano Bonora, Torino

15.35 -15.45 **Emerging SARS-CoV-2 variants and their impact in pandemics therapy**

Carlo Federico Perno, Roma

15.45 -15.55 **Fighting COVID-19 with neutralizing monoclonal antibodies: the importance of high barrier to resistance**

Andrea Antinori, Roma

15.55 -16.05 **The journey of COVID-19 patients: experiences of clinical practice**

Sergio Lo Caputo, Foggia

16.05 -16.20 **Discussion**

**EXPERT MEETING** 15.20-16.20

**POLISSENA B HALL**

Con la sponsorizzazione non condizionante di ViiV Healthcare

**Roundtable "New treatment options for heavily pretreated patients"**

Discussants: A. Castagna (Milano), F. Maggiolo (Bergamo), G. Marchetti (Milano), C. Mussini (Modena)

Patients with multidrug-resistant HIV currently make up a smaller but still challenging part of the population living with HIV. Challenges with tolerability, safety, and drug-to-drug interactions may further decrease the number of acceptable antiretroviral therapies available to design effective treatment regimens. There remains an unmet need for these individuals who are considered heavily treatment-experienced (HTE) and who are unable to successfully suppress their HIV. Until the past couple of years, there were a limited number of targets on the human immunodeficiency virus that could be hit by available medications. Recently, several new targets have emerged: the Experts will review the clinical data obtained with the different strategies pursued in this clinical setting.







Venerdì  
22 ottobre



re-search, for re-start  
together Riccione 21-23 Ottobre 2021

## SYMPOSIUM 16.25-17.25

### SARS-CoV-2 infection in persons living with HIV

Chairs: A. Calcagno (Torino), A. De Rossi (Padova)

Despite several reports have been produced that investigate COVID-19 in HIV-infected patients, there is still no consensus whether HIV+ individuals do indeed display a most severe disease course as compared to HIV-uninfected peers. Likewise, given the HIV- driven immune dysfunction, not much is known about the immune response to COVID-19 vaccination in HIV+ patients. The most recent data describing COVID-19 clinical and immunological correlates in persons living with HIV (PLWH) will be presented within this Symposium, together with data describing the immunologic response to COVID-19 vaccination in this group of patients. Retention in care has long been considered a major goal in the best management of PLWH, that has been suggested to be potentially overhung by shifts in clinical efforts towards COVID-19 patients. The Symposium will approach the most recent findings describing retention in care in PLWH during COVID-19 pandemic as well as strategies to most efficaciously support it.

16.25 - 16.30 **Introduction**

16.30 - 16.45 **Impact of HIV and comorbidities in COVID-19 clinical course**

Anna Maria Geretti, Roma

16.45 - 17.00 **HIV and SARS-CoV-2: two viruses challenging the immune system**

Chiara Agrati, Roma

17.00 - 17.15 **Retention in care during COVID-19 pandemic**

Enrico Girardi, Roma; Filippo von Schloesser, Roma

17.15 - 17.25 **Discussion on Symposium issues**

## AUDITORIUM CONCORDIA

## EXPERT MEETING 16.25-17.25

Sponsorizzato da Janssen-Cilag

### Vaccines roadmap: the humanity game-changer

Chair: A.M. Cattelan (Padova)

History is characterized by epidemic and pandemic, documented since the second century with the Antonine plague, caused by unknown pathogenic that over the years we have been able to better know and manage. The crucial course that revolutionized the humanity history saving billion of lives from certain death began with the smallpox vaccine. The scientific progress made possible the eradication of some infections that nowadays belong to the past. The aim of the Expert Meeting is to deepen the knowledge on epidemiologic and clinical data, looking at how the vaccines can still make the difference in managing the HIV and SARS-CoV 2 pandemics.

16.25-16.30 **Introduction**

Anna Maria Cattelan, Padova

16.30-16.45 **Epi-pills: deep dive on vaccine studies**

Benedetto Simone, Zurigo

16.45-17.00 **HIV Vaccine: a long path**

Antonella Castagna, Milano

17.00 - 17.15 **COVID-19 Vaccine: dynamic journey**

Paolo Bonanni, Firenze

## POLISSENA A HALL

## ORAL COMMUNICATIONS 16.25-17.25

### Antiretroviral Therapy I

Chair: E.M. Erne (Bolzano)

#### OC 19 16.25-16.35 Trajectories of CD4/CD8 ratio at 96 weeks after switch to dolutegravir-based dual therapies in a multicentre cohort of ART- experienced patients

L. Taramasso<sup>1</sup>, A. Falletta<sup>2</sup>, A. Di Biagio<sup>2</sup>, E. Ricci<sup>3</sup>, G. Orofino<sup>4</sup>, N. Squillace<sup>5</sup>, B. Menzaghi<sup>6</sup>, G.V. De Socio<sup>7</sup>, C. Molteni<sup>8</sup>, G.F. Pellicanò<sup>9</sup>, R. Gulminetti<sup>10</sup>, G. Madeddu<sup>11</sup>, E. Sarchi<sup>12</sup>, F. Vichi<sup>13</sup>, B.M. Ceselia<sup>14</sup>, P. Bonfanti<sup>15</sup> on behalf of CISAI study group

<sup>1</sup>Infectious Diseases Unit, Policlinico Hospital San Martino, Genova, Italy, <sup>2</sup>Department of Health Sciences (DISSAL), University of Genova, Genova, Italy, <sup>3</sup>Fondazione A.S.I.A. Onlus, <sup>4</sup>Division I of Infectious and Tropical Diseases, ASL Città di Torino, <sup>5</sup>Infectious Diseases Unit ASST-MONZA, San Gerardo Hospital- University of Milano-Bicocca, Monza, <sup>6</sup>Unit of Infectious Diseases, ASST della Valle Olona – Busto Arsizio (VA), <sup>7</sup>Department of Internal Medicine 2, Infectious Diseases Unit, Perugia "Santa Maria della Misericordia" General Hospital, <sup>8</sup>Infectious Diseases Unit, Ospedale A. Manzoni, Lecco, Italy, <sup>9</sup>Department of Human Pathology of the Adult and the Developmental Age "G. Barresi", Unit of Infectious Diseases, University of Messina, Messina, Italy, <sup>10</sup>Department of Medical Sciences and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo -University of Pavia, <sup>11</sup>Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, <sup>12</sup>Infectious Diseases Unit, S. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy, <sup>13</sup>Infectious Diseases Unit, Santa Maria Annunziata Hospital, Bagno a Ripoli, Florence, Italy, <sup>14</sup>Unit of Infectious Diseases University of Catania ARNAS Garibaldi Catania, <sup>15</sup>Unit of Infectious Diseases, Department of Graduated Medical Care, Sanremo Hospital, Sanremo, Italy, <sup>16</sup>Infectious Diseases Unit, University of Bari, Bari, Italy, <sup>17</sup>Infectious Diseases Unit, SS Trinità Hospital, Cagliari, Italy

## POLISSENA B HALL



38

Scientific Programme

13° CONGRESSO NAZIONALE Italian Conference on AIDS and Antiviral Research



**OC 20 16.37-16.47 Increasing Trend of Pretreatment Integrase Inhibitors Resistance in a Cohort of Antiretroviral Therapy-Naïve People Living with HIV**

C. Muccini<sup>1,2</sup>, F. Fama<sup>2</sup>, L. Galli<sup>1</sup>, A. Poli<sup>1</sup>, A. Mastrangelo<sup>2</sup>, F. Badalucco<sup>2</sup>, M. Sampaolo<sup>3</sup>, A. Castagna<sup>1,2</sup>, D. Canetti<sup>1</sup>

<sup>1</sup>Clinic of Infectious Diseases, IRCCS San Raffaele, Milano, Italy, <sup>2</sup>Vita-Salute San Raffaele University, Milano, Italy, <sup>3</sup>Laboratory of Microbiology and Virology, IRCCS San Raffaele, Milano, Italy

**OC 21 16.49-16.59 Role of genotypic testing results for predicting virological failure in persons living with HIV with HIV-RNA ≤50 copies/mL who require an ART switch**

A. Cozzi-Lepri<sup>1</sup>, B. Rossetti<sup>2</sup>, F. Incardona<sup>3,4</sup>, G. Di Teodoro<sup>5,3</sup>, D. Di Carlo<sup>6</sup>, M. Prosperi<sup>7</sup>, A. Shallvari<sup>3</sup>, M. Böhm<sup>8</sup>, C. Seguin-Devaux<sup>9</sup>, M. Zazzi<sup>10</sup>, M.M. Santoro<sup>11</sup>, on behalf of EuResist Network

<sup>1</sup>University College London, IGH, London, United Kingdom, <sup>2</sup>University Hospital of Siena, Infectious Diseases Unit, Siena, Italy, <sup>3</sup>EuResist Network GEIE, Rome, Italy, <sup>4</sup>InformaPRO, Rome, Italy, <sup>5</sup>La Sapienza University, Computer Control and Management Engineering Antonio Ruberti, Rome, Italy, <sup>6</sup>L. Sacco Hospital, Centro di Ricerca Pediatrica "Romeo ed Enrica Invernizzi", Milan, Italy, <sup>7</sup>University of Florida, Data Intelligence Systems Lab (DISL), Gainesville, United States, <sup>8</sup>University Clinics of Cologne, Institute of Virology, Cologne, Germany, <sup>9</sup>Luxembourg Institute of Health, Infection and Immunity, Luxembourg, Luxembourg, <sup>10</sup>University of Siena, Department of Medical Biotechnology, Siena, Italy, <sup>11</sup>University of Rome "Tor Vergata", Department of Experimental Medicine, Roma, Italy

**OC 22 17.01-17.11 Evaluation of virological response and resistance profile in virologically suppressed HIV-1 infected individuals switching to a bictegravir based regimen in a real-life setting**

D. Armenia<sup>1</sup>, F. Forbici<sup>2</sup>, A. Bertoli<sup>3,4</sup>, G. Berno<sup>2</sup>, V. Malagnino<sup>4</sup>, R. Gagliardini<sup>2</sup>, V. Borghi<sup>5</sup>, W. Gennari<sup>5</sup>, S. Cicalini<sup>2</sup>, A. Buonomini<sup>6</sup>, E. Teti<sup>4</sup>, S. Lanini<sup>2</sup>, A. Latini<sup>6</sup>, L. Sarmati<sup>4</sup>, C. Mussini<sup>5</sup>, M. Andreoni<sup>4</sup>, A. Antinori<sup>2</sup>, C.F. Perno<sup>7</sup>, M.M. Santoro<sup>3</sup>, F. Ceccherini-Silberstein<sup>3</sup>

<sup>1</sup>Saint Camillus International University of Health Sciences, Rome, Italy, <sup>2</sup>National Institute for Infectious Diseases L. Spallanzani, IRCCS, <sup>3</sup>University of Rome "Tor Vergata", <sup>4</sup>Polyclinic of Rome "Tor Vergata", Rome, Italy, <sup>5</sup>Polyclinic of Modena, Modena, Italy, <sup>6</sup>San Gallicano Dermatological Institute, IRCCS, Rome, Italy, <sup>7</sup>Bambino Gesù Children's Hospital, Rome, Italy

**OC 23 17.13-17.23 Evaluation of total HIV-DNA and residual viremia in HIV-1 infected individuals enrolled on the Be-OnE study who continue a two-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide: results over 96 weeks**

M.M. Santoro<sup>1</sup>, N. Gianotti<sup>2</sup>, L. Galli<sup>2</sup>, R. Scutari<sup>1</sup>, C. Alteri<sup>3</sup>, A. Poli<sup>2</sup>, L. Piermatteo<sup>1</sup>, A. Bigoloni<sup>2</sup>, C.F. Perno<sup>4</sup>, A. Lazzarin<sup>2</sup>, F. Ceccherini-Silberstein<sup>1</sup>, A. Castagna<sup>2,5</sup>

<sup>1</sup>University of Rome "Tor Vergata", Rome, <sup>2</sup>Infectious Diseases, IRCCS San Raffaele, Milan, <sup>3</sup>University of Milan, Milan, <sup>4</sup>Bambino Gesù Children's Hospital, IRCCS, Rome, Italy, <sup>5</sup>Vita-Salute San Raffaele University, Milan

**ORAL COMMUNICATIONS 16.25-17.25**

**ROOM 3**

**Epidemiology / Social Sciences III**

Chairs: B.M. Celesia (Catania), B. Suligoi (Roma)

16.25-16.40 **Breastfeeding: the ultimate U=U's goal?**

Maria Grazia Di Benedetto, Catania

**OC 24 16.40-16.50 From U = U to breastfeeding of women with viro-suppressed HIV**

T. Prestileo<sup>1,2</sup>, A. Sanfilippo<sup>1</sup>, L. Di Marco<sup>3,2</sup>, Team I Ta C A Immigrant Take Care Advocacy Team<sup>2</sup>, A. Argo<sup>4</sup>

<sup>1</sup>Infectious Disease Unit & Centre for Migration and Health, ARNAS Civico Di Cristina Benfratelli Hospital, Palermo, Italy, <sup>2</sup>ANLAIDS (Associazione Nazionale per la Lotta all'AIDS) Sicilia, Palermo, Italy, <sup>3</sup>Gastroenterology Unit, Department of Medical Specialties, University of Modena & Reggio Emilia and Azienda Ospedaliero-Universitaria di Modena, Modena, Italy, <sup>4</sup>Department of Health Promotion, Maternal and Child Care, "G. D'Alessandro", Legal Medicine Section, University of Palermo, Palermo, Italy

**OC 25 16.52-17.02 Preferences in long acting agents for HIV treatment in women living with HIV: a cross-sectional evaluation among 6 Italian clinical centers**

A. Cingolani<sup>1</sup>, F. Bai<sup>2</sup>, S. Di Giambenedetto<sup>1</sup>, A.M. Cattelan<sup>3</sup>, G. D'Etto<sup>4</sup>, M. Malena<sup>5</sup>, M. Lichtner<sup>6</sup>, V. Massaroni<sup>1</sup>, L. Sighinolfi<sup>7</sup>, C. Putaggio<sup>3</sup>, A. Lazzaro<sup>4</sup>, M. Ficon<sup>5</sup>, G. Mancarella<sup>6</sup>, L. Gazzola<sup>2</sup>, B. Beghetto<sup>8</sup>, C. Mussini<sup>8</sup>, A. d'Arminio Monforte<sup>2</sup>

<sup>1</sup>Fondazione Policlinico A. Gemelli IRCCS, Università Cattolica S. Cuore, Roma, <sup>2</sup>Università di Milano, ASST Santi Paolo e Carlo, <sup>3</sup>Azienda Ospedaliera Padova, <sup>4</sup>Policlinico Universitario Umberto I, <sup>5</sup>Osservatorio Infettivologico Aziendale, Azienda ULSS 9, Verona, <sup>6</sup>Ospedale S. Maria Goretti, Latina, <sup>7</sup>Azienda Ospedaliera Ferrara, <sup>8</sup>Università di Modena e Reggio Emilia

**OC 26 17.04-17.14 HCV infection among women prisoners: a snapshot of the Italian ROSE network**

E. Rastrelli<sup>1,2</sup>, V. Fiore<sup>2,3</sup>, R. Ranieri<sup>2,4</sup>, A. Bascià<sup>5</sup>, R. Bergamaschi<sup>6</sup>, F. Vignale<sup>7</sup>, M. Pontolillo<sup>7</sup>, F. Campanale<sup>8</sup>, L. Rapisarda<sup>9</sup>, R. Marocco<sup>10</sup>, A.M. Ialungo<sup>1,2</sup>, S. Dell'Isola<sup>1,2</sup>, Lucania<sup>2,11</sup>, S. Babudieri<sup>2,13</sup>, G. Starnini<sup>1,2</sup>

<sup>1</sup>U.O.C. Medicina Protetta-Malattie Infettive, Ospedale Belcolle, Viterbo, <sup>2</sup>SIMSPe (Società Italiana di Medicina e Sanità Penitenziaria), <sup>3</sup>Unità di Malattie Infettive, Università di Sassari, Sassari, <sup>4</sup>Azienda Ospedaliera Santi Paolo e Carlo Unità di Malattie Infettive, Università di Milano Unità di Malattie Infettive in Ambito Penitenziario, Milano, <sup>5</sup>Distretto Socio Sanitaria ASL Lecce, Poliambulatorio "Cittadella della Salute", <sup>6</sup>Casa Circondariale Pesaro, <sup>7</sup>Clinica di Malattie Infettive, Dipartimento di Medicina ed Scienze dell'Invecchiamento, Università G. d'Annunzio, Chieti, <sup>8</sup>Specialistica Ambulatoriale ASL Bat, <sup>9</sup>CC Catania, <sup>10</sup>Unità di Malattie Infettive, Università La Sapienza, Ospedale S.M., Latina, <sup>11</sup>Reggio Calabria ASP Reggio Calabria - Presidio I.P. RC "Panzerà" e "Arghilla"





Venerdi  
22 ottobre



re-search, for re-start  
together Riccione 21-23 Ottobre 2021

**SYMPOSIUM** 17.30-18.30

**AUDITORIUM CONCORDIA**

## Novel long-acting therapies for the treatment of Multidrug-Resistant (MDR) HIV-1 infection: let's go undetectable again

Chair: M. Andreoni (Roma)

The Symposium will focus on the new long-acting antiretrovirals designed to treat HIV+ persons harboring a virus resistant to other HIV treatments. Among others the symposium will share details on post attachment inhibitors through a unique mechanism of action blocks HIV-1 entry into cells, while preserving normal immune function. Effective against multiple drug-resistant strains, regardless of viral tropism, with high tolerability and safety, it represents a novel approach in the management of multi-drug-resistant (MDR) HIV infection.

17.30-17.35	<b>Introduction</b>	Massimo Andreoni, Roma
17.35-17.50	<b>New mechanism of action for durable viral suppression</b>	Carlo Federico Perno, Roma
17.50-18.05	<b>The real world experience: lessons for clinical practice</b>	Antonella Castagna, Milano
18.05-18.20	<b>Long acting ARVs: the importance of pharmacokinetics, adherence and drug-drug interactions in a new era</b>	Stefano Bonora, Torino
18.20-18.30	<b>Discussion on Symposium issues</b>	

**SYMPOSIUM** 17.30-18.30

**POLISSENA A HALL**

## Co-infections in 2021

Chairs: M. Puoti (Milano), L. Sarmati (Roma)

During the 40 years of HIV epidemic, the spectrum of opportunist infections and their clinical management has constantly evolved. In this setting, the first lecture of the symposium will be specifically dedicated to provide an overview of the most clinically relevant opportunist infections that clinicians have learnt to tackle in order improve the clinical management of people living with HIV (PLWH). Particular attention will be dedicated on the diagnostic and therapeutic challenges that have been (and still need to be) faced in these 40 years of HIV epidemic. Chronic HBV/HDV coinfection is associated with an unfavorable outcome also in PLWH, leading to liver cirrhosis, liver failure and eventually hepatocellular carcinoma within 5-10 years. Recently, the identification of the HBV/HDV receptor coupled with the development of novel in vitro and animal infection models has fueled a deepened study of the HDV life cycle and in turn the development of novel antiviral drugs. This topic will be covered during the symposium in order to provide a comprehensive overview of the novel anti-HDV drugs and their related challenges in clinical practice. Non-tuberculous mycobacteria is a collective name given to a group of more than 190 species of Mycobacterium, still afflicting PLWH. For most of them, the clinical manifestations are usually a-specific, thus resulting in delayed diagnosis. This scenario is further complicated by the difficulties to isolate such bacteria, posing challenges from a diagnostic point of view. Anti-mycobacterial treatment can be associated with severe side-effects and often lasts for several months to achieve an adequate suppression or eradication. All these aspects will be discussed during the symposium focusing also on upcoming drugs aimed at facilitating the clinical management of this form of coinfection. Collectively, these 3 lectures will provide an exhaustive and updated overview of coinfections in PLWH, covering crucial aspects for an optimized clinical management.

17.30-17.35	<b>Introduction</b>	
17.35-17.50	<b>40 years of opportunistic infections</b>	Miriam Lichtner, Latina
17.50-18.05	<b>The challenges related to the upcoming HDV drugs</b>	Simona Schivazappa, Parma
18.05-18.20	<b>New perspectives in non-tuberculous mycobacteria in HIV and non-HIV patients: focus on new therapeutic approaches</b>	Roberto Parrella, Napoli
18.20-18.30	<b>Discussion on Symposium issues</b>	



40

Scientific Programme

13° CONGRESSO NAZIONALE **Italian Conference** on **AIDS** and **Antiviral Research**



**ORAL COMMUNICATIONS** 17.30-18.30

**POLISSENA B HALL**

**Clinical HIV & Clinical Covid II**

Chairs: N. Petrosillo (Roma), S. Piconi (Lecco)

- OC 27** 17.30-17.40 **Impact of home treatment with glucocorticoids on risk of in-hospital death in patients with COVID-19 pneumonia**  
*A. Dessilani, A. Cozzi-Lepri, I. Baldisserotto, S. Esperti, F. Mediolì, A. Mazzocchi, M. Del Monte, V. Borghi, G. Guaraldi, C. Mussini*  
Infectious Disease Unit, University of Modena and Reggio Emilia, Modena, Italy
- OC 28** 17.42-17.52 **Treatment of COVID-19 severe pneumonia: do all patients benefit from adding tocilizumab to glucocorticoids? An open label non-randomized study**  
*S. Volpi, A. Cozzi-Lepri, V. Borghi, G. Guaraldi, G.J. Burastero, G. Dolci, M. Faltoni, G. Franceschi, V. Iadisernia, C. Mussini*  
Infectious Disease Unit, University of Modena and Reggio Emilia, Modena, Italy
- OC 29** 17.54-18.04 **SARS-CoV-2 viral decay in COVID-19 patients treated with monoclonal antibodies in relationship to viral variant**  
*L. Coppola<sup>1</sup>, M. Iannetta<sup>1</sup>, E. Teti<sup>1</sup>, V. Barchi<sup>1</sup>, V. Malagnino<sup>1</sup>, A. Sferrazza<sup>1</sup>, L. Campogiani<sup>1</sup>, M. Compagno<sup>1</sup>, L. Piermatteo<sup>2</sup>, M. Bellocchio<sup>2</sup>, F. Ceccherini Silberstein<sup>2</sup>, M. Andreoni<sup>1</sup>, L. Sarmati<sup>1</sup>*  
<sup>1</sup>UOC Malattie Infettive e Tropicali, Policlinico Tor Vergata, Roma, <sup>2</sup>Cattedra di Virologia, Università di Roma Tor Vergata, Roma
- OC 30** 18.06-18.16 **Effectiveness of COVID-19 vaccine in health care workers, Milan, Italy**  
*A. Lombardi<sup>1,2</sup>, D. Consonni<sup>3</sup>, P. Bono<sup>4</sup>, M. Oggioni<sup>4</sup>, S.U. Renteria<sup>4</sup>, L. Bordini<sup>3</sup>, C.D. Nava<sup>3</sup>, A. Piatti<sup>5</sup>, A.C. Pesatori<sup>3,6</sup>, S. Castaldi<sup>7,8</sup>, A. Muscatello<sup>1</sup>, M. Carugno<sup>3,6</sup>, L. Riboldi<sup>9</sup>, F. Ceriotti<sup>4</sup>, A. Bandera<sup>1,2</sup>, A. Gori<sup>1,2</sup>*  
<sup>1</sup>Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, <sup>2</sup>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, <sup>3</sup>Epidemiology Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, <sup>4</sup>Clinical Laboratory, Foundation IRCCS Ca' Granda Ospedale Maggiore, Milan, Italy, <sup>5</sup>Medical Direction, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, <sup>6</sup>Department of Clinical Sciences and Community Health, University of Milano, Milan, Italy, <sup>7</sup>Department Biomedical Sciences for Health, University of Milan, Milan, Italy, <sup>8</sup>Quality Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, <sup>9</sup>Occupational Health Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; <sup>10</sup>Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy
- OC 31** 18.18-18.28 **Immunogenicity and safety of the BNT162b2 COVID-19 mRNA vaccine in PLWH**  
*E. Milano<sup>1</sup>, A. Ricciardi<sup>1</sup>, E. De Vita<sup>1</sup>, R. Casciaro<sup>1</sup>, E. Pallara<sup>1</sup>, R. Papagni<sup>1</sup>, A. Lagioia<sup>1</sup>, A.M.V. Larocca<sup>2</sup>, P. Stefanizzi<sup>2</sup>, S. Tafuri<sup>2</sup>, A. Saracino<sup>1</sup>*  
<sup>1</sup>Clinica Malattie Infettive, Azienda Ospedaliero Consorziato Policlinico di Bari, <sup>2</sup>Istituto di Igiene, Azienda Ospedaliero Consorziato Policlinico di Bari





Sabato  
23 ottobre



re-search, for re-start  
together Riccione 21-23 Ottobre 2021

## KEYNOTE LECTURES 09.00-10.00

Chairs: P. Bagnarelli (Ancona), F. Castelli (Brescia)

09.00-09.30 **Antiretroviral therapy: future is coming**

Antonella Castagna, Milano

09.30-10.00 **From HIV to SARS-CoV-2: how pandemics affected the integration between laboratory and clinics**

Maria Rosaria Capobianchi, Roma

## AUDITORIUM CONCORDIA

## SYMPOSIUM 10.05-11.05

### Approaching the Long Acting Therapy in HIV

Chairs: A. Antinori (Roma), G. Rizzardini (Milano)

Long Acting (LA) therapies offer a key difference to currently available ART regimens: patient choice related to their preferred way to administer medications. The affected community and HIV providers are very interested in exploring the role of long-acting therapies to address some types of barriers to medication adherence. This Symposium will address the rationale and the current data supporting the efficacy and safety of the first complete LA ART regimen, cabotegravir and rilpivirine, and outline associated opportunities and challenges with the implementation of long-acting therapy for the treatment and prevention of HIV.

10.05-10.10 **Introduction**

Andrea Antinori, Roma; Giuliano Rizzardini, Milano

10.10-10.30 **Evidence of clinical data and impact in PLWH**

Silvia Nozza, Milano

10.30-10.50 **What's behind Long Acting**

Stefano Bonora, Torino

10.50-11.05 **Discussion on Symposium issues**

## AUDITORIUM CONCORDIA

## ORAL COMMUNICATIONS 10.05-11.05

### Clinical HIV & Clinical Covid III

Chairs: P.A. Grossi (Varese), E. Vaccher (Pordenone)

## POLISSENA A HALL

**OC 32 10.05-10.15 T-Lymphocyte subset absolute counts assessed at baseline represent a useful tool to predict 30-days mortality in hospitalized SARS-CoV-2 infected patients**

A. Di Lorenzo, M. Iannetta, P.G. Pace, I. Spalliera, B. Rossi, P. Vitale, S. Tedde, L. Ansaldo, L. Campogiani, C. Picarelli, V. Malagnino, E. Teti, M. Andreoni, L. Sarmati

Department of System Medicine, Tor Vergata University, Rome, Italy; Infectious Disease Clinic, Policlinico Tor Vergata, Rome, Italy

**OC 33 10.17-10.27 HIV and SARS-CoV-2 co-infection: protective role of IL-10 in HIV-positive young individuals**

C. Vanetti<sup>1,2</sup>, D. Trabattoni<sup>2</sup>, M. Stracuzzi<sup>3</sup>, A. Amendola<sup>4,5</sup>, C. Fappani<sup>4,5</sup>, V. Rubinacci<sup>3</sup>, C. Fenizia<sup>2</sup>, M. Biasin<sup>2</sup>, E. Longoni<sup>3</sup>, A. Dighera<sup>3</sup>, I. Saule<sup>1,2</sup>, F. Ardizzone<sup>2</sup>, E. Tanzi<sup>4,5</sup>, M. Clerici<sup>1,6</sup>, G.V. Zuccotti<sup>2,7</sup>, V. Giacometti<sup>4</sup>

<sup>1</sup>Chair of Immunology - Department of Pathophysiology and Transplantation, University of Milan, Milan, <sup>2</sup>Chair of Immunology, DIBIC L. Sacco, University of Milan, Milan, <sup>3</sup>Paediatric Infectious Disease Unit, Ospedale L. Sacco, Milan, <sup>4</sup>Department of Biomedical Sciences for Health, University of Milan, Milan, <sup>5</sup>Coordinated Research Center "EpiSoMI", University of Milan, Milan, <sup>6</sup>IRCCS Fondazione Don Carlo Gnocchi, Milan, <sup>7</sup>Department of Pediatrics, Ospedale dei Bambini V. Buzzi, Milan

**OC 34 10.29-10.39 Sequelae at 12 months after COVID-19 in hospitalized adults: a multicenter study**

A. Comelli<sup>1</sup>, G. Viera<sup>2</sup>, G. Bettini<sup>2</sup>, A. Nobili<sup>3</sup>, M. Tettamanti<sup>3</sup>, A.A. Galbussera<sup>3</sup>, A. Muscatello<sup>1</sup>, M. Mantero<sup>2,4</sup>, C. Canetta<sup>5</sup>, P. Bonfanti<sup>6</sup>, M. Contoli<sup>7</sup>, A. Gori<sup>1,2</sup>, A. Bandera<sup>1,2</sup> for the COVID-19 Network

<sup>1</sup>Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, <sup>2</sup>University of Milan, Department of Pathophysiology and Transplantation, Milan, Italy, <sup>3</sup>Institute for Pharmacological Research Mario Negri IRCCS, Milan, Italy, <sup>4</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Respiratory Unit and Cystic Fibrosis Adult Centre, Internal Medicine Department, Milan, Italy, <sup>5</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Acute Medical Unit, Milan, Italy, <sup>6</sup>Infectious Diseases Unit, Azienda Socio Sanitaria Territoriale (ASST) Monza, San Gerardo Hospital, Monza, Italy, <sup>7</sup>Research Centre on Asthma and Chronic Obstructive Pulmonary Disease, Department of Medical Sciences, University of Ferrara, Ferrara, Italy

**OC 35 10.41-10.51 Bloodstream infections in COVID-19 patients: first-wave versus second-wave comparison**

L. Tartaglione<sup>1</sup>, A. Pani<sup>2</sup>, S. Nerini Molteni<sup>1</sup>, N. Ughi<sup>3</sup>, J. Colombo<sup>4</sup>, M. Merli<sup>5</sup>, T. Langer<sup>4</sup>, G. Monti<sup>4</sup>, F. Di Ruscio<sup>6</sup>, E. Inglese<sup>1</sup>, A. Bielli<sup>1</sup>, G. Casalicchio<sup>1</sup>, A. Nava<sup>1</sup>, D. Fanti<sup>1</sup>, M. Puoti<sup>5</sup>, R. Fumagalli<sup>4,7</sup>, O.M. Epis<sup>3</sup>, F. Scaglione<sup>1</sup>, C. Vismara<sup>1</sup>, V. Cento<sup>2</sup>

<sup>1</sup>Chemical-Clinical and Microbiological Analyses, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, <sup>2</sup>Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy, <sup>3</sup>Rheumatology Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, <sup>4</sup>Department of Anesthesiology, Critical Care and Pain Medicine, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, <sup>5</sup>Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, <sup>6</sup>Residency in Microbiology and Virology, Università degli Studi di Milano, Milan, Italy, <sup>7</sup>School of Medicine and Surgery, University of Milano-Bicocca, Milan



42

Scientific Programme

13° CONGRESSO NAZIONALE Italian Conference on AIDS and Antiviral Research



**OC 36 10.53-11.03 Impact of a pro-active Infectious Diseases Consultation for the Management of a Multidrug-resistant Organisms Outbreak in a COVID-19 Hospital: a Three-Months Quasi-Experimental Prospective Study**  
**D.F. Bavaro<sup>1</sup>, N. De Gennaro<sup>1</sup>, A. Belati<sup>1</sup>, L. Diella<sup>1</sup>, R. Papagni<sup>1</sup>, L. Frallonardo<sup>1</sup>, M. Camporeale<sup>1</sup>, G. Guido<sup>1</sup>, C. Pellegrino<sup>1</sup>, M. Marrone<sup>2</sup>, A. Dell'Erba<sup>2</sup>, L. Gesualdo<sup>3</sup>, N. Brienza<sup>4</sup>, S. Grasso<sup>4</sup>, G. Columba<sup>4</sup>, A. Moschetta<sup>5</sup>, E. Carpagnano<sup>6</sup>, A. Daleno<sup>7</sup>, A.M. Minicucci<sup>7</sup>, G. Migliore<sup>8</sup>, A. Saracino<sup>1</sup>**

<sup>1</sup>Clinic of Infectious Diseases, Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro", Bari, Italy, <sup>2</sup>Interdisciplinary Department of Medicine, University of Bari – Section of Legal Medicine, Bari General Hospital, Bari, Italy, <sup>3</sup>Department of Emergency and Organ Transplantation, Nephrology, Dialysis and Transplantation Unit, University of Bari Aldo Moro, Bari, Italy, <sup>4</sup>Department of Emergency and Organ Transplantation, Section of Anesthesia and Intensive Care, University of Bari "Aldo Moro", Bari, Italy, <sup>5</sup>Department of Interdisciplinary Medicine, University of Bari "Aldo Moro", Bari, Italy, <sup>6</sup>Department of Basic Medical Science, Institute of Respiratory Disease, Neuroscience, and Sense Organs, University of Bari "Aldo Moro", Bari, Italy, <sup>7</sup>Section of Health Management, Policlinico Hospital, Bari, Italy, <sup>8</sup>General Direction, Policlinico Hospital, Bari, Italy

**EXPERT MEETING 10.05-11.05**

**POLISSENA B HALL**

Con la sponsorizzazione non condizionante di Gilead Sciences

**Hepatitis D virus in 2021: new challenges in tough-to-treat patients**

Chair: N. Coppola (Napoli)

Hepatitis delta virus (HDV), first discovered in Italy in 1977, is a small defective RNA virus which requires the helper function of HBV for its replication and transmission to anti-HDV-negative individuals. HDV infection can be transmitted either simultaneously with HBV infection (co-infection) or to people who are already chronic HBV carriers (super-infection). It has been estimated that 15 -20 million people worldwide have a chronic HDV infection; in Italy prevalence is estimated around 7-8% among HBV infected people. Coinfections lead to more serious liver disease than hepatitis B infection alone. They are associated with faster progression to liver fibrosis, increased risk of liver cancer, and early decompensated cirrhosis and liver failure. Up to 90% of superinfected individuals will develop chronic infections of both hepatitis B and delta, of which approximately 70% will progress to cirrhosis (liver scarring), compared to 15-30% of those infected only with the hepatitis B virus. Until now, people with HDV had very limited treatment options and poor diagnosis. The Expert Meeting will focus on a new agent – bulevirtide - a first-in-class HBV and HDV entry inhibitor that targets the human NTCP (sodium taurocholate cotransporting polypeptide) transmembrane protein.

10.05-10.10	<b>Introduction</b>	Nicola Coppola, Napoli
10.10-10.30	<b>Current challenges in Hepatitis D: epidemiology, diagnosis and management 44 years after discovery</b>	Maurizia Brunetto, Pisa
10.30-10.50	<b>A new option for the treatment of chronic hepatitis delta: scientific evidence of the first-in-class entry inhibitor Bulevirtide</b>	Pietro Lampertico, Milano
10.50-11.00	<b>Discussion</b>	
11.00-11.05	<b>Take-home messages and conclusions</b>	Nicola Coppola, Napoli

**SYMPOSIUM 11.10-12.10**

**AUDITORIUM CONCORDIA**

**Rethinking antiretroviral therapy: new issues, new approaches**

Chairs: G.M. Corbelli (Bologna), M.E. Quiros Roldan (Brescia)

Great strides have been made in HIV prevention and treatment. Life expectancy of people living with Hiv infection, appropriately treated is now almost the same as the general population, a huge success that needs to be maintained and translated into a good quality of life. The range of available antiretroviral therapies has expanded considerably over the years to now include several classes of antiretrovirals. New drugs with unique mechanisms of action likely effective also against HIV strains with resistance will be available very soon and long-acting therapies that could be taken once every month, once every two months or even less will be available in the next years. This Symposium will debate the most critical points for a proper management of HIV prevention and treatment in this dynamic scenario.

11.10-11.25	<b>Prevention</b>	Silvia Nozza, Milano
11.25-11.40	<b>Naive</b>	Vincenzo Spagnuolo, Milano
11.40-11.55	<b>Switch</b>	Lucia Taramasso, Genova
11.55- 12.10	<b>Failure</b>	Roberta Gagliardini, Roma







Sabato  
23 ottobre



re-search, for re-start  
together Riccione 21-23 Ottobre 2021

## ORAL COMMUNICATIONS 11.10-12.10

## POLISSENA A HALL

### Immunopathogenesis I

Chairs: G. d'Ettore (Roma), G. Nunnari (Messina)

11.25-11.40 **Pregnancy and Sars-Cov-2: a novel virus in a unique population**

Mara Biasin, Milano

**OC 37 11.40-11.50 SARS-CoV-2 plasmatic viremia and T-cell immune response in hospitalized COVID-19 patients**

R. Rovito, V. Bono, M. Augello, C. Tincati, F. Bai, M. Allegrini, M. Hadla, A. d'Arminio Monforte, G. Marchetti

Clinic of Infectious Diseases and Tropical Medicine San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy

**OC 38 11.52-12.02 T-lymphocyte specific response to SARS-CoV-2 peptides is detectable in patients with multiple sclerosis under treatment with disease modifying therapies, despite absent or low-level anti-Spike antibody titers. Which are the possible clinical implications?**

M. Iannetta<sup>1</sup>, D. Landi<sup>2</sup>, G. Cola<sup>2</sup>, A. Di Lorenzo<sup>1</sup>, L. Campogiani<sup>1</sup>, I. Spalliera<sup>1</sup>, P. Vitale<sup>1</sup>, V. Malagnino<sup>1</sup>, E. Teti<sup>1</sup>, L. Coppola<sup>1</sup>, D. Fraboni<sup>3</sup>, F. Buccisano<sup>3</sup>, S. Grelli<sup>4</sup>, G.A. Marfia<sup>2,5</sup>, M. Andreoni<sup>1</sup>, L. Sarmati<sup>1</sup>

<sup>1</sup>Infectious Disease Unit, Department of System Medicine, Tor Vergata University and Hospital, Rome, Italy, <sup>2</sup>Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine, Tor Vergata University and Hospital, Rome, Italy, <sup>3</sup>Department of Biomedicine and Prevention, Tor Vergata University and Hospital, Rome, Italy, <sup>4</sup>Virology Unit, Department of Experimental Medicine, Tor Vergata University and Hospital, Rome, Italy, <sup>5</sup>Unit of Neurology, IRCCS Istituto Neurologico Mediterraneo NEUROMED, Pozzilli (Is), Italy

## EXPERT MEETING 11.10-12.10

## POLISSENA B HALL

Con la sponsorizzazione di Gilead Sciences

### Remdesivir from the pivotal trials to the real world experiences: are there other open questions?

Moderator: S. Rusconi (Milano)

Discussants: F. De Rosa (Torino), M. Falcone (Pisa), T.A. Santantonio (Foggia), F.S. Serino (Venezia)

The use of remdesivir, the first and only antiviral drug authorized in Europe for the treatment of COVID-19, is increasingly supported by numerous real-world data, which confirm the results of three randomized and controlled clinical trials, including the ACTT-1 study, the gold standard randomized, double-blind, placebo-controlled clinical trial on the efficacy of remdesivir. While in these studies no benefit on mortality rates or a non-statistically significant trend towards benefit for mortality were reported, the results of recent international real-world retrospective analyses on large data sets complete the picture provided by the randomized and controlled clinical trials, showing that hospitalised COVID-19 patients treated with remdesivir had a statistically significant reduction in mortality and improved survival compared to matched controls. These robust findings have been observed not only in the overall population but also across all subgroups of patients requiring supplemental oxygen. The meeting will be an opportunity to present a scientific update on the efficacy data and to share opinions and experiences about a year after the introduction of remdesivir in clinical practice in Italy. The Expert Meeting will be carried out through an interactive discussion between young and experienced infectious disease specialists, who will talk about their experience on the use of remdesivir in clinical practice.

11.10-11.15 **COVID-19: Remdesivir from the pivotal trials to the real-world experience**

Stefano Rusconi, Milano

11.15-11.30 **Remdesivir from the clinical trials to the real Practice: the open questions**

Teresa Antonia Santantonio, Foggia

11.30-11.45 **Evidence from the real-world analyses: the initial answers**

Francesco Giuseppe De Rosa, Torino

11.45-12.05 **Interactive discussion. Round table: "The answers from the experts"**

12.05-12.10 **Closure**

Stefano Rusconi, Milano



44

Scientific Programme

13° CONGRESSO NAZIONALE Italian Conference on AIDS and Antiviral Research



## MEET THE COMMUNITY 11.10-12.10

ROOM 3

### Sex Check for PrEP

Chair: V. Puro (Roma)

11.10 - 12.10 **Sex Check for PrEP**

Sandro Mattioli, Bologna

## SATELLITE SYMPOSIUM 12.15-13.15

Con la sponsorizzazione non condizionante di Janssen-Cilag

### How the past shapes the future

Chair: C. Mussini (Modena)

In this changing scenario caring for HIV is constantly a challenge and with it both the management of long-term antiretroviral therapy and the unmet needs of every single HIV-positive patient and at-risk population. PLWH require long-life treatments while maintaining durability and tolerability of antiretroviral regimen. The aim of symposium is going through the long innovation path focusing on value of ART history in the new global landscape depicted by COVID-19 pandemic. Furthermore, data obtained from experience will be discussed to better support treatment strategies in daily practice for improving patients care.

12.15-12.25 **Introduction: HInnoVation History**

Cristina Mussini, Modena

12.25-12.45 **Knowledge value**

Stefano Bonora, Torino

12.45-13.05 **PI consolidated experience 2.0**

Andrea Antinori, Roma

13.05-13.15 **Discussion on Symposium issues**

## ORAL COMMUNICATIONS 12.15-13.15

POLISSENA A HALL

### Comorbidities I

Chairs: P. Nasta (Brescia), G. Parruti (Pescara)

12.15 - 12.30 **Into the lung: is there a synergy between HIV and SARS- CoV2?**

Antonio Di Biagio, Genova

**OC 39** 12.30-12.40 **SARS-CoV-2 infection and COVID-19 disease in a large cohort of PLWHIV**

F. Maggiolo<sup>1</sup>, D. Valenti<sup>2</sup>, M. Arosio<sup>1</sup>, L. Goisis<sup>1</sup>, D. Guarneri<sup>1</sup>, M. Rizzi<sup>1</sup>, A.P. Callegaro<sup>1</sup>

<sup>1</sup>ASST Papa Giovanni XXIII, <sup>2</sup>Associazione FROM, Bergamo

**OC 40** 12.42-12.52 **Meningococcus B Vaccination Effectiveness against Neisseria gonorrhoeae Infection in PLWH: a Case-control Study**

A.R. Raccagni<sup>1</sup>, A. Poli<sup>2</sup>, L. Galli<sup>2</sup>, V. Spagnuolo<sup>1,2</sup>, E. Bruzzesi<sup>1</sup>, C. Muccini<sup>2</sup>, S. Bossolasco<sup>2</sup>, M. Ranzenigo<sup>1</sup>, N. Gianotti<sup>2</sup>, I. Mainardi<sup>1</sup>, A. Castagna<sup>1,2</sup>, S. Nozza<sup>2</sup>

<sup>1</sup>Vita-Salute San Raffaele University - Milan (Italy), <sup>2</sup>Infectious Diseases Unit, San Raffaele Scientific Institute - Milan (Italy)

**OC 41** 12.54-13.04 **A Machine Learning-Based Model to Predict the 15-Year Risk for Cardiovascular Disease in a Cohort of People Living with HIV**

C. Muccini<sup>1,2</sup>, C. Masci<sup>3</sup>, F. Corso<sup>3</sup>, L. Galli<sup>1</sup>, A. Poli<sup>1</sup>, M. Ranzenigo<sup>2</sup>, R. Monardo<sup>2</sup>, A.M. Paganoni<sup>3,4</sup>, A. Castagna<sup>1,2</sup>, F. Ieva<sup>3,4</sup>

<sup>1</sup>Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, <sup>2</sup>Vita-Salute San Raffaele University, Milan, Italy, <sup>3</sup>MOX Laboratory for Modeling and Scientific Computing - Department of Mathematics, Milan, Italy, <sup>4</sup>Centre for Analysis, Decision and Society (CADS), Human Technopole, Milan, Italy





Sabato  
23 ottobre



re-search, for re-start  
together

Riccione 21-23 Ottobre 2021

## ORAL COMMUNICATIONS 12.15-13.15

## POLISSENA B HALL

### Immunopathogenesis II

Chairs: V. Borghi (Modena), A.P. Callegaro (Bergamo)

#### OC 42 12.15-12.25 The interplay between SARS-CoV-2 infected airway epithelium and immune cells modulates the immunoregulatory/inflammatory signals

V. Bordoni<sup>1</sup>, G. Matusali<sup>1</sup>, D. Mariotti<sup>1</sup>, M. Antonoli<sup>1</sup>, E. Cimini<sup>1</sup>, A. Sacchi<sup>1</sup>, E. Tartaglia<sup>1</sup>, R. Casetti<sup>1</sup>, G. Grassi<sup>1</sup>, S. Notari<sup>1</sup>, C. Castil-letti<sup>1</sup>, G.M. Fimia<sup>1,2</sup>, G. Ippolito<sup>1</sup>, C. Agrati<sup>1</sup>

<sup>1</sup>National Institute for Infectious Diseases Lazzaro Spallanzani - IRCCS, Rome, Italy, <sup>2</sup>Department of Molecular Medicine, University of Rome "Sapienza", Rome, Italy

#### OC 43 12.27-12.37 Detection of SARS-CoV-2 RNA and evaluation of neurofilament light chain in cerebrospinal fluid and plasma of COVID-19 patients

M.A. Zingaropoli<sup>1</sup>, M. Iannetta<sup>2</sup>, P. Lorenzo<sup>3</sup>, P. Pasculli<sup>1</sup>, L. Mazzuti<sup>4</sup>, R. Scutari<sup>3</sup>, M. Antonacci<sup>1</sup>, L. Campogiani<sup>2</sup>, G. Antonelli<sup>4</sup>, M. Andreoni<sup>2</sup>, C. M. Mastroianni<sup>1</sup>, O. Turriziani<sup>4</sup>, F. Ceccherini-Silberstein<sup>3</sup>, L. Sarmati<sup>2</sup>, M.R. Ciardi<sup>1</sup>

<sup>1</sup>Department of Public Health and Infectious Diseases, Sapienza, University of Rome, <sup>2</sup>Department of Systems Medicine, Tor Vergata, University of Rome, <sup>3</sup>Department of Experimental Medicine, Tor Vergata, University of Rome, <sup>4</sup>Department of Molecular Medicine, Sapienza, University of Rome

#### OC 44 12.39-12.49 MMP-9 and TIMP-1 as a potential disease biomarker in patients with COVID-19 pneumonia

M.A. Zingaropoli<sup>1</sup>, P. Pasculli<sup>1</sup>, T. Latronico<sup>2</sup>, V. Pierri<sup>1</sup>, R. Merz<sup>1</sup>, F. Fornasiere<sup>1</sup>, P. Nijhawan<sup>1</sup>, M. Lichtner<sup>1</sup>, G. M. Liuzzi<sup>2</sup>, M. R. Ciardi<sup>1</sup>, C.M. Mastroianni<sup>1</sup>

<sup>1</sup>Department of Public Health and Infectious Diseases, Sapienza, University of Rome, <sup>2</sup>Department of Biosciences, Biotechnology and Biopharmaceutics, Aldo Moro University, Bari, Italy

#### OC 45 12.51-13.01 An NF- $\kappa$ B/Jak/Stat signaling pathways is involved in APOBEC3A induction following CCL2 neutralization in primary human macrophages

D.A. Covino<sup>1</sup>, L. Catapano<sup>1</sup>, I. Farina<sup>1</sup>, S. Sozzi<sup>1</sup>, F. Spadaro<sup>2</sup>, S. Cecchetti<sup>2</sup>, C. Purificato<sup>1</sup>, M.C. Gauzzi<sup>1</sup>, L. Fantuzzi<sup>1</sup>

<sup>1</sup>National Center for Global Health, Istituto Superiore di Sanità, Rome, Italy, <sup>2</sup>Core Facilities, Istituto Superiore di Sanità, Rome, Italy

#### OC 46 13.03-13.13 Oral mucosal immunity in SARS-CoV-2 infected and/or vaccinated subjects

M. Garziano<sup>1,2</sup>, O. Utyro<sup>1</sup>, G. Cappellelli<sup>1</sup>, F. Limanaqi<sup>1,2</sup>, C. Fenizia<sup>1,2</sup>, D. Trabattoni<sup>1</sup>, M. Clerici<sup>2,3</sup>, M. Biasin<sup>1</sup>

<sup>1</sup>Dipartimento di Scienze Biomediche e Cliniche "L. Sacco", Milan, Italy, <sup>2</sup>Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Milan, Italy, <sup>3</sup>Don C. Gnocchi Foundation, IRCCS, Milano, Italy

## ORAL POSTER 13.15-14.15

## FOYER AUDITORIUM

### Antiretroviral Therapy II

Chair: A. Londero (Udine)

#### OP 43 13.15-13.20 Changes in serum inflammatory and immune activation markers associated with lamivudine/dolutegravir and tenofovir alafenamide/emtricitabine/bictegravir as initial antiretroviral treatment

L. Calza<sup>1</sup>, V. Colangeli<sup>1</sup>, T. Miani<sup>1</sup>, I. Bon<sup>2</sup>, T. Lazzarotto<sup>2</sup>, P. Viale<sup>1</sup>

<sup>1</sup>Unit of Infectious Diseases, S.Orsola-Malpighi Hospital, University of Bologna, <sup>2</sup>Unit of Microbiology, S.Orsola-Malpighi Hospital, University of Bologna

#### OP 44 13.22-13.27 Cardiovascular risk and lipid profile after switching to TAF/FTC/RPV or TAF/FTC/EVG/cobi in people living with HIV and controlled plasma viremia

F. Conti<sup>1,2</sup>, L. Pezzati<sup>1,2</sup>, G. Pagani<sup>3</sup>, D. Bernacchia<sup>3</sup>, L. Oreni<sup>2</sup>, A. Giacomelli<sup>1,2</sup>, S. Rusconi<sup>1,3</sup>

<sup>1</sup>Luigi Sacco Department of Biomedical and Clinical Sciences DIBIC, University of Milan, Italy, <sup>2</sup>Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy, <sup>3</sup>Infectious Diseases Unit, Legnano General Hospital, ASST Ovest Milanese, Legnano, Italy

#### OP 45 13.29-13.34 Who could be eligible for long-acting antiretroviral treatment? A snapchat from Antiviral Response Cohort Analysis (ARCA) Italian cohort

A. De Vito<sup>1</sup>, A. Botta<sup>2</sup>, M. Berruti<sup>3,4</sup>, V. Castelli<sup>5,6</sup>, V. Lai<sup>7</sup>, C. Casso<sup>8,9</sup>, A. Lanari<sup>8,9</sup>, G. Stella<sup>8,9</sup>, A. Sallvari<sup>10,11</sup>, A. Bezenchek<sup>10,11</sup>, A. Di Biagio<sup>4</sup>

<sup>1</sup>Unit of Infectious Diseases, Department of Medical, Surgical, and Experimental Sciences, University of Sassari, Sassari, Italy, <sup>2</sup>Infectious and Tropical Disease Unit, University Hospital Careggi, University of Florence, Florence, Italy, <sup>3</sup>Department of Health Sciences, University of Genoa, Genoa, Italy, <sup>4</sup>Clinica Malattie Infettive, Università degli Studi di Genova, Ospedale Policlinico San Martino, Genoa, Italy, <sup>5</sup>University of Milano, Department of Pathophysiology and Transplantation, Milano, Italy, <sup>6</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Infectious Disease Unit, Milano, Italy, <sup>7</sup>Struttura complessa di Microbiologia e Virologia, Dipartimento di scienze Biomediche, Università di Sassari, Sassari, Italy, <sup>8</sup>Dipartimento Biotecnologie Mediche, Università degli Studi di Siena, Siena, Italy, <sup>9</sup>UOC Malattie Infettive e Tropicali, AOU Senese, Siena, Italy, <sup>10</sup>INFORMAPRO s.r.l., Rome, Italy, <sup>11</sup>EuResist Network GEIE, Rome, Italy



46

Scientific Programme

13° CONGRESSO NAZIONALE Italian Conference on AIDS and Antiviral Research



**OP 46 13.36-13.41 HIV-DNA decay in ART-naïve patients starting dolutegravir plus lamivudine vs triple therapy**  
**F. Lombardi<sup>1</sup>, S. Belmonti<sup>2</sup>, A. Sanfilippo<sup>1</sup>, A. Ciccullo<sup>1</sup>, A. Borghetti<sup>1</sup>, S. Di Giambenedetto<sup>1,2</sup>**

<sup>1</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC malattie infettive, Roma Italia, <sup>2</sup>Università Cattolica del Sacro Cuore, Istituto di Clinica Malattie Infettive, Roma Italia

**OP 47 13.43-13.48 Real-life impact of drug toxicity on dolutegravir tolerability: clinical practice data from a multicenter Italian cohort**

**A. Ciccullo<sup>1</sup>, G. Baldin<sup>2,3</sup>, V. Borghi<sup>4</sup>, F. Lagi<sup>5</sup>, A. Latini<sup>6</sup>, G. d'Etto<sup>7</sup>, L. Oreni<sup>8</sup>, A. Capetti<sup>9</sup>, M. Fabbiani<sup>10</sup>, A. Grimaldi<sup>1</sup>, G. Madeddu<sup>11</sup>, G. Sterrantino<sup>5</sup>, S. Rusconi<sup>12</sup>, C. Mussini<sup>4</sup>, S. Di Giambenedetto<sup>3,13</sup>**

<sup>1</sup>Infectious Diseases Unit, San Salvatore Hospital, L'Aquila, Italy, <sup>2</sup>Mater Olbia Hospital, Olbia, Italy, <sup>3</sup>Infectious Diseases Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy, <sup>4</sup>Department of Infectious Diseases, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy, <sup>5</sup>Division of Tropical and Infectious Diseases, 'Careggi' Hospital, Florence, Italy, <sup>6</sup>Infectious Dermatology and Allergology Unit, IFO S. Galliciano Institute (IRCCS), Rome, Italy, <sup>7</sup>Department of Public Health and Infectious Diseases, Azienda Policlinico Umberto I, Rome, Italy, <sup>8</sup>Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Milan, Italy, <sup>9</sup>Division of Infectious Diseases, Department of Infectious Diseases, Luigi Sacco University Hospital, Milan, Italy, <sup>10</sup>Infectious Diseases Unit, University Hospital of Siena, Siena, Italy, <sup>11</sup>Department of Clinical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy, <sup>12</sup>Infectious Diseases Unit, Legnano General Hospital, ASST Ovest Milanese, and DIBIC Luigi Sacco, University of Milan, Italy, <sup>13</sup>Catholic University of the Sacred Heart, Rome, Italy

**OP 48 13.50-13.55 Prevalence and incidence of multidrug resistance in the ARCA database, 2020 update**

**F. Incardona<sup>1,2</sup>, L. Timelli<sup>3</sup>, I. Vicenti<sup>3</sup>, S. Di Giambenedetto<sup>4</sup>, W. Gennari<sup>5</sup>, F. Lombardi<sup>4</sup>, V. Micheli<sup>6</sup>, D. Francisci<sup>7</sup>, E. Pontali<sup>8</sup>, S.T. Kiros<sup>9</sup>, M. Zazzi<sup>3</sup>; on behalf of the ARCA network**

<sup>1</sup>EuResist Network GEIE, Rome, <sup>2</sup>InformaPRO, Rome, <sup>3</sup>University of Siena, Siena, <sup>4</sup>Università Cattolica del Sacro Cuore, Rome, <sup>5</sup>Azienda Ospedaliera Universitaria di Modena, Modena, <sup>6</sup>Hospital L. Sacco, Milan, <sup>7</sup>University of Perugia, Perugia, <sup>8</sup>Hospital Galliera, Genova, <sup>9</sup>Hospital Careggi, Florence

13.57-14.15 **Discussion**

**ORAL POSTER 13.15-14.15**

**HIV & Covid 19**

Chair: M.A. Di Pietro (Firenze)

**OP 49 13.15-13.20 Real life use of the anti-SARS CoV-2 monoclonal antibodies in the early phase of infection: planning, enrollment, administration and monitoring**

**C. Del Borgo<sup>1</sup>, D. Caianiello<sup>2</sup>, D. Di Trento<sup>2</sup>, S. Garattini<sup>2</sup>, G. Bagaglino<sup>3</sup>, B. Kertusha<sup>2</sup>, A. Carraro<sup>2</sup>, A. Parente<sup>2</sup>, P. Fabietti<sup>1</sup>, O. D'Onofrio<sup>1</sup>, S. Di Somma<sup>4</sup>, G. Visconti<sup>5</sup>, G. Bonanni<sup>3</sup>, M. Lichtner<sup>2</sup>**

<sup>1</sup>Infectious Disease Unit, S.M. Goretti Hospital, AUSL Latina, Italy, <sup>2</sup>Infectious Disease Unit, Sapienza University, S.M. Goretti Hospital, Latina, Italy, <sup>3</sup>Pharmacy Unit, S.M. Goretti Hospital, AUSL Latina, Italy, <sup>4</sup>Department of Medical-Surgery Sciences and Translational Medicine, University of Rome Sapienza, Rome, Italy, <sup>5</sup>Health management service, AUSL Latina, Italy

**OP 50 13.22-13.27 Learning by doing: effects of monoclonal antibody treatment on the outcome of ambulatory patients with COVID-19**

**C. Leanza, A. Destro, C. Cappuccilli, E. Binetti, S. Trapani, S. Lobello, F. Cogliati Dezza, M.A. Zingaropoli, C. Ajassa, C.M. Mastroianni**

Department of Public Health and Infectious Diseases, AOU Policlinico Umberto 1, Sapienza University, Rome

**OP 51 13.29-13.34 Efficacy, safety and virological clearance in course of treatment with anti-SARS-CoV-2 monoclonal antibodies in patients diagnosed with mild-moderate COVID-19**

**C. Falcinella<sup>1</sup>, F. Bai<sup>1</sup>, D. Tomasoni<sup>1</sup>, T. Beringheli<sup>1</sup>, N. Gemignani<sup>1</sup>, E. Ottaviano<sup>2</sup>, S. Bianchi<sup>2</sup>, E. Borghi<sup>2</sup>, A. d'Arminio Monforte<sup>1</sup>, G. Marchetti<sup>1</sup>**

<sup>1</sup>Clinic of Infectious Diseases, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, Università degli Studi di Milano, Milan, <sup>2</sup>Laboratory of Microbiology, Department of Health Sciences, Università degli Studi di Milano, Milan

**OP 52 13.36-13.41 Ex vivo efficacy of currently licensed anti-SARS-CoV-2 monoclonal antibodies**

**F. Dragoni<sup>1</sup>, I. Vicenti<sup>1</sup>, A. Gidari<sup>2</sup>, E. Schiaroli<sup>2</sup>, G.V. De Socio<sup>2</sup>, S. Bastianelli<sup>2</sup>, L. Fiaschi<sup>1</sup>, N. Bartolini<sup>1</sup>, M. Zazzi<sup>1</sup>, D. Francisci<sup>2</sup>**

<sup>1</sup>Department of Medical Biotechnologies, University of Siena, Italy, <sup>2</sup>Department of Medicine and Surgery, Clinic of Infectious Diseases, "Santa Maria della Misericordia" Hospital, University of Perugia, Italy

**OP 53 13.43-13.48 Real-life use of remdesivir-containing regimens in Coronavirus Disease-2019: a retrospective case-control study**

**F. Cogliati Dezza, A. Oliva, V. Mauro, F.E. Romani, R. Aronica, F. Cancelli, G. Savelloni, P. Pasculli, S. Valeri, S. Carli, S. Di Bari, E. Casali, C.M. Mastroianni**

Department of Public Health and Infectious Diseases, Sapienza University of Rome





Sabato  
23 ottobre



re-search, for re-start  
together Riccione 21-23 Ottobre 2021

**OP 54** 13.50-13.55 **SARS-CoV-2 infection Among Persons living with HIV**  
S.R. Bruno, E.P. Drago, S. Ferrara, M. Polisenò, J.R. Fiore, S. Sica, S. Lo Caputo, T.A. Santantonio  
Infectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Foggia

13.57-14.15 **Discussion**

**ORAL POSTER** 13.15-14.15

## Immunopathogenesis II

Chair: L. Sasset (Padova)

**OP 55** 13.15-13.20 **Increased rates of indeterminate QuantiFERON-TB Gold Plus assay in severe COVID-19 patients reflect an impaired interferon- gamma secretion and correlate with the profound reduction of T-lymphocyte subsets in peripheral blood**  
A. Imeneo, G. Alessio, M. Iannetta, A. Di Lorenzo, A. Lodi, F. Barreca, V. Barchi, B. Massa, L. Campogiani, M. Compagno, L. Coppola, V. Malagnino, E. Teti, M. Andreoni, L. Sarmati  
Policlinico Tor Vergata, Roma

**OP 56** 13.22-13.27 **Role of serum E-selectin as a biomarker of infection severity in Coronavirus Disease-19**  
E. Rando<sup>2,3</sup>, D. Al Ismail<sup>1</sup>, M. De Angelis<sup>1</sup>, M.C. Miele<sup>1</sup>, C.M. Mastroianni<sup>1</sup>, A. Oliva<sup>1</sup>  
<sup>1</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy, <sup>2</sup>Institute of Infectious Diseases Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy, <sup>3</sup>Sapienza School for Advanced Studies (SSAS), Sapienza University of Rome, Italy

**OP 57** 13.29-13.34 **Effects of viremia and CD4 recovery on the gut "microbiome-immunity" axis in naïve HIV-1 patients undergoing ART therapy**  
E. Russo<sup>1</sup>, G. Nannini<sup>1</sup>, G. Sterrantino<sup>1</sup>, S.T. Kiro<sup>1</sup>, V. Di Pilato<sup>2</sup>, M. Coppi<sup>1,5</sup>, S. Baldi<sup>1</sup>, E. Niccolai<sup>1</sup>, F. Ricci<sup>1</sup>, M. Ramazzotti<sup>4</sup>, M. Pallecchi<sup>4</sup>, F. Lagi<sup>1</sup>, G.M. Rossolini<sup>1,5</sup>, A. Bartoloni<sup>1</sup>, G. Bartolucci<sup>3</sup>, A. Amedei<sup>1</sup>  
<sup>1</sup>Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, <sup>2</sup>Department of Surgical Sciences and Integrated Diagnostics, University of Genoa, Genoa, Italy, <sup>3</sup>Department of Neurosciences, Psychology, Drug Research and Child Health Section of Pharmaceutical and Nutraceutical Sciences, Florence, Italy, <sup>4</sup>Department of Biomedical, Experimental and Clinical "Mario Serio" University of Florence, Florence, Italy, <sup>5</sup>Microbiology and Virology Unit, Florence Careggi University Hospital, Florence, Italy

**OP 58** 13.36-13.41 **Cytokine profile of COVID-19 patients with and without active tuberculosis**  
S. Villa<sup>1</sup>, A. Lombardi<sup>1,2,3</sup>, P. Zucchi<sup>4</sup>, L. Porretti<sup>5</sup>, E. Trombetta<sup>5</sup>, A. Bandera<sup>1,2,3</sup>, P. Viggiani<sup>4</sup>, M. Raviglione<sup>1</sup>, A. Gori<sup>1,2,3</sup>  
<sup>1</sup>Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy, <sup>2</sup>Infectious Disease Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, <sup>3</sup>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, <sup>4</sup>Phthisiology Unit, Sondalo Hospital, ASST Valtellina e Alto Lario, Sondrio, Italy, <sup>5</sup>Clinical Laboratory, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

**OP 59** 13.43-13.48 **Role of Tocilizumab in down regulating the concentration of sCD163 in a cohort of SARS-COV 2 infected patients with varying severity**  
P. Nijhawan<sup>1</sup>, A. Carraro<sup>2</sup>, M.A. Zingaropoli<sup>1</sup>, P. Zuccalà<sup>2</sup>, V. Perri<sup>1</sup>, E. Chichi<sup>2</sup>, A. Parente<sup>2</sup>, R. Marocco<sup>2</sup>, B. Kertusha<sup>2</sup>, G. Siccardi<sup>1</sup>, C. Del Borgo<sup>2</sup>, V. Belvisi<sup>2</sup>, E. Del Giudice<sup>2</sup>, L. Fondaco<sup>2</sup>, S. Carli<sup>2</sup>, C. Ajassa<sup>1</sup>, F. Mengoni<sup>1</sup>, M.R. Ciardi<sup>1</sup>, C.M. Mastroianni<sup>1</sup>, M. Lichtner<sup>1,2</sup>  
<sup>1</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, <sup>2</sup>Infectious Disease Unit, SM Goretti Hospital Latina, Latina

**OP 60** 13.50-13.55 **Clinical and immunological characterization of SARS-CoV-2 infection in children**  
C. Vanetti<sup>1,2</sup>, F. Limanaqi<sup>2</sup>, S.C. Pagliara<sup>1</sup>, C. Fenizia<sup>1,2</sup>, C. Loretelli<sup>2</sup>, M. Stracuzzi<sup>3</sup>, L. Paradiso<sup>3</sup>, E. Longoni<sup>3</sup>, L. Barcellini<sup>4</sup>, V. Lampasona<sup>5</sup>, L. Piemontesi<sup>5</sup>, I. Marzinotto<sup>5</sup>, S. Dispinseri<sup>6</sup>, G. Scarlatti<sup>6</sup>, P. Fiorina<sup>2</sup>, M. Biasin<sup>2</sup>, V. Giacometti<sup>3</sup>, M. Clerici<sup>1,7</sup>, G.V. Zuccotti<sup>2,4</sup>, D. Trabattoni<sup>2</sup>  
<sup>1</sup>Chair of Immunology - Department of Pathophysiology and Transplantation, University of Milan, Milan, <sup>2</sup>Chair of Immunology, DIBIC L. Sacco, University of Milan, Milan, <sup>3</sup>Paediatric Infectious Disease Unit, Ospedale L. Sacco, Milan, <sup>4</sup>Department of Pediatrics, Ospedale dei Bambini V. Buzzi, Milan, <sup>5</sup>Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, <sup>6</sup>Viral Evolution and Transmission Unit, IRCCS Ospedale San Raffaele, Milan, <sup>7</sup>IRCCS Fondazione Don Carlo Gnocchi

13.57-14.15 **Discussion**



48

Scientific Programme

13<sup>o</sup> CONGRESSO NAZIONALE Italian Conference on AIDS and Antiviral Research



ORAL POSTER 13.15-14.15

FOYER AUDITORIUM

**Immunopathogenesis III**

Chair: M. Massari (Reggio Emilia)

**OP 61 13.15-13.20 Binding and neutralizing antibodies to interferon (IFN) / and defective IFN transcriptional profile in COVID-19 patients**

E. Frasca<sup>1</sup>, M. Scordio<sup>1</sup>, G. Oliveto<sup>1</sup>, L. Sorrentino<sup>1</sup>, A. Viscido<sup>1</sup>, C. Bitossi<sup>1</sup>, A. D'Auria<sup>1</sup>, G. Bugani<sup>1</sup>, A. Pierangeli<sup>1</sup>, L. Celani<sup>2</sup>, G. Ceccarelli<sup>2</sup>, C. Pinacchio<sup>2</sup>, L. Santinelli<sup>2</sup>, C. Mastroianni<sup>2</sup>, G. D'Ettoire<sup>2</sup>, G. Antonelli<sup>1,3</sup>, C. Scagnolari<sup>1</sup>

<sup>1</sup>Virology Laboratory, Department of Molecular Medicine, <sup>2</sup>Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy, <sup>3</sup>Microbiology and Virology Unit, Sapienza University Hospital "Policlinico Umberto I", Rome, Italy

**OP 62 13.22-13.27 Plasma cytokine landscape reveals the importance of different molecular pathways in predicting COVID-19 severity and survival**

A. Cozzi-Lepri<sup>1</sup>, S. De Biasi<sup>2</sup>, M. Meschiaro<sup>3</sup>, A. Paolini<sup>2</sup>, R. Borella<sup>2</sup>, M. Mattioli<sup>2</sup>, D. Lo Tartaro<sup>2</sup>, L. Fidanza<sup>2</sup>, A. Neroni<sup>2</sup>, C. Simonini<sup>2</sup>, S. Busani<sup>4</sup>, M. Girardis<sup>4</sup>, G. Guaraldi<sup>3</sup>, C. Mussini<sup>3</sup>, A. Cossarizza<sup>2</sup>, L. Gibellini<sup>2</sup>

<sup>1</sup>Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia School of Medicine, Modena, Italy, <sup>2</sup>Institute for Global Health, University College of London, London, UK, <sup>3</sup>Infectious Diseases Clinics, AOU Policlinico and University of Modena and Reggio Emilia, Modena, Italy, <sup>4</sup>Department of Anesthesia and Intensive Care, AOU Policlinico and University of Modena and Reggio Emilia, Modena, Italy

**OP 63 13.29-13.34 Pregnant women develop a specific immunological long-lived memory against SARS-CoV-2**

C. Fenizia<sup>1,2</sup>, C. Vanetti<sup>1,2</sup>, I. Cetin<sup>3</sup>, D. Mileto<sup>4</sup>, I. Saulle<sup>1,2</sup>, M. di Giminiani<sup>5</sup>, M. Saresella<sup>6</sup>, F. Parisi<sup>5</sup>, D. Trabattoni<sup>2</sup>, M. Clerici<sup>1,6</sup>, M. Biasin<sup>2</sup>, V. Savasi<sup>5</sup>

<sup>1</sup>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, <sup>2</sup>Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy, <sup>3</sup>Department of Woman, Mother and Neonate Buzzi Children's Hospital, ASST Fatebenefratelli Sacco, Department of Biomedical and Clinical Sciences, Milan, Italy, <sup>4</sup>Clinical Microbiology, Virology and Bio-emergence Diagnosis, ASST Fatebenefratelli-Sacco, Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy, <sup>5</sup>Unit of Obstetrics and Gynecology, ASST Fatebenefratelli-Sacco, Department of Biological and Clinical Sciences, University of Milan, Milan, Italy, <sup>6</sup>IRCCS Fondazione don Carlo Gnocchi, Milan, Italy

**OP 64 13.36-13.41 Role of Type-I and -II interferons in SARS-CoV-2 infection: convergent effect, different mechanisms**

E. Limanaqi<sup>1,2</sup>, G. Cappellelli<sup>2</sup>, M. Garziano<sup>1,2</sup>, S. Strizzi<sup>2</sup>, C. Fenizia<sup>1,2</sup>, D. Trabattoni<sup>2</sup>, M. Clerici<sup>1,3</sup>, M. Biasin<sup>2</sup>

<sup>1</sup>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, <sup>2</sup>Department of Biomedical and Clinical Sciences L. Sacco, University of Milan, Milan, Italy, <sup>3</sup>IRCCS Fondazione Don Carlo Gnocchi ONLUS, Milan, Italy

**OP 65 13.43-13.48 Persistence of humoral immune response after one year from COVID-19 diagnosis: evidence from a monocentric study**

R. Ungaro<sup>1</sup>, S. Villa<sup>2</sup>, Valeria Castelli<sup>1,3</sup>, P. Saltini<sup>1,3</sup>, A. Muscatello<sup>1</sup>, M. Mantero<sup>3,4</sup>, S. Aliberti<sup>5,6</sup>, A. Nobili<sup>7</sup>, C. Canetta<sup>8</sup>, A. L. Francanzani<sup>3,9</sup>, M. Oggioni<sup>10</sup>, A. Gori<sup>1,2,3</sup>, A. Bandera<sup>1,2,3</sup> on behalf of the COVID-19 Network working group

<sup>1</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Infectious Disease Unit, Milan, Italy, <sup>2</sup>Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy, <sup>3</sup>University of Milano, Department of Pathophysiology and Transplantation, Milan, Italy, <sup>4</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Respiratory Unit and Cystic Fibrosis Adult Centre, Internal Medicine Department, Milan, Italy, <sup>5</sup>Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy, <sup>6</sup>IRCCS Humanitas Research Hospital, Respiratory Unit, Rozzano, Milan, Italy, <sup>7</sup>Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy, <sup>8</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Acute Medical Unit, Milan, Italy, <sup>9</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Internal Medicine, Milan, Italy, <sup>10</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Clinical Laboratory, Milan, Italy

**OP 66 13.50-13.55 Immunogenicity and safety of two doses of BNT162b2 vaccine in very elderly subjects**

M. Tagliabue<sup>1</sup>, A.L. Ridolfo<sup>2</sup>, L. Oreni<sup>2</sup>, P. Clerici<sup>3</sup>, M. De Paschale<sup>3</sup>, M. Beltrami<sup>2</sup>, C. Resnati<sup>4</sup>, S. Belbusti<sup>1</sup>, L. Milazzo<sup>2</sup>, S. Antinori<sup>2</sup>, D. Cattaneo<sup>4,5</sup>, C. Gervasoni<sup>2,5</sup>

<sup>1</sup>Cesare e Emilio Prandoni ONLUS, Torno, Italy, <sup>2</sup>Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy, <sup>3</sup>Legnano Hospital, ASST Ovest Milanese, Legnano, Italy, <sup>4</sup>Unit of Clinical Pharmacology, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy, <sup>5</sup>Gestione Ambulatoriale Politerapie (GAP) Outpatient Clinic, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy

13.57-14.15 Discussion

ORAL POSTER 13.15-14.15

FOYER AUDITORIUM

**Social Sciences / Miscellaneous**

Chairs: A. Franco (Siracusa), G. Madeddu (Sassari)

**OP 67 13.15-13.20 Patient outreach strategy to enhance retention to care of HIV-positive adolescent and youths: experience from HIV high burden setting**







Sabato  
23 ottobre



re-search, for re-start  
together

Riccione 21-23 Ottobre 2021

**F. Di Gennaro**<sup>1,2</sup>, **A. Pozniak**<sup>3</sup>, **L. Ramirez**<sup>4</sup>, **H. Cardoso**<sup>4</sup>, **A. Chivite**<sup>4</sup>, **V. Cinturao**<sup>4</sup>, **D.F. Bavaro**<sup>1</sup>, **N. Chimundi**<sup>4</sup>, **C. Marotta**<sup>2</sup>, **I. Chagurua**<sup>4</sup>, **F. Tognon**<sup>2</sup>, **E. Namarime**<sup>4</sup>, **E. Occa**<sup>4</sup>, **G. Putoto**<sup>2</sup>, **A. Saracino**<sup>1</sup>

<sup>1</sup>Clinic of Infectious Diseases, University of Bari, University Hospital Policlinico, Bari, Italy, <sup>2</sup>Operational Research Unit, Doctors with Africa CUAMM, Padua, Italy, <sup>3</sup>Department of HIV Medicine, Chelsea & Westminster Hospital NHS Foundation Trust, London, UK, <sup>4</sup>Doctors with Africa CUAMM, Beira 2100, Mozambique

**OP 68 13.22-13.27 Knowledge of HIV and STIs: which are the most vulnerable populations? Results from a web-based survey in Italy**

**A. Colpani**, **A. De Vito**, **B. Zauli**, **V. Fiore**, **G.A. Pintus**, **V.G. Nardi**, **S. Babudieri**, **G. Madeddu**

Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari

**OP 69 13.29-13.34 HIV and Adolescents. Evaluation of an HIV and STI prevention project for high school students**

**F. Rossi**<sup>1</sup>, **A. Bianchi**<sup>1</sup>, **D. Zagato**<sup>1</sup>, **R. Repossi**<sup>1</sup>, **E. Garavaglia**<sup>1</sup>, **M. Cernuschi**<sup>1,2</sup>

<sup>1</sup>ASA Associazione Solidarietà AIDS, Milano, Italy, <sup>2</sup>San Raffaele Hospital, Milano, Italy

**OP 70 13.36-13.41 SARS-CoV-2 variants surveillance highlights local emergence of different genotypes**

**C. Veneziano**<sup>1</sup>, **C. De Marco**<sup>1</sup>, **N. Marascio**<sup>2</sup>, **A. Cerantonio**<sup>1</sup>, **G. Santamaria**<sup>3</sup>, **M.C. Liberto**<sup>2</sup>, **E.M. Treccarichi**<sup>4</sup>, **A. Quirino**<sup>2</sup>, **F. Longhini**<sup>5</sup>, **A. Russo**<sup>7</sup>, **F.S. Costanzo**<sup>5</sup>, **G. Matera**<sup>2</sup>, **C. Torti**<sup>4</sup>, **G. Viglietto**<sup>1</sup>

<sup>1</sup>Department of Experimental and Clinical Medicine, "Magna Graecia", University Catanzaro, Italy, <sup>2</sup>Department of Health Sciences, Clinical Microbiology Unit, "Magna Graecia" University, Catanzaro, Italy, <sup>3</sup>Klinikum rechts der Isar, Department of Regenerative Medicine in Cardiovascular Disease, Technical University of Munich, Munich, Germany, <sup>4</sup>Department of Medical and Surgical Sciences, Infectious and Tropical Disease Unit, "Magna Graecia" University of Catanzaro, Catanzaro, Italy, <sup>5</sup>Department of Experimental and Clinical Medicine, CIS for Genomics and Molecular Pathology, "Magna Graecia" University of Catanzaro, Catanzaro, Italy, <sup>6</sup>Department of Medical and Surgical Sciences, Intensive Care Unit, University "Magna Graecia" of Catanzaro, Italy, <sup>7</sup>Department of Medical and Surgical Sciences, "Magna Graecia" University of Catanzaro, Catanzaro, Italy

**OP 71 13.43-13.48 Access to HIV testing before and after SARS-CoV-2 pandemic in Milan: comparison between a health-care setting and a community setting**

**L. Biasoli**<sup>1,3</sup>, **A. Tavelli**<sup>1,3</sup>, **R. Rossotti**<sup>1,4</sup>, **A. De Bona**<sup>1,3</sup>, **D. Calzavara**<sup>1</sup>, **P. Vinti**<sup>1</sup>, **C. Muccini**<sup>1,2</sup>, **G. Mulè**<sup>3</sup>, **C. Baiguera**<sup>4</sup>, **R. Repossi**<sup>1</sup>, **A. D'Armino Monforte**<sup>1,3</sup>, **M. Cernuschi**<sup>1,2</sup> on behalf of the Milano Checkpoint Group

<sup>1</sup>Milano Checkpoint, Milano, <sup>2</sup>IRCCS San Raffaele Scientific Institute, Milano, <sup>3</sup>ASST Santi Paolo e Carlo, Milano, <sup>4</sup>ASST Niguarda Hospital, Milano

**OP 72 13.50-13.55 Characterization of PLWH with low-level viremia: results from the Italian ARCA cohort**

**M. Ranzenigo**<sup>1</sup>, **E. Bruzzesi**<sup>1</sup>, **D. Di Carlo**<sup>2</sup>, **V. Costabile**<sup>3</sup>, **F. Lombardi**<sup>4</sup>, **Y. Boubas**<sup>5</sup>, **F. Maggiolo**<sup>6</sup>, **A.P. Callegaro**<sup>7</sup>, **A. Zoncada**<sup>8</sup>, **S. Paolucci**<sup>9</sup>, **V. Micheli**<sup>10</sup>, **S. Renica**<sup>3</sup>, **A. Bezencheck**<sup>11,12</sup>, **B. Rossetti**<sup>13</sup>, **M.M. Santoro**<sup>14</sup>

<sup>1</sup>Università Vita-Salute San Raffaele, Milan, Italy, <sup>2</sup>CRC Pediatric "Romeo and Enrica Invernizzi", Department of Biosciences, University of Milan, Milan, Italy, <sup>3</sup>Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy, <sup>4</sup>UOC Malattie Infettive, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, <sup>5</sup>Chantal BIYA International Reference Centre for research on HIV/AIDS prevention and management (CIRCB), Yaoundé, Cameroon, <sup>6</sup>Department of Infectious Diseases, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy, <sup>7</sup>Department of Laboratory Medicine, ASST Papa Giovanni XXIII, Bergamo, Italy, <sup>8</sup>UO Malattie Infettive, ASST Cremona, Cremona, Italy, <sup>9</sup>Molecular Virology Unit, Division of Microbiology and Virology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, <sup>10</sup>Department of Clinical Microbiology Virology and Diagnosis of Bioemergency, Luigi Sacco University Hospital, Milan, Italy, <sup>11</sup>IPRO - InformaPRO S.r.l., Rome, Italy, <sup>12</sup>EuResist Network GEIE, Rome, Italy, <sup>13</sup>Infectious Diseases Unit, Department of Medical Sciences, University Hospital of Siena, Siena, Italy, <sup>14</sup>Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy

13.57-14.15 **Discussion**

**ORAL POSTER 13.15-14.15**

**FOYER AUDITORIUM**

**Epidemiology / Social Sciences III**

Chairs: **M. Farinella** (Roma), **V. Giacomè** (Milano), **C. Iaria** (Palermo)

**OP 73 13.15-13.20 Pre-Exposure Prophylaxis (PrEP) though the SARS-CoV-2 pandemic period: the experience of the dedicated service of Tuscany Region in S.M. Annunziata Hospital, Florence**

**E. Salomoni**, **C. Costa**, **L. Attala**, **B. Romanin**, **M. Paoletti**, **M. Brizzi**, **M.A. Di Pietro**, **F. Vichi**

SOC Malattie Infettive 1, Ospedale S. Maria Annunziata, Firenze, Azienda USL Toscana Centro

**OP 74 13.22-13.27 PrEP experience at Milano Checkpoint: promoting health and well-being through the integration of complementary skills**

**A. Bianchi**<sup>1,2</sup>, **A. Tavelli**<sup>3</sup>, **P.L. Vinti**<sup>2</sup>, **D. Calzavara**<sup>2</sup>, **A. Antonino**<sup>1,2</sup>, **F. Rossi**<sup>1,2</sup>, **M. Massa**<sup>2</sup>, **M. Lanza**<sup>1</sup>, **A. De Bona**<sup>3</sup>, **D. Rossotti**<sup>4</sup>, **S. Bosolasco**<sup>5</sup>, **D. Canetta**<sup>5</sup>, **A. Foschi**<sup>6</sup>, **D. Tesoro**<sup>3</sup>, **R. Repossi**<sup>1,2</sup>, **E. Garavaglia**<sup>1,2</sup>, **C. Ferrara**<sup>1,2</sup>, **D. De Cia Warzanowski**<sup>2</sup>, **M. Cernuschi**<sup>1,2,5</sup>

<sup>1</sup>ASA. Associazione Solidarietà AIDS, Milan, Italy, <sup>2</sup>Milano Checkpoint, Milan, <sup>3</sup>San Paolo Hospital, Milan, Italy, <sup>4</sup>ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, <sup>5</sup>San Raffaele Hospital, Milan, Italy, <sup>6</sup>Luigi Sacco Hospital, Milan, Italy



50

Scientific Programme

13<sup>o</sup> CONGRESSO NAZIONALE Italian Conference on AIDS and Antiviral Research



- OP 75** 13.29-13.34 **Rapid tests in the pandemic: the “continuum of care” of Villa Maraini during the Covid-19 emergency**  
T. Di Giovanni<sup>1</sup>, E. Teti<sup>2</sup>, G.F.M. Direnzo<sup>1</sup>, A.R. Cavasio<sup>1,2</sup>, P. Sammarco<sup>1</sup>, D. Masci<sup>1</sup>, B. Coladarce<sup>1</sup>, G. Rodoquino<sup>1</sup>, M. Andreoni<sup>2</sup>, E. Rossi<sup>1</sup>, M. Barra<sup>1</sup>  
<sup>1</sup>Fondazione Villa Maraini (Rome, Italy), <sup>2</sup>Infectious Disease Clinic, Tor Vergata University, Rome, Italy
- OP 76** 13.36-13.41 **Covid-19 in HIV/AIDS out-of-hospital facilities in Lombardy**  
L. Rancilio, G. Gaiera, P. Meli  
Coordinamento Case Alloggio per persone con HIV/AIDS della Lombardia (C.R.C.A. Lombardia)
- OP 77** 13.43-13.48 **The COVID-19 pandemic impact on retention in care and viral suppression at the Infectious Diseases Unit of S. M. Annunziata Hospital, Florence: comparing 2019 and 2020 data**  
C. Costa<sup>1</sup>, L. Attala<sup>1</sup>, B. Romanin<sup>1</sup>, P. Pierotti<sup>1</sup>, E. Salomoni<sup>1</sup>, M. Brizzi<sup>1</sup>, A. Gabbuti<sup>1</sup>, A. Poggi<sup>2</sup>, P. Nizzoli<sup>2</sup>, L. Rabatti<sup>2</sup>, A. Bellucci<sup>3</sup>, F. Vichi<sup>1</sup>, M. Di Pietro<sup>1</sup>  
<sup>1</sup>SOC Malattie Infettive 1, Ospedale S. Maria Annunziata, Firenze, Azienda USL Toscana Centro, <sup>2</sup>Farmacia Ospedaliera, Ospedale S. Maria Annunziata, Firenze, Azienda USL Toscana Centro, <sup>3</sup>SOC Patologia Clinica e Immunopatologia, Ospedale Nuovo S. Giovanni di Dio, Firenze, Azienda USL Toscana Centro
- OP 78** 13.50-13.55 **Reaching 90-90-90 in the municipality of Kilamba Kiaxi, Luanda, Angola. The experience of PIPSA project**  
G. Natali<sup>1</sup>, S. Da Silva<sup>2</sup>, Y. Tembe<sup>2</sup>, T. Almeida<sup>3</sup>, T. Lomba Jamba<sup>4</sup>, T. Baldoni<sup>1</sup>, L. Nigro<sup>2,5</sup> for the PIPSA Group. The PIPSA Group: E. Do Nascimento, M. Silvestre, S. Rocca, J. Bengui, M. Cardoso, U. Fernandes, M. Fundumuca, B. Gaspar, P. Kalandula, T. Mambo, C. Salvador, R. Salvador, J. Yemba, J. Massango, N. Comandante, B. Gonçaves P. João, M. Miguel, N. Cardoso  
<sup>1</sup>Unione Medico Missionaria Italiana, Negrar, Italy, <sup>2</sup>Cuamm - Medicos com Africa, Luanda, Angola, <sup>3</sup>Gabinete Provincial de Saúde, Luanda, Angola, <sup>4</sup>República Municipal de Saúde, Kilamba Kiaxi, Luanda, Angola, <sup>5</sup>LHIVE Diritti e Prevenzione, Catania, Italy

13.57-14.15 **Discussion**

## ORAL POSTER 13.15-14.15

### Virology

Chairs: V. Cento (Milano), B. Rossetti (Siena)

- OP 79** 13.15-13.20 **Molecular evidence of HIV-1 transmission in a criminal case in Italy**  
L. Fabeni<sup>1</sup>, I. Abbate<sup>1</sup>, G. Rozera<sup>1</sup>, M. Selleri<sup>1</sup>, G. Berno<sup>1</sup>, F. Forbici<sup>1</sup>, E. Giombini<sup>1</sup>, A. Bertoli<sup>2</sup>, R. Salpini<sup>2</sup>, R. Santangelo<sup>3,4</sup>, O. Turriziani<sup>3</sup>, C.F. Perno<sup>5</sup>, G. Ippolito<sup>1</sup>, M.R. Capobianchi<sup>1</sup>  
<sup>1</sup>Laboratory of Virology, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, Rome, Italy, <sup>2</sup>Department of Experimental Medicine and Surgery, University of Rome “Tor Vergata”, Rome, Italy, <sup>3</sup>Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy, <sup>4</sup>Università Cattolica del Sacro Cuore, Rome, Italy, <sup>5</sup>Laboratory of Microbiology and Virology, Department of Molecular Medicine, University of Rome “Sapienza”, Rome, Italy, <sup>6</sup>Microbiology and Immunology Diagnostics, Bambino Gesù Children’s Hospital IRCCS, Rome, Italy
- OP 80** 13.22-13.27 **Assessment of specific immunological response after administration of anti-meningococcal quadrivalent conjugate vaccine MENVEO® in a population with vertically-transmitted HIV infection**  
C. Vanetti<sup>1,2</sup>, C. Fenizia<sup>1,2</sup>, M. Garziano<sup>2</sup>, I. Saulle<sup>1</sup>, M. Stracuzzi<sup>3</sup>, F. Da Pozzo<sup>3</sup>, L. Paradiso<sup>3</sup>, E. Longoni<sup>3</sup>, L. Barcellini<sup>4</sup>, M. Biasin<sup>2</sup>, M. Clerici<sup>1,5</sup>, G.V. Zuccotti<sup>2,4</sup>, V. Giacometti<sup>3</sup>, D. Trabattoni<sup>2</sup>  
<sup>1</sup>University of Milan, Department of Pathophysiology and Transplantation, Milan, <sup>2</sup>University of Milan, Department of Biomedical and Clinical Sciences “Luigi Sacco”, Milan, Italy, <sup>3</sup>Ospedale “Luigi Sacco”, University of Milan, Department of Pediatric Infectious Diseases, Milan, <sup>4</sup>Ospedale dei Bambini V. Buzzi, University of Milan, Department of Pediatrics, Milan, <sup>5</sup>IRCCS Fondazione Don Gnocchi, Milan
- OP 81** 13.29-13.34 **Regulation of m6A methylation as new therapeutic option against COVID-19**  
C. Zannella<sup>1</sup>, V. Folliero<sup>1</sup>, R. Giugliano<sup>1</sup>, B.M. Nastro<sup>1</sup>, A. De Filippis<sup>1</sup>, M. Galdiero<sup>1</sup>, G. Franci<sup>2</sup>  
<sup>1</sup>Department of Experimental Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy, <sup>2</sup>Department of Medicine, Surgery and Dentistry Scuola Medica Salernitana, University of Salerno, Salerno, Italy
- OP 82** 13.36-13.41 **Characterization of humoral and cellular immune response after SARS-CoV-2 mRNA vaccine in HIV-1 infected patients**  
L. Santinelli<sup>1</sup>, G.P. Innocenti<sup>1</sup>, C. Mazzei<sup>2</sup>, C. Pinocchio<sup>1</sup>, M. Scordio<sup>3</sup>, L. Bortolani<sup>1</sup>, G. Recchia<sup>1</sup>, L. Battistini<sup>1</sup>, G. De Girolamo<sup>1</sup>, C. Scagnolari<sup>3</sup>, G. Ceccarelli<sup>1</sup>, C.M. Mastroianni<sup>1</sup>, M. Andreotti<sup>2</sup>, G. d’Ettore<sup>1</sup>  
<sup>1</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy, <sup>2</sup>National Center for Global Health, Istituto Superiore di Sanità, Rome, Italy, <sup>3</sup>Virology Laboratory, Department of Molecular Medicine, Sapienza University of Rome, Italy





Sabato  
23 ottobre



re-search, for re-start  
together Riccione 21-23 Ottobre 2021

**OP 83 13.43-13.48 Safety and tolerability of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine in a diverse cohort of people with HIV (PWH)**

*L. Ferrari*<sup>1</sup>, *F. Caldara*<sup>1</sup>, *E. Teti*<sup>1</sup>, *L. Piermatteo*<sup>2</sup>, *E. Andreassi*<sup>2</sup>, *M. Compagno*<sup>1</sup>, *T. Mulas*<sup>1</sup>, *G. De Simone*<sup>1</sup>, *D. Checchi*<sup>1</sup>, *A. Crea*<sup>1</sup>, *L. Ceccarelli*<sup>1</sup>, *A. Bertoli*<sup>2,3</sup>, *M. Iannetta*<sup>1</sup>, *F. Ceccherini Silberstein*<sup>2</sup>, *L. Sarmati*<sup>1</sup>, *M. Andreoni*<sup>1</sup>, *A.M. Geretti*<sup>1,4</sup>

<sup>1</sup>University of Rome Tor Vergata, Department of Systems Medicine, Infectious Diseases Clinic, Rome, Italy, <sup>2</sup>University of Rome Tor Vergata, Experimental Medicine, Rome, Italy, <sup>3</sup>Polyclinic Tor Vergata Foundation, Laboratory of Clinical Microbiology and Virology, Rome, Italy, <sup>4</sup>King's College London, Infectious Diseases, School of Immunology & Microbial Sciences, London, United Kingdom

**OP 84 13.50-13.55 Differences in response to mRNA BNT162b2 vaccine among a cohort of Health Care Workers (HCWs): insights into the potential of a booster dose**

*A. Tavelli*<sup>1</sup>, *M. Allegri*<sup>1</sup>, *P. Perrone*<sup>2</sup>, *V. Bordoni*<sup>3</sup>, *A. Longo*<sup>3</sup>, *V. Bono*<sup>1</sup>, *M. Augello*<sup>1</sup>, *L. Romanò*<sup>2</sup>, *W. De Francesco*<sup>4</sup>, *R. Grande*<sup>4</sup>, *C. Colosio*<sup>3</sup>, *G. Marchetti*<sup>1</sup>, *A. d'Arminio Monforte*<sup>1</sup>

<sup>1</sup>Clinic of Infectious Diseases, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Italy, <sup>2</sup>Department of Biomedical Sciences for Health, University of Milan, Milan, Italy, <sup>3</sup>Occupational Health Unit, International Centre for Rural Health, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy, <sup>4</sup>Microbiology Unit, ASST Santi Paolo e Carlo, Milan, Italy

13.57-14.15 **Discussion**

**SYMPOSIUM 14.00-14.45**

Con la sponsorizzazione non condizionante di Gilead Sciences e ViiV Healthcare

**The Italian Fast-Track Cities Network**

Chair: *A. d'Arminio Monforte* (Milano)

Discussants: *M. Cernuschi* (Milano), *F. Maggiolo* (Bergamo)

The Fast-Track Cities initiative is a global partnership between cities and municipalities around the world and four core partners: the International Association of Providers of AIDS-Care (IAPAC), the Joint United Nations Programme on HIV/AIDS (UNAIDS), the United Nations Human Settlements Programme (UN-Habitat) and the City of Paris. Launched on World AIDS Day 2012, the Network has grown to include more than 300 Cities and municipalities that are committed to attain the UNAIDS 95-95-95 targets by 2030. The aim of the Symposium is to discuss the global initiatives and to focus on the Italian Fast-Track Cities state of the art, in a round table involving the different Italian Fast-Track Cities' stakeholders.

14.00-14.05 **Introduction**

Antonella d'Arminio Monforte, Milano

14.05-14.15 **The Global Network and ICAR-IAPAC partnership**

Bertrand Audoin, Parigi F

14.15-14.40 **Round Table "The Italian Fast-Track Cities network: common actions"**

14.40-14.45 **Final considerations**

Bertrand Audoin, Parigi F; Antonella d'Arminio Monforte, Milano

**ORAL COMMUNICATIONS 14.15-14.45**

**Antiretroviral Therapy II**

Chairs: *A.M. Cattelan* (Padova), *N. Gianotti* (Milano)

**OC 47 14.15-14.25 Associations between weight changes and plasmatic pro-inflammatory cytokines in PLWH following ART initiation: data from the ICONA cohort**

*F. Bai*<sup>1</sup>, *A. Tavelli*<sup>2</sup>, *A. Cozzi-Lepri*<sup>3</sup>, *M. Hadla*<sup>1</sup>, *S. Cicalini*<sup>4</sup>, *D. Vincenti*<sup>2</sup>, *E. Quiros Roldan*<sup>5</sup>, *E. Schiaroli*<sup>2</sup>, *P. Meraviglia*<sup>6</sup>, *L. Taramasso*<sup>7</sup>, *G. Guaraldi*<sup>8</sup>, *A. d'Arminio Monforte*<sup>1</sup>, *G. Marchetti*<sup>1</sup>, *N. Gianotti*<sup>9</sup>

<sup>1</sup>Clinic of Infectious Diseases, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, <sup>2</sup>Icona Foundation, Milan, <sup>3</sup>Institute for Global Health, University College London, London, <sup>4</sup>HIV/AIDS Department, National Institute for Infectious Diseases, IRCCS, Lazzaro Spallanzani, Rome, <sup>5</sup>University Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Brescia, <sup>6</sup>Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, Milan, <sup>7</sup>Infectious Diseases Unit, Ospedale Policlinico San Martino - IRCCS, Department of Health Sciences (DISSAL), University of Genoa, Genoa, <sup>8</sup>Department of Medical and Surgical Sciences for Adults and Children, Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Modena, <sup>9</sup>Infectious Diseases, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan

**OC 48 14.27-14.37 Weight gain after switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to bicitgravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in patient with stable viral suppression**

*S. Cicalini*, *P. Lorenzini*, *E. Grilli*, *S. Ottou*, *M.M. Plazzi*, *F. De Zottis*, *M. Camici*, *M. Fusto*, *R. Gagliardini*, *R. Bellagamba*, *A. Antinori*  
National Institute for Infectious Diseases "Lazzaro Spallanzani", IRCCS, Rome



52

Scientific Programme

13<sup>o</sup> CONGRESSO NAZIONALE Italian Conference on AIDS and Antiviral Research



## ORAL COMMUNICATIONS 14.15-14.45

## POLISSENA B HALL

### Comorbidities II

Chair: M. Borderi (Bologna)

**OC 49 14.15-14.25 Viral dynamics in cerebrospinal fluid of patients with Progressive Multifocal Leukoencephalopathy**  
M. Negri<sup>1</sup>, I. Mainardi<sup>1</sup>, A. Tarantino<sup>1</sup>, S. Gerevini<sup>2</sup>, R. Vercesi<sup>1</sup>, R. Caccia<sup>1</sup>, F. Turrini<sup>1</sup>, A. Boschini<sup>3</sup>, S. Bossolasco<sup>1</sup>, H. Hasson<sup>1</sup>, A. Castagna<sup>1</sup>, P. Cinque<sup>1</sup>

<sup>1</sup>Unit of Infectious Diseases, San Raffaele Scientific Institute, Milano, <sup>2</sup>Unit of Neuroradiology, Papa Giovanni XXIII Hospital, Bergamo, <sup>3</sup>San Patrignano Medical Centre, Ospitaletto di Rimini

**OC 50 14.27-14.37 Switching to INSTI offsets negative effects of weight gain on incidence of insulin resistance in people living with HIV**

J. Milic<sup>1,2</sup>, S. Renzetti<sup>3</sup>, D. Ferrari<sup>1</sup>, S. Barbieri<sup>1</sup>, M. Menozzi<sup>2,4</sup>, G. Cuomo<sup>2,4</sup>, F. Carli<sup>2,4</sup>, G. Dolci<sup>2,4</sup>, G. Ciusa<sup>2,4</sup>, V. Iadisernia<sup>2,4</sup>, D. Yaacoub<sup>2,4</sup>, G. Burastero<sup>2,4</sup>, E. Bacca<sup>2,4</sup>, C. Mussini<sup>1,4</sup>, S. Calza<sup>4</sup>, G. Guaraldi<sup>1,2,4</sup>

<sup>1</sup>Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Italy, <sup>2</sup>Modena HIV Metabolic Clinic (MHMC), University of Modena and Reggio Emilia, Italy, <sup>3</sup>Department of Molecular and Translational Medicine, University of Brescia, Italy, <sup>4</sup>Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy

## ORAL COMMUNICATIONS 14.15-14.45

## ROOM 3

### Virology and Pharmacology I

Chairs: D. Cattaneo (Milano), M. Santoro (Roma)

**OC 51 14.15-14.25 Virological and Serological Characterization of SARS-CoV-2 Infections Diagnosed After mRNA BNT162b2 Vaccination**

F. Colavita, S. Meschi, C. E. M. Gruber, M. Rueca, F. Vairo, G. Matusali, D. Lapa, E. Giombini, G. De Carli, M. Spaziante, F. Messina, G. Bonfiglio, F. Carletti, E. Lalle, L. Fabeni, G. Berno, V. Puro, A. Di Caro, B. Bartolini, G. Ippolito, M.R. Capobianchi, C. Castilletti, on behalf of INMI Covid-19 laboratory surveillance team

National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Rome, Italy

**OC 52 14.27-14.37 Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected**

A. Gidari<sup>1</sup>, S. Sabbatini<sup>2</sup>, S. Bastianelli<sup>1</sup>, S. Pierucci<sup>1</sup>, C. Busti<sup>1</sup>, C. Monari<sup>2</sup>, B. Luciani Pasqua<sup>3</sup>, F. Dragoni<sup>4</sup>, E. Schiaroli<sup>1</sup>, M. Zazzi<sup>4</sup>, D. Francisci<sup>1</sup>

<sup>1</sup>Department of Medicine and Surgery, Clinic of Infectious Diseases, "Santa Maria della Misericordia" Hospital, University of Perugia, Perugia, Italy, <sup>2</sup>Department of Medicine and Surgery, Medical Microbiology Section, University of Perugia, Perugia, Italy, <sup>3</sup>Centro Regionale Sangue, Servizio Immunotrasfusionale, Azienda Ospedaliera di Perugia, Perugia, Italy, <sup>4</sup>Department of Medical Biotechnologies, University of Siena, Siena, Italy

## SYMPOSIUM 14.50-15.50

## AUDITORIUM CONCORDIA

### Long-COVID and HIV: which signatures?

Chairs: G. Guaraldi (Modena), E. Vicenzi (Milano)

COVID-19 has the potential to affect people living with HIV (PLWH) in various ways, including be increased risk of COVID-19 acquisition and interruptions of HIV treatment and care. The purpose of this session is to evaluate the impact of COVID-19 among PLWH. In particular to explore how different processes involving aging, inflammation, and cardiovascular risk may interact in HIV and SARS-CoV-2 co-infection, particularly the long-term effects generated by the collision of the two pandemics.

14.50-15.05 **Geroscience in long-COVID and HIV**

Nir Barzilay, New York USA

15.05-15.20 **Inflammaging in HIV & in long-COVID**

Monty Montano, Boston USA

15.20-15.30 **Discussion**

15.30-15.40 **Fat matters in HIV and COVID-19**

Giulia Besutti, Reggio Emilia

15.40-15.50 **Physical activity as pleasure and medicine**

Paola Cinque, Milano





Sabato  
23 ottobre



re-search, for re-start  
together

Riccione 21-23 Ottobre 2021

**ORAL COMMUNICATIONS** 14.50-16.20

**POLISSENA A HALL**

## Antiretroviral Therapy III

Chairs: S. Cicalini (Roma), C. Torti (Catanzaro)

### OC 53 14.50-15.00 Effectiveness of lamivudine + dolutegravir (3TC+DTG) in persons living with HIV (PLWH) starting their first antiretroviral treatment

A. Cozzi-Lepri<sup>1</sup>, A. Vergori<sup>2</sup>, S. Lo Caputo<sup>3</sup>, A. Cingolani<sup>4</sup>, F. Ceccherini-Silberstein<sup>5</sup>, R. Gagliardini<sup>2</sup>, M. Lichtner<sup>6</sup>, A. Calcagno<sup>7</sup>, G. Madeddu<sup>8</sup>, A. Castagna<sup>9</sup>, A. d'Arminio Monforte<sup>10</sup>, A. Antinori<sup>2</sup> on behalf of the Icona Foundation Study cohort

<sup>1</sup>IGH, University College London, UK, <sup>2</sup>INMI Lazzaro Spallanzani, Rome, Italy, <sup>3</sup>Università di Foggia, Foggia, Italy, <sup>4</sup>Policlinico Gemelli, Roma, Italy, <sup>5</sup>Università di Tor Vergata, Roma, Italy, <sup>6</sup>Università La Sapienza, Roma, Italy, <sup>7</sup>Università di Torino, Torino, Italy, <sup>8</sup>Università degli Studi di Sassari, Sassari, Italy, <sup>9</sup>San Raffaele Hospital, Milano, Italy, <sup>10</sup>San Paolo Hospital, Milano, Italy

### OC 54 15.02-15.12 Reasons for choosing a TAF-based 3DR instead of a DTG-based 2DR as ART switch strategy for virologically suppressed PLWH in Italy

A. Vergori<sup>1</sup>, A. Cozzi-Lepri<sup>2</sup>, A. Tavelli<sup>3</sup>, S. Lo Caputo<sup>4</sup>, E. Quiros-Roldan<sup>5</sup>, G. De Girolamo<sup>6</sup>, F. Bai<sup>7</sup>, C. Mussini<sup>8</sup>, A. Di Biagio<sup>9</sup>, L. Sarmati<sup>10</sup>, A. Antinori<sup>1</sup>, A. d'Arminio Monforte<sup>7</sup> for Icona Foundation Study Group

<sup>1</sup>HIV/AIDS Clinical Department, "Lazzaro Spallanzani" - IRCCS, National Institute for Infectious Diseases, Rome, Italy, <sup>2</sup>Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME) Institute for Global Health UCL, London, UK, <sup>3</sup>Icona Foundation, Milan, Italy, <sup>4</sup>Clinic of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy, <sup>5</sup>Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy, <sup>6</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, <sup>7</sup>Department of Health Sciences, Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy, <sup>8</sup>Department of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy, <sup>9</sup>Infectious Diseases Unit, San Martino Policlinico Hospital - IRCCS, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, <sup>10</sup>Infectious Diseases, University Hospital of Rome Tor Vergata, University of Rome Tor Vergata, Rome, Italy

### OC 55 15.14-15.24 An Italian non-interventional retrospective and prospective study in HIV-positive adult outpatients treated with D/C/F/TAF: the DIAMANTE study

A. Antinori<sup>1</sup>, D. Ripamonti<sup>2</sup>, G. Rizzardini<sup>3</sup>, S. Rusconi<sup>4,5</sup>, V. Esposito<sup>6</sup>, A. Cascio<sup>7</sup>, G. Orofino<sup>8</sup>, M. Andreoni<sup>9</sup>, E. Manzillo<sup>10</sup>, A. Castagna<sup>11,12</sup>, D. Mancusi<sup>13</sup>, M. Portaro<sup>13</sup>, A. Uglietti<sup>13</sup>, R. Termini<sup>13</sup>

<sup>1</sup>HIV/AIDS Unit, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, <sup>2</sup>Infectious Diseases Clinic, Papa Giovanni XXIII Hospital, Bergamo, Italy, <sup>3</sup>1st Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Milano, Italy, <sup>4</sup>DIBIC Luigi Sacco, University of Milan, Milan, Italy, <sup>5</sup>Infectious Diseases Unit, Legnano Hospital ASST Ovest Milanese, <sup>6</sup>Infectious Diseases and Gender Medicine Unit D. Cotugno Hospital - AO dei Colli Naples, Italy, <sup>7</sup>Infectious Diseases Clinic, AOU Policlinico "P.Giaccone", Palermo, Italy, <sup>8</sup>Amedeo di Savoia Hospital Unit of Infectious Diseases Torino, Italy, <sup>9</sup>Infectious Diseases Clinic, Fondazione Policlinico Tor Vergata University Hospital, Rome, Italy, <sup>10</sup>Infectious Disease and Infectious Emergencies, Azienda Ospedaliera dei Colli, Naples, Italy, <sup>11</sup>IRCCS San Raffaele Scientific Institute, Department of Infectious Diseases, Milan, Italy, <sup>12</sup>Università Vita-Salute San Raffaele, Milan, Italy, <sup>13</sup>Medical Affairs Department, Infectious Disease and Vaccines, Janssen-Cilag SpA, Cologno Monzese, Italy

### OC 56 15.26-15.36 Prevalence, characteristics and outcome of Heavily treated experienced (HTE) HIV-infected patients: data from the Italian ICONA Cohort

S. Lo Caputo<sup>1</sup>, A. Tavelli<sup>2</sup>, R. Gagliardini<sup>3</sup>, S. Rusconi<sup>4</sup>, G. Lapadula<sup>5</sup>, A. Antinori<sup>3</sup>, D. Francisci<sup>6</sup>, L. Sarmati<sup>7</sup>, A. Gori<sup>8</sup>, F. Ceccherini-Silberstein<sup>9</sup>, A. d'Arminio Monforte<sup>10</sup>, A. Cozzi-Lepri<sup>11</sup> on behalf of Icona Foundation Study Group

<sup>1</sup>University of Foggia, Infectious Diseases Unit, Department of Clinical and Experimental Medicine, Foggia, Italy, <sup>2</sup>Icona Foundation, Milan, Italy, <sup>3</sup>INMI L Spallanzani IRCC, HIV/AIDS Department, Rome, Italy, <sup>4</sup>ASST Ovest Milanese Ospedale di Legnano, University of Milan, Department of Infectious Diseases, Legnano, Italy, <sup>5</sup>ASST Monza, University of Milano-Bicocca, Clinic of Infectious Diseases, Monza, Italy, <sup>6</sup>University of Perugia, Department of Medicine and Surgery, Clinic of Infectious Diseases, Perugia, Italy, <sup>7</sup>Policlinico Tor Vergata, University of Rome Tor Vergata, Department of System Medicine, Infectious Disease Clinic, Rome, Italy, <sup>8</sup>Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Department of Pathophysiology and Transplantation, Infectious Diseases Unit, Milan, Italy, <sup>9</sup>University of Rome Tor Vergata, Department of Experimental Medicine, Rome, Italy, <sup>10</sup>University of Milan, ASST Santi Paolo e Carlo, Clinic of Infectious Diseases, Department of Health Sciences, Milan, Italy, <sup>11</sup>UCL, Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, London, United Kingdom

### OC 57 15.38-15.48 BIC/FTC/TAF is effective on PLWH with low CD4 counts: real-life data from the Icona cohort

A. d'Arminio Monforte<sup>1</sup>, A. Tavelli<sup>2</sup>, F. Maggiolo<sup>3</sup>, A. Castagna<sup>4</sup>, F. Ceccherini-Silberstein<sup>5</sup>, A. Cozzi-Lepri<sup>6</sup>, E. Girardi<sup>7</sup>, S. Lo Caputo<sup>8</sup>, C. Mussini<sup>9</sup>, M. Puoti<sup>10</sup>, A. Gori<sup>11</sup>, A. Antinori<sup>12</sup> for Icona Foundation Study Group

<sup>1</sup>Department of Health Sciences, Clinic of Infectious Disease, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy, <sup>2</sup>Icona Foundation, Milan, Italy, <sup>3</sup>Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy, <sup>4</sup>Department of Infectious Diseases, IRCCS Ospedale San Raffaele, University Vita-Salute San Raffaele, Milan, Italy, <sup>5</sup>Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy, <sup>6</sup>Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK, <sup>7</sup>Department of Epidemiology and Pre-Clinical Research, National Institute for Infectious Diseases L. Spallanzani, Rome, Italy, <sup>8</sup>Infectious Diseases Department, University of Foggia, Foggia, Italy, <sup>9</sup>Infectious Diseases Unit, Azienda Ospedaliero-Universitaria Policlinico di Modena, University of Modena and Reggio Emilia, Modena, Italy, <sup>10</sup>Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, <sup>11</sup>Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, <sup>12</sup>HIV/AIDS Department, National Institute for Infectious Diseases L. Spallanzani, Rome, Italy

### OC 58 15.50-16.00 ART switch for pro-active, re-active or cost-saving reasons: a real world evaluation of the determinants over the period 2017 -2020 in the Veneto Region

A.M. Cattelan<sup>1</sup>, A. Cozzi-Lepri<sup>2</sup>, M. Mazzitelli<sup>1,3</sup>, M. Malena<sup>4</sup>, L. Sasse<sup>1</sup>, P. Rovere<sup>5</sup>, V. Manfrin<sup>6</sup>, R. Ferretto<sup>5</sup>, M. Fison<sup>4</sup>, M. Vincenzi<sup>5</sup>, G. Battagin<sup>6</sup>, I. Coledan<sup>7</sup>, L. Da Ros<sup>8</sup>, M. Lanzafame<sup>7</sup> for the Veneto Collaborative Group

<sup>1</sup>Azienda Ospedale Università Padova, <sup>2</sup>UCL, London, UK, <sup>3</sup>Magna Graecia University of Catanzaro, <sup>4</sup>U.O.S.D. Centro Malattie Diffusive ULSS 9 Verona, <sup>5</sup>U.O. Malattie Infettive Ospedale "Mater Salutaris" Legnago, <sup>6</sup>U.O. Malattie Infettive e Tropicali Ospedale S. Bortolo Vicenza, <sup>7</sup>U.O. Malattie Infettive A.O.U.I. Verona, <sup>8</sup>Fondazione Smith Kline.

Other members of Veneto Collaborative Group: S. Panese, U.O. Malattie Infettive Ospedale dell'Angelo Mestre (VE), M.G. Cecchetto, U.O. Malattie Infettive Ospedale "Santa Maria della Misericordia" Rovigo, C. Granata, U.O. Malattie Infettive Ospedale San Martino di Belluno, P. Scotton, M.C. Rossi, U.O. Malattie Infettive Ospedale Ca' Foncello Treviso



54

Scientific Programme

13° CONGRESSO NAZIONALE Italian Conference on AIDS and Antiviral Research





**OC 59 16.02-16.12 Switching to Emtricitabine/Tenofovir Alafenamide/Bictegravir on metabolic and hepatic safety: preliminary data from Surveillance Cohort Long-term Toxicity Antiretrovirals/antivirals (SCOLTA) project**  
**N. Squillace<sup>1</sup>, E. Ricci<sup>2</sup>, B. Menzaghi<sup>3</sup>, G.V. De Socio<sup>4</sup>, G. Orofino<sup>5</sup>, B.M. Ceslasia<sup>6</sup>, F. Vichi<sup>7</sup>, A. Di Biagio<sup>8</sup>, L. Taramasso<sup>8</sup>, C. Molteni<sup>9</sup>, E. Sarchi<sup>10</sup>, L. Valsecchi<sup>11</sup>, G.F. Pellicanò<sup>12</sup>, P. Bonfanti<sup>1</sup>, for the CISAI Study Group**

<sup>1</sup>Infectious Diseases Unit ASST-MONZA, San Gerardo Hospital-University of Milano-Bicocca, Monza, <sup>2</sup>Fondazione ASIA Onlus, Buccinasco, Milano, Italy, <sup>3</sup>Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio, Varese, <sup>4</sup>Unit of Infectious Diseases, Santa Maria Hospital, Perugia, <sup>5</sup>Division I of Infectious and Tropical Diseases, ASL Città di Torino, <sup>6</sup>Unit of Infectious Diseases, Garibaldi Hospital, Catania, <sup>7</sup>Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Florence, <sup>8</sup>Infectious Diseases, San Martino Hospital Genoa, University of Genoa, Genoa, <sup>9</sup>Unit of Infectious Diseases, A. Manzoni Hospital, Lecco, <sup>10</sup>Infectious Diseases Unit, S. Antonio Biagio e Cesare Arrigo Hospital, Alessandria, Italy, <sup>11</sup>1st Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, Italy, <sup>12</sup>Infectious Diseases, G. Martino Hospital University of Messina, Messina

**ORAL COMMUNICATIONS 14.50-16.20**

**POLISSENA B HALL**

**Virology and Pharmacology II**

Chairs: S. Parisi (Padova), O. Turriziani (Roma)

14.50-15.05 **An update on the pharmacological strategies in the treatment of viral infections**

Stefano Bonora, Torino

15.05-15.20 **Pharmacology as a tool for polypharmacy management in HIV**

Cristina Gervasoni, Milano

**OC 60 15.20-15.30 Evaluation of factors potentially associated with Low-level viremia in PLWH from the Italian ARCA cohort: a matched Case- Control Study**

**E. Lombardi<sup>1</sup>, Y. Bouba<sup>2</sup>, D. Di Carlo<sup>3</sup>, V. Costabile<sup>4</sup>, E. Bruzzesi<sup>5</sup>, M. Ranzenigo<sup>5</sup>, F. Maggiolo<sup>6</sup>, A.P. Callegaro<sup>7</sup>, A. Zoncada<sup>8</sup>, S. Paolucci<sup>9</sup>, V. Micheli<sup>10</sup>, S. Renica<sup>3</sup>, A. Bezencheck<sup>11,12</sup>, B. Rossetti<sup>13</sup>, M.M. Santoro<sup>14</sup>**

<sup>1</sup>UOC Malattie Infettive, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, <sup>2</sup>Chantal BIYA International Reference Centre for research on HIV/AIDS prevention and management (CIRCB), Yaoundé, Cameroon, <sup>3</sup>CRC Pediatric "Romeo and Enrica Invernizzi", Department of Biosciences, University of Milan, Milan, Italy, <sup>4</sup>Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy, <sup>5</sup>Università Vita-Salute San Raffaele, Milan, Italy, <sup>6</sup>Department of Infectious Diseases, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy, <sup>7</sup>Department of Laboratory Medicine, ASST Papa Giovanni XXIII, Bergamo, Italy, <sup>8</sup>UO Malattie Infettive, ASST Cremona, Cremona, Italy, <sup>9</sup>Molecular Virology Unit, Division of Microbiology and Virology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, <sup>10</sup>Department of Clinical Microbiology Virology and Diagnosis of Bioemergency, Luigi Sacco University Hospital, Milan, Italy, <sup>11</sup>IPRO - InformaPRO S.r.l., Rome, Italy, <sup>12</sup>EuResist Network GEIE, Rome, Italy, <sup>13</sup>Infectious Diseases Unit, Department of Medical Sciences, University Hospital of Siena, Siena, Italy, <sup>14</sup>Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy

**OC 61 15.32-15.42 Distribution of tenofovir plasma trough concentrations in PLWH treated with doravirine**

**D. Cattaneo, M. Fusi, V. Micheli, C. Resnati, P. Meraviglia, M.V. Cossu, S. Vimercati, C.G. Bisinella, S. Baldelli, S. Antinori, C. Gervasoni**

ASST Fatebenefratelli Sacco University Hospital, Milano, Italy

**OC 62 15.44-15.54 SNP-168 of the protein kinase and CD4 or CD8 dynamic in HIV-1 patients**

**C. Brombin<sup>1,2</sup>, S. Bagaglio<sup>3</sup>, A. Castagna<sup>2,3</sup>, C. Uberti-Foppa<sup>2,3</sup>, S. Salpietro<sup>3</sup>, C. Di Serio<sup>1,2</sup>, G. Morsica<sup>3</sup>**

<sup>1</sup>University Centre for Statistics in the Biomedical Sciences (CUSSB), Milano, Italy, <sup>2</sup>Vita-Salute San Raffaele University, Milano, Italy, <sup>3</sup>Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy

**OC 63 15.56-16.06 Interpatient variability in the pharmacokinetics of the remdesivir and main metabolite GS-441524 in treated COVID-19 subjects**

**M. Tempestilli<sup>1</sup>, T. Ascoli-Bartoli<sup>2</sup>, L. Lepore<sup>2</sup>, L. Marchioni<sup>2</sup>, E. Nicastrì<sup>2</sup>, C. Agrati<sup>1</sup>**

<sup>1</sup>Cellular Immunology and Pharmacology Laboratory, National Institute for Infectious Diseases "L. Spallanzani" I.R.C.C.S., Rome, Italy, <sup>2</sup>Clinical Department, National Institute for Infectious Diseases "L. Spallanzani" I.R.C.C.S., Rome, Italy

**OC 64 16.08-16.18 Temporal trend of drug-resistance and APOBEC editing in PBMC genotypic resistance tests on isolates with contextual undetectable HIV-1 plasma viral load performed for clinical routine**

**D. Armenia<sup>1</sup>, V. Cento<sup>2</sup>, C. Alteri<sup>2,3</sup>, V. Borghi<sup>4</sup>, R. Gagliardini<sup>5</sup>, A. Vergori<sup>5</sup>, F. Forbici<sup>5</sup>, A. Bertoli<sup>6,7</sup>, W. Gennari<sup>4</sup>, V. Malagnino<sup>7</sup>, M. Andreoni<sup>7</sup>, C. Mussini<sup>4</sup>, A. Antinori<sup>5</sup>, C.F. Perno<sup>3</sup>, F. Ceccherini-Silberstein<sup>6</sup>, M.M. Santoro<sup>6</sup>**

<sup>1</sup>Unit Camillus, Saint Camillus International University of Health Sciences, Rome, Italy, <sup>2</sup>University of Milan, Milan, Italy, <sup>3</sup>Bambino Gesù Children's Hospital, Rome, Italy, <sup>4</sup>University of Modena and Reggio Emilia, Modena, Italy, <sup>5</sup>National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, <sup>6</sup>University of Rome "Tor Vergata", Rome, Italy, <sup>7</sup>Polyclinic of Rome "Tor Vergata", Rome Italy







Sabato  
23 ottobre



re-search, for re-start  
together

Riccione 21-23 Ottobre 2021

## ORAL COMMUNICATIONS 14.50-16.20

ROOM 3

### Epidemiology / Social Sciences IV

Chair: G. Verucchi (Bologna)

- OC 65 14.50-15.00 Interest in injecting Long-Acting agents by people living with HIV in Italy: a picture from the Icona Network**  
A. Cingolani<sup>1</sup>, A. Tavelli<sup>2</sup>, F. Maggiolo<sup>3</sup>, A. Perziano<sup>4</sup>, A. Saracino<sup>5</sup>, F. Vichi<sup>6</sup>, M. Cernuschi<sup>7</sup>, G. Guaraldi<sup>8</sup>, E. Quiros Roldan<sup>9</sup>, A. Castagna<sup>7</sup>, A. Antinori<sup>10</sup>, A. d'Arminio Monforte<sup>11</sup> on behalf of Icona Network  
<sup>1</sup>Infectious Diseases Unit, Fondazione Policlinico Universitario A. Gemelli - Università Cattolica Del Sacro Cuore, Rome, Italy, <sup>2</sup>Icona Foundation, Milan, Italy, <sup>3</sup>Division of Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy, <sup>4</sup>For CAB Icona Associazione Arcobaleno AIDS ODV, Torino, Italy, <sup>5</sup>University of Bari "Aldo Moro," Department of Biomedical Sciences and Human Oncology, Clinic of Infectious Diseases, Bari, Italy, <sup>6</sup>Infectious Diseases Unit 1, Santa Maria Annunziata Hospital, Azienda USL Toscana Centro, Florence, Italy, <sup>7</sup>Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, University Vita-Salute San Raffaele, Milan, Italy, <sup>8</sup>Department of Infectious Diseases, University Hospital of Modena, University Hospital of Modena, Modena, Italy, <sup>9</sup>University Department of Infectious and Tropical Diseases, University of Brescia, ASST Spedali Civili, Brescia, Italy, <sup>10</sup>HIV/AIDS Department, INMI, L. Spallanzani, IRCCS, Rome, Italy, <sup>11</sup>Clinic of Infectious Diseases, Department of Health Sciences, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy
- OC 66 15.02-15.12 Milan Fast Track City: study on HIV prevalence in two different settings**  
A. d'Arminio Monforte<sup>1</sup>, A. Tavelli<sup>1</sup>, D. Barbanotti<sup>1</sup>, G. Pigliapochi<sup>2</sup>, A. Ruggeri<sup>2</sup>, R. Repossi<sup>2</sup>, D. Calzavara<sup>2</sup>, A. de Bona<sup>1</sup>, T. Bini<sup>1</sup>, C. Tincati<sup>1</sup>, R. Rossotti<sup>2</sup>, M. Cernuschi<sup>2</sup>  
<sup>1</sup>Clinic of Infectious and Tropical Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, Milan, <sup>2</sup>Milan Check Point, Milan
- OC 67 15.14-15.24 Impact of COVID-19 on HIV testing and counselling services in Lazio Region**  
N. Orchi<sup>1</sup>, A. Navarra<sup>2</sup>, R. Esvani<sup>1</sup>, F. Gili<sup>1</sup>, S. Pittalis<sup>2</sup>, V. Puro<sup>1</sup>, for the Regional Group of HIV testing and counselling sites<sup>3</sup>  
<sup>1</sup>Regional AIDS Reference Center, National Institute for Infectious Diseases L. Spallanzani, Rome, Italy, <sup>2</sup>Clinical Epidemiology Unit, National Institute for Infectious Diseases L. Spallanzani, Rome, Italy, <sup>3</sup>Regional Group of HIV testing and counselling sites
- OC 68 15.26-15.36 Estimation of the proportion of people living with HIV in ART and virally suppressed, using surveillance and cohort data. Italy, 2012-2019**  
L. Timelli<sup>1</sup>, A. Navarra<sup>2</sup>, P. Piselli<sup>1</sup>, V. Regine<sup>2</sup>, A. Mammone<sup>3</sup>, A. Caraglia<sup>3</sup>, L. Pugliese<sup>2</sup>, M. Oldrini<sup>5</sup>, L. Rancilio<sup>6</sup>, L. Cosmaro<sup>5</sup>, M. Farinella<sup>7</sup>, A. Tavelli<sup>4</sup>, A. d'Arminio Monforte<sup>4</sup>, B. Suligoi<sup>2</sup>, E. Girardi<sup>1</sup>  
<sup>1</sup>Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani" - IRCCS, Roma, <sup>2</sup>Istituto Superiore di Sanità, Roma, <sup>3</sup>Ministero della Salute, Roma, <sup>4</sup>Fondazione ICONA, Milano, <sup>5</sup>Fondazione LILA Milano, Milano, <sup>6</sup>Caritas Ambrosiana, Milano, <sup>7</sup>Circolo Mario Mieli, Roma
- OC 69 15.38-15.48 Prevalence of HIV infection in the PIPSA project carried out in Luanda, Angola. Data analysis by sex and age group**  
G. Natali<sup>1</sup>, F. Cavallin<sup>2</sup>, T.S.S. Almeida<sup>3</sup>, T. Lomba Jamba<sup>4</sup>, T. Baldoni<sup>1</sup>, S. Rocca<sup>1</sup>, P. João<sup>5</sup>, M. Miguel<sup>5</sup>, L. Nigro<sup>5,6</sup> for the PIPSA Group. The PIPSA Group: E. Do Nascimento, M. Silvestre, J. Bengui, M. Cardoso, S. Da Silva, U. Fernandes, M. Fundumuca, B. Gaspar, P. Kalandula, T. Mambo, C. Salvador, R. Salvador, J. Vemba, N. Cardoso.  
<sup>1</sup>Unione Medico Missionaria Italiana, Negrar, Italy, <sup>2</sup>Independent Statistician, Solagna, Italy, <sup>3</sup>Gabineto Provincial de Saúde, Luanda, Angola, <sup>4</sup>Repartição Municipal de Saúde, Kilamba Kiaxi, Luanda, Angola, <sup>5</sup>Cuamm - Medicos com Africa, Luanda, Angola, <sup>6</sup>LHIVE Diritti e Prevenzione, Catania, Italy
- OC 70 15.50-16.00 High prevalence of mental health disorders in HIV positive adolescents and youths: an observational study from 8 health services in Beira district, Mozambique**  
F. Di Gennaro<sup>1,2</sup>, A. Pozniak<sup>3</sup>, L. Ramirez<sup>4</sup>, H. Cardoso<sup>4</sup>, A. Chivite<sup>4</sup>, V. Cinturao<sup>4</sup>, D.F. Bavaro<sup>1</sup>, N. Chimundi<sup>4</sup>, C. Marotta<sup>2</sup>, I. Chaguruca<sup>4</sup>, F. Tognon<sup>2</sup>, E. Namarime<sup>4</sup>, E. Ocça<sup>4</sup>, G. Putoto<sup>2</sup>, A. Saracino<sup>1</sup>  
<sup>1</sup>Clinic of Infectious Diseases, University of Bari, University Hospital Policlinico, Bari, Italy, <sup>2</sup>Operational Research Unit, Doctors with Africa CUAMM, Padua, Italy, <sup>3</sup>Department of HIV Medicine, Chelsea & Westminster Hospital NHS Foundation Trust, London, UK; Department Clinical Research, London School of Hygiene & Tropical Medicine, London, UK, <sup>4</sup>Doctors with Africa CUAMM, Beira, Mozambique
- OC 71 16.02-16.12 High prevalence of asymptomatic Sars-Cov2 infection in the cohort of Liver Transplant Recipients at INMI Spallanzani**  
U. Visco-Comandini<sup>1</sup>, C. Castilletti<sup>2</sup>, R. Lionetti<sup>1</sup>, M. Montalbano<sup>1</sup>, A. Rianda<sup>1</sup>, C. Taibi<sup>1</sup>, C. Sorace<sup>1</sup>, S. Meschi<sup>2</sup>, N. Guglielmo<sup>3</sup>, P. Paci<sup>4</sup>, G.M. Ettore<sup>3</sup>, G. D'Offizi<sup>1</sup>  
<sup>1</sup>Polo Ospedaliero Interaziendale Trapianti POIT 1 UOC Malattie Infettive Epatologia, INMI L. Spallanzani, <sup>2</sup>Laboratorio di Virologia, INMI Spallanzani, <sup>3</sup>UOC Chirurgia Oncologica e dei Trapianti d'Organo, Az Ospedaliera San Camillo, <sup>4</sup>Dipartimento di Ingegneria Informatica, Automatica e Gestionale "A. Ruberti" Università di Roma La Sapienza



56

Scientific Programme

13° CONGRESSO NAZIONALE Italian Conference on AIDS and Antiviral Research



## SIMIT & ICAR-CROI AWARDS 16.20-16.40

Chairs: G.V. Calvino (Roma), M.R. Capobianchi (Roma), A.M. Cattelan (Padova), A. d'Arminio Monforte (Milano), C.M. Mastroianni (Roma), C. Mussini (Modena), G. Silvestri (Atlanta USA), M. Tavio (Ancona), S. Vella (Roma)

## AUDITORIUM CONCORDIA

The 13rd edition of ICAR Awards:

### ICAR-CROI Awards 2021 for young Italian investigators

Selected Italian Investigators who presented their works in virtual mode at CROI 2021:

- **High and persistent neutralizing antibodies in children recovered from COVID-19**  
Francesco Bonfante, Legnaro (PD)
- **Modulation of gut flora promotes the regression of anal dysplasia in HIV+ MSM**  
Eugenio Nelson Cavallari, Roma
- **Asymptomatic SARS-CoV-2 children have lower infectivity and intact memory responses**  
Nicola Cotugno, Roma
- **Intracellular disposition of darunavir/ritonavir and dolutegravir with rifampin**  
Amedeo De Nicolò, Torino
- **Impairment of type I/III IFN response in the upper airways of SARS-CoV-2 patients**  
Federica Frasca, Roma
- **Characteristics and outcomes of Covid-19-related hospitalization among PLWH**  
Roberta Gagliardini, Roma
- **High specific immune response and low T-CELL activation in children with COVID-19**  
Maria Raffaella Petrara, Padova
- **Uprising circulation of HBV-complex profiles with HBsAG vaccine-escape mutations**  
Lorenzo Piermatteo, Roma
- **Characterisation of SARS-CoV-2-infected children developing neutralising antibodies**  
Alessandra Ruggiero, Roma
- **Compartmental T-CELL profile and IFN response in SARS-CoV-2-infected subjects**  
Letizia Santinelli, Roma
- **Lack of TLRs activation in anal cells of HIV+ men may contribute to HPV persistence**  
Letizia Santinelli, Roma
- **Immuno-inflammatory profile of advanced-HIV-infected persons in a COVID-19 outbreak**  
Alessandra Vergori, Roma
- **Impact of switch from EFV/F/TDF to B/F/TAF on psychiatric symptoms and neurocognition**  
Alessandra Vergori, Roma

### ICAR 2021 Scientific Committee Awards

### SIMIT Awards to Best Oral Communications for Young Researchers

### ICAR 2021 Closing Remarks

G.V. Calvino (Roma), M.R. Capobianchi (Roma), A.M. Cattelan (Padova), C. Mussini (Modena)



*re-search for re-start together*

Riccione 21-23 Ottobre 2021



**13° CONGRESSO NAZIONALE Italian Conference on AIDS and Antiviral Research**

Presidenza del Congresso:  
**G. V. Calvino, M. R. Capobianchi, A. M. Cattelan, C. Mussini**

POSTER  
EXHIBITION



re-search, for re-start  
together Riccione 21-23 Ottobre 2021

## Antiretroviral therapy

### ISSUES ON ANTIRETROVIRAL THERAPY

- P 1 Switching to BICTegrovir in Elderly people living with HIV-1 under virologic control: a retrospective data analysis (BICTEL cohort)**  
*A. Lazzaro, E. Gentilini, C. Borrazzo, E. Cavallari Nelson, G. Innocenti, C. Fimiani, I. Mezzaroma, C. Mastroianni, G. d'Etto*  
Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, Rome, Italy
- P 2 When the color matters: drug induced hypersensitivity to DTG/RPV coformulation**  
*G. Del Fabro, E. Quiros-Roldan*  
Department of Infectious Diseases and Tropical Medicine, University of Brescia, Brescia
- P 3 An extended follow-up of naïve patients with <100,000 copies/ml HIV-RNA treated with dolutegravir monotherapy**  
*M. Lanzafame<sup>1</sup>, S. Rizzardo<sup>2</sup>, E. Lattuada<sup>3</sup>, S. Vento<sup>4</sup>*  
<sup>1</sup>Unit of Infectious Diseases, S. Maria della Misericordia Hospital, Rovigo, Italy, <sup>2</sup>Unit of Internal Medicine, S. Maria del Carmine Hospital, Rovereto (Trento), Italy, <sup>3</sup>Infectious Diseases Unit, G.B. Rossi University Hospital, Verona, Italy, <sup>4</sup>Faculty of Medicine, University of Puthisastra, Phnom Penh, Cambodia
- P 4 Immunological outcomes of persons receiving dolutegravir-based antiretroviral therapy for treatment of HIV in the Italian MaSTER cohort**  
*S.N. Rich<sup>1,9</sup>, P. Nasta<sup>1</sup>, M.C. Pezzoli<sup>1</sup>, E. Di Filippo<sup>2</sup>, R. Cauda<sup>3</sup>, A. Saracino<sup>4</sup>, D. Segala<sup>5</sup>, G. Lapadula<sup>6</sup>, C. Costa<sup>7</sup>, A. Ferraresi<sup>8</sup>, N. Mazzini<sup>9</sup>, M. Prosperi<sup>10</sup>, G. Carosi<sup>9</sup> for the MaSTER cohort group*  
<sup>1</sup>U.O. Malattie Infettive, ASST Spedali Civili, Brescia, <sup>2</sup>Divisione di Malattie Infettive, ASST Papa Giovanni XXIII, Bergamo, <sup>3</sup>Dipartimento di Sicurezza e Bioetica – Università Cattolica del Sacro Cuore, Roma, <sup>4</sup>Clinica Malattie Infettive, Policlinico di Bari, <sup>5</sup>Divisione Malattie Infettive, Nuovo Polo Ospedaliero di Cona, Ferrara, <sup>6</sup>Divisione di Malattie Infettive, ASST San Gerardo, Monza, <sup>7</sup>SOC 1 Malattie Infettive, USL CENTRO, Firenze, <sup>8</sup>Divisione di Malattie Infettive, ASST Istituti Ospitalieri, Cremona, <sup>9</sup>Fondazione Malattie Infettive e Salute Internazionale, Brescia, <sup>10</sup>Department of Epidemiology, University of Florida, USA
- P 5 Preliminary findings on the efficacy and safety of a 2DR with dolutegravir plus doravirine in clinical practice**  
*A. Ciccullo<sup>1</sup>, G. Baldin<sup>2,3</sup>, L. Celani<sup>1,4</sup>, F. Lagi<sup>5</sup>, G. d'Etto<sup>4</sup>, G. Sterrantino<sup>5</sup>, A. Grimaldi<sup>1</sup>, S. Rusconi<sup>6</sup>, V. Borghi<sup>7</sup>, S. Di Giambenedetto<sup>3,8</sup>*  
<sup>1</sup>Infectious Diseases Unit, San Salvatore Hospital, L'Aquila, Italy, <sup>2</sup>Mater Olbia Hospital, Olbia, Italy, <sup>3</sup>Infectious Diseases Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy, <sup>4</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, <sup>5</sup>Infectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy, <sup>6</sup>Infectious Diseases Unit, Legnano General Hospital, ASST Ovest Milanese, and DIBIC Luigi Sacco, University of Milan, Italy, <sup>7</sup>Department of Infectious Diseases, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy, <sup>8</sup>Catholic University of the Sacred Heart, Rome, Italy
- P 6 Delayed seroconversion in patient with acute HIV infection in early TARV**  
*V. Viscusi, A. Toschi, L. Calza, I. Bon*  
Sant'Orsola Malpighi, Bologna
- P 7 Switching from FTC/TAF to DOR/3TC/TDF: effects on lipid metabolism and renal function on a small case-series**  
*M. Ceccarelli<sup>1</sup>, G. Bruno<sup>2</sup>, V. Coco<sup>2</sup>, B. Bellocchi<sup>2,3</sup>, E. Campanella<sup>2,3</sup>, E. Pistarà<sup>2,3</sup>, L. Todaro<sup>2,3</sup>, F. Tosto<sup>2,3</sup>, V. Moscatelli<sup>2,3</sup>, F. Cosentino<sup>2,3</sup>, A. Marino<sup>2,3</sup>, V. Boscia<sup>2</sup>, G. Lupo<sup>2</sup>, G. Nunnari<sup>3</sup>, B. Cacopardo<sup>1</sup>, B.M. Ceslesia<sup>2</sup>*  
<sup>1</sup>Department of Clinical and Experimental Medicine, Unit of Infectious Diseases, University of Catania, Catania, Italy, <sup>2</sup>Unit of Infectious Diseases, ARNAS "Garibaldi", "Nesima" Hospital, Catania, Italy, <sup>3</sup>Department of Clinical and Experimental Medicine, Unit of Infectious Diseases, University of Messina, Messina, Italy
- P 8 Effects of lockdown in a cohort of HIV subjects**  
*A. Auricchio, C. Ucciferri, M. Pontolillo, Z. Di Rosa, L. Moffa, F. Mucedola, A. Di Gasbarro, G. Taraschi, A. Di Marcello, A. Brandimarte, J. Vecchiet, K. Falasca*  
Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University "G. d'Annunzio", Chieti-Pescara, Italy





## Clinical HIV, Clinical COVID-19

### HIV AND COVID-19

**P 9 Towards “Fast-Track Cities” at the time of SARS-CoV2 pandemic: the combination of HIV blood test and nasopharyngeal swab on 1st December 2020 World AIDS Day**

G. Mancarella<sup>2</sup>, V. Belvisi<sup>1</sup>, M. Jamhour Meriem<sup>1</sup>, R. Marocco<sup>1</sup>, V.S. Mercurio<sup>1</sup>, S. Cacace<sup>2</sup>, P. Zuccalà<sup>1</sup>, L. Fondaco<sup>1,2</sup>, A. Carraro<sup>1,2</sup>, M. D’Achille<sup>1</sup>, V. Rossi<sup>1</sup>, O. D’Onofrio<sup>1</sup>, A.C. Petrillo<sup>3</sup>, V. Vitale<sup>3</sup>, M. Lichtner<sup>1,2</sup>

<sup>1</sup>Infectious Diseases Unit, S.M. Goretti Hospital, Latina, <sup>2</sup>Department of Public Health and Infectious Diseases, “Sapienza” University, Rome, <sup>3</sup>Arcigay Latina - Seicomesei

**P 10 The impact of infection with SARS-Cov2 among people living with human immunodeficiency virus (PLWH)**

A. Di Marcello, A. Brandimarte, A. Di Gasbarro, G. Taraschi, F. Mucedola, L. Moffa, F. Vignale, C. Ucciferri, J. Vecchiet, K. Falasca  
Ospedale SS.ma Annunziata, Malattie Infettive, Chieti

**P 11 Did lockdown due to SARS-Cov-2 pandemic jeopardize the efficacy of antiretroviral therapy?**

N. Gianotti<sup>1</sup>, A. Poli<sup>1</sup>, L. Galli<sup>1</sup>, S. Bossolasco<sup>1</sup>, G. Morsica<sup>1</sup>, G. Gaiera<sup>1</sup>, T. Clemente<sup>1,2</sup>, R. Papaioannu<sup>1,2</sup>, M. Bottanelli<sup>1,2</sup>, A. Lazzarin<sup>1</sup>, A. Castagna<sup>1,2</sup>

<sup>1</sup>San Raffaele Scientific Institute, Infectious Diseases, Milano, Italy, <sup>2</sup>Università Vita-Salute San Raffaele, Infectious and Tropical Diseases, Milano, Italy

**P 12 COVID-19 and HIV Care: Diagnostic Delays**

M. Pontolillo, A. Auricchio, G. Taraschi, L. Moffa, A. Di Gasbarro, F. Mucedola, A. Brandimarte, F. Vignale, C. Ucciferri, K. Falasca, J. Vecchiet

Clinic of Infectious Diseases, “G. d’Annunzio” University Chieti-Pescara, Chieti, Italy

**P 13 Florence Fast-Track Cities activities during the Sars-Covid 19 period**

M. Russo<sup>1</sup>, F. Cuddretto<sup>2</sup>, S. Bellini<sup>3</sup>, M. Stagnitta<sup>4</sup>, E. Salomoni<sup>5</sup>, A. Zucconi<sup>6</sup>, M. Mazzetti<sup>7</sup>, M. Scopelliti<sup>8</sup>

<sup>1</sup>IREOS, Florence, <sup>2</sup>LILA Toscana, Florence, <sup>3</sup>Cooperativa CATT, Florence, <sup>4</sup>USL Toscana Centro, Florence, <sup>5</sup>Fondazione Solidarietà Caritas, Florence, <sup>6</sup>AOU Careggi, Florence, <sup>7</sup>ARCIGAY Firenze - altre sponde, Florence

**P 14 Risk factors for severe COVID-19 and post-COVID-19 syndrome in a cohort of PLWH on treatment**

M. Mazzitelli<sup>1,2</sup>, M. Trunfio<sup>3</sup>, L. Sasseti<sup>1</sup>, D. Leoni<sup>1</sup>, E. Castelli<sup>1</sup>, M. Brundu<sup>1</sup>, P. Garzotto<sup>1</sup>, A.M. Cattelan<sup>1</sup>

<sup>1</sup>Infectious and Tropical Diseases Unit, Padua, Italy, <sup>2</sup>Magna Graecia University of Catanzaro, Italy, <sup>3</sup>Infectious and Tropical Diseases Unit, Turin, Italy

**P 15 Prolonged SARS-CoV-2 B.1.177 lineage infection in a HIV advanced naïve patient**

F. Balena<sup>1</sup>, C. Pellegrino<sup>1</sup>, E. Milano<sup>1</sup>, V. Totaro<sup>1</sup>, G. De Iaco<sup>1</sup>, F. Signorile<sup>1</sup>, D. Loconsole<sup>2</sup>, M. Chironna<sup>2</sup>, A. Saracino<sup>1</sup>

<sup>1</sup>Clinic of Infectious Disease, University of Bari, Bari, <sup>2</sup>Department of Biomedical Sciences and Human Oncology-Hygiene Section, University of Bari, Bari

**P 16 HIV viral load and COVID-19 pandemic: findings of an HIV reference center in Rome**

A. Latini<sup>1</sup>, M.G. Donà<sup>1</sup>, M. Giuliani<sup>1</sup>, M. Pontone<sup>2</sup>, E. Giuliani<sup>3</sup>, C. Stingone<sup>1</sup>, L. Gianserra<sup>1</sup>, M. Zaccarelli<sup>4</sup>

<sup>1</sup>STI/HIV Unit, San Gallicano Dermatological Institute IRCCS, Rome, <sup>2</sup>Microbiology and Clinical Pathology, San Gallicano Dermatological Institute IRCCS, Rome, <sup>3</sup>Scientific Direction, San Gallicano Dermatological Institute IRCCS, Rome, <sup>4</sup>Infectious Diseases, San Camillo de Lellis Hospital, Rieti

**P 17 Syphilis diagnoses among HIV-infected and HIV-uninfected individuals during a year of SARS-CoV-2 pandemic: the experience of an HIV/STI reference center in Rome**

A. Latini<sup>1</sup>, F. Magri<sup>2</sup>, E. Giuliani<sup>3</sup>, M. Giuliani<sup>1</sup>, V. Garelli<sup>1</sup>, M. Pontone<sup>4</sup>, M. Salvi<sup>1</sup>, C. Stingone<sup>1</sup>, L. Gianserra<sup>1</sup>, F. Pimpinelli<sup>1</sup>, A.R. Buonominì<sup>1</sup>, A. Morrone<sup>3</sup>, M.G. Donà<sup>1</sup>, M. Zaccarelli<sup>5</sup>

<sup>1</sup>STI/HIV Unit, San Gallicano Dermatological Institute IRCCS, Rome, <sup>2</sup>Department of Dermatology, Policlinico Umberto I, Sapienza University, Rome, <sup>3</sup>Scientific Direction, San Gallicano Dermatological Institute IRCCS, Rome, <sup>4</sup>Clinical Pathology and Microbiology, San Gallicano Dermatological Institute IRCCS, Rome, <sup>5</sup>Infectious Diseases, San Camillo de Lellis Hospital, Rieti

**P 18 COVID-19 in a patient with HIV infection: Monoclonal Antibody as a new therapeutic strategy?**

F. Mucedola, L. Moffa, A. Di Marcello, G. Taraschi, A. Auricchio, M. Pontolillo, A. Di Gasbarro, A. Brandimarte, F. Vignale, K. Falasca, J. Vecchiet

Clinic of Infectious Diseases, Dept. of Medicine and Science of Aging, University “G. d’Annunzio”, Chieti, Italy

**P 19 Pharmacoeconomics assessments during the SARS-COVID 19 pandemic comparing pharmaceutical expenditure for antiretroviral therapy (ART) between 2019 and 2020: impact of the lockdown in the Infectious Disease Center in Florence**

L. Attala<sup>1</sup>, C. Costa<sup>1</sup>, B. Romanin<sup>1</sup>, P. Pierotti<sup>1</sup>, E. Salomoni<sup>1</sup>, M. Brizzi<sup>1</sup>, A. Gabbuti<sup>1</sup>, A. Poggi<sup>2</sup>, P. Nizzoli<sup>2</sup>, L. Rabatti<sup>2</sup>, A. Bellucci<sup>3</sup>, F. Vichi<sup>1</sup>, M. Di Pietro<sup>1</sup>

<sup>1</sup>SOC Malattie Infettive 1, Ospedale S. Maria Annunziata, Firenze, Azienda USL Toscana Centro, <sup>2</sup>Farmacia Ospedaliera, Ospedale S. Maria Annunziata, Firenze, Azienda USL Toscana Centro, <sup>3</sup>SOC Patologia Clinica e Immunoallergologia, Ospedale Nuovo S. Giovanni di Dio, Firenze, Azienda USL Toscana Centro







## ISSUES ON COVID-19 THERAPY

### P 20 Remdesivir for the treatment of COVID-19: data from a real-life experience

M. Polisenò<sup>1</sup>, C. Gallo<sup>2</sup>, D.C. Cibelli<sup>1</sup>, G.A. Minafra<sup>1</sup>, I.F. Bottalico<sup>1</sup>, G. Custodero<sup>1</sup>, D. Lo Muzio<sup>1</sup>, T.A. Santantonio<sup>1</sup>, S. Lo Caputo<sup>1</sup>

<sup>1</sup>Department of Clinical and Experimental Medicine, Unit of Infectious Diseases, Policlinico Riuniti University Hospital, Foggia, Italy, <sup>2</sup>Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy

### P 21 Early treatment with Bamlanivimab alone does not prevent COVID-19 hospitalization and its post-acute sequelae. A real experience in Umbria, Italy

E. Schiaroli<sup>1</sup>, G.V. De Socio<sup>1</sup>, L. Martinelli<sup>2</sup>, L. Malincarne<sup>1</sup>, A. Gidari<sup>1</sup>, F. Paciosi<sup>1</sup>, D. Francisci<sup>1</sup>

<sup>1</sup>Unit of Infectious Diseases, University of Perugia, Perugia, Italy, <sup>2</sup>Internal Medicine of Città di Castello Hospital, USL Umbria1, Italy

### P 22 Heart rate changes in patients treated with Remdesivir for COVID-19

I.F. Bottalico, M. Polisenò, C. Gallo, A. Centola, A. La Marca, L. Barbera, A. Miucci, C. Muscatiello, T.A. Santantonio, S. Lo Caputo

Infectious Disease Unit, Clinical experimental Medicine Department University of Foggia, Foggia

### P 23 Influence of early corticosteroids therapy in COVID-19 disease progression

F. Balena, E. Pallara, E. De Vita, D.F. Bavaro, A. Saracino

Clinic of Infectious Diseases, University of Bari, Bari

### P 24 Remdesivir milk levels in a COVID infected-breastfeeding woman: A case report

S. Boni<sup>1</sup>, A. Parisini<sup>1</sup>, M. Feasi<sup>1</sup>, E. Blasi Vacca<sup>1</sup>, F. Del Puente<sup>1</sup>, N. Bobbio<sup>1</sup>, E. Pontali<sup>1</sup>, A. Palermi<sup>2</sup>, A. De Nicolò<sup>2</sup>, A. D'Avolio<sup>2</sup>

<sup>1</sup>Department of Infectious Diseases - Galliera Hospital - Genoa, <sup>2</sup>Laboratory of Clinical Pharmacology and Pharmacogenetics - Amedeo di Savoia Hospital - Turin

### P 25 Convalescent hyperimmune plasma use: a case series of 6 immunocompromised patients

A. Parente<sup>1,2</sup>, B. Kertusha<sup>2</sup>, R. Marocco<sup>2</sup>, T. Tieghi<sup>2</sup>, C. Del Borgo<sup>2</sup>, V. Belvisi<sup>2</sup>, R. Marzano<sup>2</sup>, F. Equitani<sup>2</sup>, M. Lichtner<sup>1,2</sup>

<sup>1</sup>Sapienza Università di Roma, Dipartimento di Igiene e Sanità Pubblica, <sup>2</sup>UOC Malattie Infettive, Ospedale S. M. Goretti, Latina

## MANAGEMENT OF COVID-19

### P 26 Comparison between antigen and molecular tests for the detection of SARS-CoV-2 infection: a retrospective clinical study

L. Sasseti<sup>1</sup>, A. Ferrari<sup>1</sup>, M. Mazzitelli<sup>1</sup>, S. Cocchio<sup>2</sup>, S. Lo Menzo<sup>1</sup>, S. Marinello<sup>1</sup>, L. Rossi<sup>3</sup>, V. Baldo<sup>2</sup>, A.M. Cattelan<sup>1</sup>

<sup>1</sup>Infectious Diseases Unit, Department of Medicine, Azienda Ospedale Università di Padova, <sup>2</sup>Department of Cardiac Thoracic Vascular Sciences and Public Health, Università di Padova, <sup>3</sup>Clinical Microbiology and Virology Unit, Department of Molecular Medicine, Azienda Ospedale Università di Padova

### P 27 BMI changes and weight loss in patients hospitalized for COVID-19: a single-centre experience

S. Gardin<sup>1</sup>, A. Guarnaccia<sup>2</sup>, E. Vogliotti<sup>2</sup>, M. Brundu<sup>2</sup>, F. Barbaro<sup>1</sup>, L. Sasseti<sup>1</sup>, A.M. Cattelan<sup>1</sup>, M. Trevenzoli<sup>1</sup>

<sup>1</sup>Infectious Diseases Unit, Department of Medicine, Azienda Ospedale Università di Padova, <sup>2</sup>Department of Medicine (DIMED), Geriatrics Division, Università di Padova

### P 28 Factors associated with mortality in patients aged over 65 years with SARS-CoV-2 infection

C. Fanelli, A. De Vito, V. Fiore, N. Geremia, E. Princic, A.A. Muredda, C.P. Napodano, G. Moi, I. Maida, G. Sotgiu, G. Madeddu, S. Babudieri

Unit of Infectious Diseases, Department of Medical, Surgical, and Experimental Sciences, University of Sassari, Sassari, Italy

### P 29 Posterior reversible encephalopathy syndrome (PRES) and COVID-19: a case report

S.B. Morella, M. Gilio, C. Acierio, F. Picaro, G. Mastroberti, M. D. Palazzo, A. Erezanu, G. De Stefano

San Carlo Hospital, Infectious Diseases, Potenza, Italy

### P 30 Clinical characteristics of healthcare workers with SARS-CoV-2 infection after vaccination with BNT162b2 vaccine

A. Lombardi<sup>1,2</sup>, G. Renisi<sup>1</sup>, D. Consonni<sup>3</sup>, M. Oggioni<sup>4</sup>, P. Bono<sup>4</sup>, S.U. Renteria<sup>4</sup>, A. Piatti<sup>5</sup>, A.C. Pesatori<sup>3,6</sup>, S. Castaldi<sup>7,8</sup>, A. Muscatello<sup>1</sup>, L. Riboldi<sup>9</sup>, F. Ceriotti<sup>4</sup>, A. Gori<sup>1,2,10</sup>, A. Bandera<sup>1,2,10</sup>

<sup>1</sup>Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, <sup>2</sup>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, <sup>3</sup>Epidemiology Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, <sup>4</sup>Clinical Laboratory, Foundation IRCCS Ca' Granda Ospedale Maggiore, Milan, Italy, <sup>5</sup>Medical Direction, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, <sup>6</sup>Department of Clinical Sciences and Community Health, University of Milano, Milan, Italy, <sup>7</sup>Department Biomedical Sciences for Health, University of Milan, Milan, Italy, <sup>8</sup>Quality Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, <sup>9</sup>Occupational Health Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, <sup>10</sup>Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy

### P 31 Mediastinal adipose tissue as inflammatory biomarker in Covid19 pneumoniae

L. Loiacono, P. Campioni, C. Sorace, E. Biliotti, A. Abdeddaim, F. Faraglia, S. Ianiello, G. D'offizi

National Institute of Infectious Diseases L Spallanzani - Rome







**P 32 Early predictors of clinical deterioration of COVID-19 in a cohort of out-patients in southern Italy: a multicenter observational study**

C. Monari<sup>1</sup>, L. Onorato<sup>1</sup>, V. Gentile<sup>1</sup>, M. Macera<sup>1</sup>, P. Maggi<sup>2</sup>, F.G. Numis<sup>3</sup>, I. Gentile<sup>4</sup>, C. Rescigno<sup>5</sup>, V. Sangiovanni<sup>6</sup>, V. Esposito<sup>7</sup>, E. Manzillo<sup>8</sup>, G. Calabria<sup>9</sup>, A. Salomone Megna<sup>10</sup>, M. Gambardella<sup>11</sup>, G. Russo<sup>12</sup>, M. Pisaturo<sup>1</sup>, N. Coppola<sup>1</sup>

<sup>1</sup>Infectious Diseases Unit, Department of Mental Health and Public Medicine, University of Campania "L. Vanvitelli", Napoli, Italy, <sup>2</sup>Infectious Diseases Unit, A.O. S Anna e S Sebastiano Caserta, Italy, <sup>3</sup>Emergency Unit, PO Santa Maria delle Grazie, Pozzuoli, Italy, <sup>4</sup>Infectious Diseases Unit, University Federico II, Naples, Italy, <sup>5</sup>1st Infectious Diseases Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>6</sup>3rd Infectious Diseases Unit, AORN dei Colli, P.O. Cotugno, Naples, Italy, <sup>7</sup>4th Infectious Diseases Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>8</sup>8th Infectious Diseases Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>9</sup>9th Infectious Diseases Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>10</sup>Infectious Diseases Unit, A.O. San Pio, PO Rummo, Benevento, Italy, <sup>11</sup>Infectious Diseases Unit, PO S. Luca, Vallo della Lucania, ASL Salerno, Italy, <sup>12</sup>Infectious Diseases Unit, Ospedale Maria S.S. Addolorata di Eboli, ASL Salerno, Italy

**P 33 COVID-19 and myotonic dystrophy: case reports and systematic review**

M. Mazzitelli<sup>1,2</sup>, M. Trevenzoli<sup>1</sup>, M. Brundu<sup>1</sup>, G. Squarzone<sup>3</sup>, A. Cattelan<sup>1</sup>

<sup>1</sup>Infectious and Tropical Diseases Unit, Padua Hospital, Padua, Italy, <sup>2</sup>Department of Medical and Surgical Sciences, Magna Graecia University of Catanzaro, Catanzaro, Italy, <sup>3</sup>Respiratory Disease Unit, Department of Cardiac Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy

**P 34 Monocytes CD169 and HLADR expression in SARS-CoV2 infection**

A. Gatti<sup>1</sup>, P. Fassini<sup>2</sup>, I. Caramma<sup>3</sup>, P. Clerici<sup>4</sup>, B. Brando<sup>1</sup>, S. Rusconi<sup>3,5</sup>

<sup>1</sup>Haematology Laboratory - Transfusion Center, <sup>2</sup>Intensive Care Unit, <sup>3</sup>Infectious Diseases Unit, <sup>4</sup>Microbiology Unit, Legnano Hospital, Milano, Italy; <sup>5</sup>Department of Biomedical and Clinical Sciences DIBIC "Luigi Sacco", University of Milan, Italy

**P 35 Use of nasal swab as a predictor of MRSA superinfection in SARS-COV-2 related pneumonia**

R. Lattanzio<sup>1</sup>, G. Guido<sup>1</sup>, D. F. Bavaro<sup>1</sup>, A.G. Solimando<sup>2</sup>, A. Cinelli<sup>2</sup>, A. Vacca<sup>2</sup>, A. Saracino<sup>1</sup>

<sup>1</sup>Clinic of Infectious Disease, University of Bari "Aldo Moro", Bari, <sup>2</sup>Unit of Internal Medicine and Clinical Oncology, University of Bari "Aldo Moro", Bari

**P 36 Comparison between COVID-19 patients harboring variants of SARS-COV-2 and a population from the first pandemic wave**

L. Mazzuti<sup>1</sup>, M.A. Zingaropoli<sup>2</sup>, P. Pasculli<sup>2</sup>, G.M. Masci<sup>3</sup>, R. Campagna<sup>1</sup>, G. Oliveto<sup>1</sup>, F. Iafrate<sup>3</sup>, C. Catalano<sup>3</sup>, P. Ricci<sup>3</sup>, M.R. Ciardi<sup>2</sup>, C.M. Mastroianni<sup>2</sup>, A. Carattoli<sup>1</sup>, A. Pierangeli<sup>1</sup>, A. Angeloni<sup>4</sup>, O. Turriziani<sup>1</sup>, G. Antonelli<sup>1</sup>

<sup>1</sup>Department of Molecular Medicine, Sapienza University of Rome, Italy, <sup>2</sup>Department of Public Health and Infectious Diseases, Sapienza, University of Rome, Italy, <sup>3</sup>Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Italy, <sup>4</sup>Department of Experimental Medicine Sapienza, University of Rome, Italy

**P 37 Radiological and clinical sequelae in patients with mild/moderate COVID-19 disease**

D. Fiordelisi, R. Casciaro, E. Pallara, G. Brindicci, D. Virgilio, A. Scardapane, A.A.S. Ianora, A. Saracino

Clinic of Infectious and Tropical diseases, University of Bari, Bari; Department of Radiology and Diagnostic Imaging, University of Bari, Bari

**P 38 Covid-19 infection and a severe autoimmune hemolytic anemia case: a case report and review of the literature**

Y. Rusotto, C. Micali, L. Marletta, E. Venanzi Rullo, G. Nunnari

U.O.C. Malattie Infettive dell' A.O.U. "G. Martino", Messina

**P 39 The role of Tocilizumab in the treatment of COVID-19 associated persistent hiccups: case report and concise review**

M. Gilio<sup>1</sup>, S. Morella<sup>1</sup>, F. Picaro<sup>1</sup>, A. Erezanu<sup>1</sup>, M. Frontuto<sup>1</sup>, G. Mastroberti<sup>1</sup>, D. Palazzo<sup>1</sup>, C. Acierno<sup>1</sup>, G.A. Mennillo<sup>1</sup>, G. De Stefano<sup>1,2</sup>

<sup>1</sup>Infectious Diseases Unit - San Carlo Hospital, Potenza, Italy, <sup>2</sup>Infectious Diseases Unit - Madonna delle Grazie Hospital, Matera, Italy

**P 40 Ivermectin use in COVID-19: a case-control retrospective study**

F. Tosto<sup>1,2</sup>, B. Bellocchi<sup>1,2</sup>, E. Campanella<sup>1,2</sup>, E. Pistarà<sup>1,2</sup>, L. Todaro<sup>1,2</sup>, V. Moscatelli<sup>1,2</sup>, F. Cosentino<sup>1,2</sup>, A. Marino<sup>1,2</sup>, R. Bruno<sup>1</sup>, V. Boscia<sup>1</sup>, G. Lupo<sup>1</sup>, A. Onorante<sup>1</sup>, M. Gussio<sup>1</sup>, L. Larocca<sup>1</sup>, G. Vinci<sup>1</sup>, A. Zagami<sup>1</sup>, R. Restivo<sup>1</sup>, F. Benanti<sup>1</sup>, G. Nunnari<sup>2</sup>, B. Cacopardo<sup>3</sup>, B.M. Celesia<sup>1</sup>, M. Ceccarelli<sup>3</sup>

<sup>1</sup>Unit of Infectious Diseases, ARNAS "Garibaldi", "Nesima" Hospital, Catania, Italy, <sup>2</sup>Department of Clinical and Experimental Medicine, Unit of Infectious Diseases, University of Messina, Messina, Italy, <sup>3</sup>Department of Clinical and Experimental Medicine, Unit of Infectious Diseases, University of Catania, Catania, Italy

**P 41 Characterization of long-COVID symptoms in an Italian clinical center**

G. Picchi<sup>1</sup>, L. Celani<sup>1,2</sup>, A. Ciccullo<sup>1</sup>, M. Di Norcia<sup>3</sup>, F. Tonello<sup>3</sup>, A.C. Carucci<sup>1</sup>, V. Cofini<sup>4</sup>, S. Necozone<sup>4</sup>, A. Grimaldi<sup>1</sup>

<sup>1</sup>Infectious Disease Unit, San Salvatore Hospital, L'Aquila, Italy, <sup>2</sup>Department of Public Health and Infectious Disease, University of Rome "Sapienza", Roma, Italy, <sup>3</sup>Department of Clinical Medicine, Public Health, Life and Environmental Science, School of Internal Medicine, L'Aquila University, L'Aquila, Italy, <sup>4</sup>Department of Clinical Medicine, Public Health, Life and Environmental Science, L'Aquila University, L'Aquila, Italy





re-search, for re-start  
together Riccione 21-23 Ottobre 2021

**P 42 Management of SARS-CoV-2 persistency in a 20-year-old male affected by agammaglobulinemia: a case report**

*V. Castelli<sup>1,2</sup>, G. Bozzi<sup>2</sup>, S. Ludovisi<sup>2</sup>, L. Alagna<sup>2</sup>, N. Iannotti<sup>2</sup>, P. Saltini<sup>1,2</sup>, R.M. Dellepiane<sup>3</sup>, L.A. Baselli<sup>3</sup>, A. Gori<sup>1,2</sup>, A. Bandera<sup>1,2</sup>, A. Muscatello<sup>2</sup>*

<sup>1</sup>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, <sup>2</sup>Infection Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Milan, Italy, <sup>3</sup>Pediatric Intermediate Care, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

**P 43 Characteristics and treatment response of patients with SARS-CoV-2 infection treated with monoclonal antibodies in two reference hospitals in Catanzaro (southern Italy)**

*S. Rotundo<sup>1</sup>, A. Cimellaro<sup>2</sup>, V. La Gamba<sup>1</sup>, D. Addesi<sup>2</sup>, P. Fusco<sup>1</sup>, M. Cavallo<sup>2</sup>, M. T. Tassone<sup>1</sup>, F. Spagnolo<sup>2</sup>, R. Cordaro<sup>2</sup>, E. Suraci<sup>2</sup>, I. Spinelli<sup>2</sup>, C. Costa<sup>3</sup>, A. Russo<sup>1,3</sup>, E.M. Trecarichi<sup>1,3</sup>, C. Pintaudi<sup>2</sup>, C. Torti<sup>1,3</sup>*

<sup>1</sup>University "Magna Graecia", Catanzaro, <sup>2</sup>A.O. "Pugliese-Giacco", Catanzaro, <sup>3</sup>A.O.U. "Mater Domini", Catanzaro

**P 44 Don't forget MIS-C : a typical case in a 16ya obese boy**

*M. Gnappi, F. Raumer, M. Trevenzoli, AM. Cattelan*

Azienda Ospedaliera Universitaria di Padova, Padova

## MANAGEMENT OF HIV INFECTION

**P 45 A EU collaborative partnership for active lifestyles for the adherence to the HIV therapy and to promote fitness as therapy**

*C. Falanga<sup>1</sup>, D. Mainieir<sup>2</sup>, S. Negri<sup>3</sup>*

<sup>1</sup>Anlaidis Sezione Lombardia, Milan, <sup>2</sup>Anlaidis Sezione Lombardia, Milan, <sup>3</sup>GVMAS ONLUS, Milan

**P 46 Silence may kill you**

*A. Brandimarte, G. Taraschi, A. Di Gasbarro, L. Moffa, F. Mucedola, A. Di Marcello, M. Pontolillo, A. Auricchio, J. Vecchiet, K. Falasca*

PO SS. Annunziata, Chieti, Malattie infettive e tropicali

## PEDIATRIC, ADOLESCENT, MATERNAL, FETAL ASPECTS IN HIV

**P 47 Weight gain in a cohort of pregnant women living with HIV**

*C. Sepulcri<sup>1</sup>, S. Iannini<sup>1</sup>, S. Lerta<sup>1</sup>, L. Taramasso<sup>1</sup>, A. Ferraiolo<sup>2</sup>, C. Gustavino<sup>2</sup>, M. Bassetti<sup>1</sup>, A. Di Biagio<sup>1</sup>*

<sup>1</sup>Infectious Disease Clinic, Department of Health Sciences, IRCCS Policlinico San Martino Hospital, University of Genoa, Genoa, Italy, <sup>2</sup>Ostetricia e Ginecologia, IRCCS Policlinico San Martino Hospital, University of Genoa, Genoa, Italy

## Coinfections and Hepatitis

### BACTERIAL AND FUNGAL INFECTIONS IN IMMUNOCOMPROMISED HOST

**P 48 A case of complicated tricuspidal endocarditis in a patient with undiagnosed HIV and HCV infections**

*G. Taraschi, A. Di Gasbarro, A. Di Marcello, L. Moffa, F. Mucedola, A. Brandimarte, A. Auricchio, M. Pontolillo, K. Falasca, J. Vecchiet*

Clinica Malattie Infettive, P.O. S.S. Annunziata, Chieti

**P 49 Diffuse MAC lymphadenitis in a HIV patient under antimycobacterial treatment**

*M. Giglia, M. Tadolini, L. Calza, P. Viale*

Infectious Disease Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy

**P 50 Evidence of paediatric sepsis caused by a *L.garvieae* contaminated platelet concentrate**

*C. Alteri<sup>1,2</sup>, V. Costabile<sup>1,2</sup>, L. Colagrossi<sup>3</sup>, R. Scutari<sup>1,2</sup>, M. Agosta<sup>3</sup>, M. Onori<sup>3</sup>, L. Mancinelli<sup>3</sup>, B. Lucignano<sup>3</sup>, I. Zullino<sup>3</sup>, V. Cetra<sup>3</sup>, G. Del Baldo<sup>4</sup>, A. Mastronuzzi<sup>4</sup>, G. Trua<sup>5</sup>, M. Montanari<sup>5</sup>, P. Bernaschi<sup>3</sup>, C.F. Perno<sup>2,3</sup>*

<sup>1</sup>Department of Oncology and Hemato-oncology University of Milan, Milan, <sup>2</sup>Multimodal Research Area Bambino Gesù Children's Hospital IRCCS, Rome, <sup>3</sup>Department of Laboratories Unit of Diagnostic Microbiology and Immunology Bambino Gesù Children's Hospital, Rome, <sup>4</sup>Department of Pediatric Hematology/Oncology and Cellular and Gene Therapy Bambino Gesù Children's Hospital IRCCS, Rome, <sup>5</sup>Department of Transfusion Medicine Bambino Gesù Children's Hospital IRCCS, Rome

**P 51 An atypical pulmonary pattern in a patient with new HIV diagnosis**

*R. Pasquali, D. Testi, A. Cascavilla, P. Viale, G. Verucchi, L. Calza*

Infectious disease Unit, Alma Mater Studiorum University of Bologna





**P 52 Hystoplamosis in HIV. Two case reports from a Northern Italy Hospital**

*E. Blasi Vacca, A. Parisini, S. Boni, F. Del Puente, N. Bobbio, F. Feasi, E. Pontali*

Department of Infectious Disease, Galliera Hospital, Genoa

**HCV ELIMINATION**

**P 53 Villa Maraini Point Of Care Testing: HCV elimination among People Who Use Drug in Rome outside the hospital setting is possible**

*E. Teti<sup>1</sup>, L. Sarmati<sup>1</sup>, T. Mulas<sup>1</sup>, L. Ferrari<sup>1</sup>, G. De Simone<sup>1</sup>, D. Checchi<sup>1</sup>, M. Compagno<sup>1</sup>, M. Iannetta<sup>2</sup>, B. Coladarce<sup>2</sup>, P. Sammarco<sup>2</sup>, D. Masci<sup>2</sup>, G. Rodoquino<sup>2</sup>, G. Sandri<sup>2</sup>, T. Di Giovanni<sup>2</sup>, E. Rossi<sup>2</sup>, M. Andreoni<sup>2</sup>, M. Barra<sup>2</sup>*

<sup>1</sup>UOC Malattie Infettive, Policlinico Tor Vergata, Roma, Italy, <sup>2</sup>Fondazione Villa Maraini, Roma, Italy

**P 54 HCV DAAs Treated Patients: Case Series 2015 - 2020 Infectious Diseases Unit Vasto Hospital (ASL2 Abruzzo)**

*S. Antonelli, P. Mancino, M.P. Sciotti*

Infectious Diseases Unit Vasto Hospital (ASL2 Abruzzo)

**HEPATITIS EPIDEMIOLOGY**

**P 55 HBV and HCV screening in patients hospitalized for SARS-COV-2. Prevalence of viral hepatitis in an unselected, consecutively enrolled patient population**

*S. Dettori<sup>1,2</sup>, C. Russo<sup>1,2</sup>, S. Mora<sup>3</sup>, M. Giacomini<sup>3</sup>, L. Taramasso<sup>2</sup>, M. Bassetti<sup>1,2</sup>, A. Di Biagio<sup>1,2</sup>*

<sup>1</sup>Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, <sup>2</sup>Infectious Diseases Unit, Ospedale Policlinico San Martino IRCCS, Genoa, Italy, <sup>3</sup>Department of Informatics Bioengineering, Robotics, and Systems Engineering (DIBRIS), University of Genoa, Genoa, Italy

**Comorbidities**

**CANCERS IN HIV**

**P 56 Characteristics of a group of PLWH and cancer in Umbria Region**

*M. Nofri<sup>1,3</sup>, V. De Angelis<sup>2</sup>, C. Papalini<sup>1</sup>, S. Benedetti<sup>1</sup>, D. Francisci<sup>1</sup>*

<sup>1</sup>Clinica Malattie Infettive, Ospedale Santa Maria della Misericordia, Università degli Studi di Perugia, Perugia, Italy, <sup>2</sup>S.C. Oncologia Medica, Ospedale Santa Maria della Misericordia, Perugia, Italy, <sup>3</sup>U.O.C. Malattie Infettive, Ospedale Misericordia, Grosseto, Italy

**P 57 Successful management of primary CNS EVB-related lymphoma in a late advanced naïve HIV**

*A. Carraro<sup>1</sup>, S. Cacace<sup>1</sup>, S. Garattini<sup>1</sup>, S. Perrone<sup>2</sup>, R. Marocco<sup>1</sup>, C. Del Borgo<sup>1</sup>, V. Belvisi<sup>1</sup>, T. Tieghi<sup>1</sup>, M. Jamhour<sup>1</sup>, G. Mancarella<sup>1</sup>, A. Parente<sup>1</sup>, B. Kertusha<sup>1</sup>, L. Fondaco<sup>1</sup>, C. Spota<sup>3</sup>, D. Armocida<sup>4</sup>, A. Pompucci<sup>4</sup>, G. Cimino<sup>2</sup>, M. Lichtner<sup>1</sup>*

<sup>1</sup>Infectious Diseases Unit - Sapienza University of Rome, Latina, Italy, <sup>2</sup>Hematology Unit - Sapienza University of Rome, Latina, Italy, <sup>3</sup>Oncology Unit - S.M. Goretti Hospital, Latina, Italy, <sup>4</sup>Neurosurgery Unit - S.M. Goretti Hospital, Latina, Italy

**P 58 Epidemiologic results from the first two years of activity of a newly established ambulatory for anal cancer prevention in Rome**

*E.N. Cavallari<sup>1</sup>, G. De Girolamo<sup>1</sup>, L. Santinelli<sup>1</sup>, G.P. Innocenti<sup>1</sup>, C. Pinacchio<sup>1</sup>, I. De Angelis<sup>1</sup>, G. Ceccarelli<sup>1</sup>, A. Ciardi<sup>2</sup>, S. Arcieri<sup>3</sup>, A. Pierangeli<sup>4</sup>, C.M. Mastroianni<sup>1</sup>, G. d'Ettore<sup>1</sup>*

<sup>1</sup>Department of Public Health and Infectious Diseases "Sapienza" University of Rome, <sup>2</sup>Department of Radiology, Oncology and Human Pathology "Sapienza" University of Rome, <sup>3</sup>Department of Surgical Sciences "Sapienza" University of Rome, <sup>4</sup>Department of Molecular Virology "Sapienza" University of Rome

**P 59 Malignancies in HIV patients: a retrospective study in an Italian University Hospital and systematic review of literature**

*M. Abbott, G. Bosco, C. Colomba, P. Di Carlo, C. Gioé, A. Gizzi, F. Guida Marascia, M. Trizzino, A. Cascio*

Infectious and Tropical Disease Unit, AOU Policlinico "P. Giaccone", Palermo, Italy; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties- University of Palermo, Palermo, Italy





re-search, for re-start  
together Riccione 21-23 Ottobre 2021

## HIV AND NERVOUS SYSTEM

### P 60 Evolution of cognitive performance over the last ten years in people living with HIV

V. Delle Donne<sup>1</sup>, V. Massaroni<sup>1</sup>, N. Ciccarelli<sup>2</sup>, A. Borghetti<sup>3</sup>, A. Ciccullo<sup>4</sup>, A. Dusina<sup>3</sup>, D. Farinacci<sup>3</sup>, M. Fabbiani<sup>5</sup>, S. Di Giambenedetto<sup>1,3</sup>

<sup>1</sup>Infectious Diseases Institute, Department of Safety and Bioethics, Catholic University of Sacred Heart, Rome, Italy, <sup>2</sup>Department of Psychology, Catholic University, Milan, Italy, <sup>3</sup>UOC Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, <sup>4</sup>UOC Infectious Diseases, Ospedale S. Salvatore, L'Aquila, Italy, <sup>5</sup>UOC Infectious Diseases, Azienda Ospedaliera Universitaria Senese, Siena, Italy

### P 61 A winning parasite: high prevalence of *Toxoplasma gondii*-seropositivity in patients with HIV infection naïve to antiretroviral therapy

S. Biscarini<sup>1,2</sup>, S. Villa<sup>3</sup>, S. Ludovisi<sup>1</sup>, G. Bozzi<sup>1</sup>, A. Muscatello<sup>1</sup>, A. Gori<sup>1,3,4</sup>, A. Bandera<sup>1,3,4</sup>

<sup>1</sup>Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, <sup>2</sup>Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy, <sup>3</sup>Centre for Multidisciplinary Research in Health Science, University of Milan, Milan, Italy, <sup>4</sup>Department of Pathophysiology and Transplantation, University of Milano, Milan, Italy

## NON INFECTIOUS COMORBIDITIES IN HIV

### P 62 Factors associated with significant weight gain in HIV-1-infected patients starting an initial antiretroviral therapy: a case-control study

L. Calza<sup>1</sup>, M. Borderi<sup>1</sup>, V. Viscusi<sup>1</sup>, A. Toschi<sup>1</sup>, I. Bon<sup>2</sup>, T. Lazzarotto<sup>2</sup>, P. Viale<sup>1</sup>

<sup>1</sup>Unit of Infectious Diseases, S.Orsola-Malpighi Hospital, University of Bologna, <sup>2</sup>Unit of Microbiology, S.Orsola-Malpighi Hospital, University of Bologna

### P 63 Low vitamin D concentration is associated with hypercoagulable state HIV-1-infected patients on combination antiretroviral therapy

L. Calza<sup>1</sup>, B. Nuti<sup>1</sup>, M.C. Susini<sup>1</sup>, V. Colangeli<sup>1</sup>, M. Borderi<sup>1</sup>, I. Bon<sup>2</sup>, T. Lazzarotto<sup>2</sup>, P. Viale<sup>1</sup>

<sup>1</sup>Unit of Infectious Diseases, S.Orsola-Malpighi Hospital, University of Bologna, <sup>2</sup>Unit of Microbiology, S.Orsola-Malpighi Hospital, University of Bologna

### P 64 Cognitive profile and functional performance in older people living with HIV: a cohort study

G. Micheli<sup>1</sup>, S. Andaloro<sup>2</sup>, D. Ronconi<sup>3</sup>, R. Liperoti<sup>2,3</sup>, M.C. Cipriani<sup>3</sup>, S. Rocchi<sup>3</sup>, C. Falsiroli<sup>3</sup>, M. Chiuchiarelli<sup>1</sup>, E. Tamburrini<sup>1,4</sup>, E. Visconti<sup>1,4</sup>, S. Di Giambenedetto<sup>1,4</sup>, A. Cingolani<sup>1,4</sup>

<sup>1</sup>Università Cattolica S. Cuore, Malattie Infettive, Roma, <sup>2</sup>Università Cattolica S. Cuore, Facoltà di Medicina e Chirurgia, Roma, <sup>3</sup>Fondazione Policlinico A. Gemelli, IRCCS, Dipartimento di Scienze geriatriche e ortopediche, <sup>4</sup>Fondazione Policlinico A. Gemelli, IRCCS, Istituto di Clinica delle Malattie Infettive, Roma

### P 65 Weight changes in overweight and obese people living with HIV. Retrospective analysis of 10-years of follow up

L. Taramasso<sup>1</sup>, S. Cavagnaro<sup>2</sup>, G. Mazzarello<sup>1</sup>, A.I. Alessandrini<sup>1</sup>, M. Bassetti<sup>2</sup>, A. Di Biagio<sup>2</sup>

<sup>1</sup>Infectious Diseases Clinic, Policlinico San Martino Hospital-IRCCS, Genoa, Italy, <sup>2</sup>Infectious Diseases Clinic, Dept. of Health Sciences, University of Genoa, San Martino Hospital-IRCCS, Genoa, Italy

### P 66 Management of polypharmacy in people living with HIV: A 5-year experience of a multidisciplinary outpatient clinic

C. Resnati, D. Cattaneo, L. Oreni, P. Meraviglia, D. Minisci, N. Astuti, S. Lazzarin, S. Antinori, C. Gervasoni

ASST Fatebenefratelli Sacco University Hospital, Milano, Italy

### P 67 Metabolic impact of switching from E/c/F/TAF to B/F/TAF in HIV-1 infected patients

N. De Gennaro, P. Laghetti, R. Casciaro, E. Pallara, F. Balena, D. Fiordelisi, D.F. Bavaro, A. Saracino

University of Bari "Aldo Moro", Department of Biomedical Sciences and Human Oncology, Clinic of Infectious Diseases, Bari, Italy





## Pathogenesis and Immunology

### COVID-19 PATHOGENESIS

#### P 68 COVID-19 pneumonia with migratory pattern in agammaglobulinemic patients: a report of two cases

M. Degli Antoni<sup>1</sup>, V. Crosato<sup>1</sup>, F. Pennati<sup>1</sup>, A. Borghesi<sup>2</sup>, G. Cristini<sup>3</sup>, R. Allegri<sup>3</sup>, S. Capone<sup>3</sup>, A. Bergamasco<sup>3</sup>, A.R. Soresina<sup>4</sup>, R. Maroldi<sup>2</sup>, R. Badolato<sup>5,6</sup>, E. Quiros-Roldan<sup>1</sup>, F. Castelli<sup>1</sup>, E. Focà<sup>1</sup>

<sup>1</sup>Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Italy, <sup>2</sup>Department of Radiology, University of Brescia, Brescia, Italy,

<sup>3</sup>Unit of Infectious and Tropical Diseases, ASST Spedali Civili di Brescia, Italy, <sup>4</sup>Pediatric Immunology Unit, Brescia, Italy, <sup>5</sup>Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, <sup>6</sup>A. Nocivelli Institute of Molecular Medicine, Brescia, Italy

#### P 69 Mass cytometry reveals reduction of circulating CD4 T follicular helper and CD4 T cell exhaustion in aged COVID-19 patients

D. Lo Tartaro<sup>1</sup>, L. Gibellini<sup>1</sup>, A. Paolini<sup>1</sup>, A. Quong<sup>2</sup>, C. Petes<sup>2</sup>, G. Awong<sup>2</sup>, S. Douglas<sup>2</sup>, D. Lin<sup>2</sup>, J. Nieto<sup>2</sup>, R. Borella<sup>1</sup>, L. Fidanza<sup>1</sup>, M. Mattioli<sup>1</sup>, M. Meschiari<sup>3</sup>, T. Trenti<sup>4</sup>, M. Sarti<sup>4</sup>, S. Busani<sup>5</sup>, M. Girardis<sup>5</sup>, G. Guaraldi<sup>3</sup>, C. Mussini<sup>3</sup>, A. Cossarizza<sup>1</sup>, S. De Biasi<sup>1</sup>

<sup>1</sup>Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia School of Medicine, Modena, Italy, <sup>2</sup>Fluidigm Corporation, South San Francisco, CA, USA, <sup>3</sup>Infectious Diseases Clinics, AOU Policlinico and University of Modena and Reggio Emilia, Modena, Italy, <sup>4</sup>Department of Clinical Pathology, AOU Policlinico, Modena, Italy, <sup>5</sup>Department of Anesthesia and Intensive Care, AOU Policlinico and University of Modena and Reggio Emilia, Modena, Italy

#### P 70 Pathogenic HERV-W envelope in swab samples and in T lymphocytes is associated with the respiratory outcome of COVID-19 patients

V. Petrone<sup>1</sup>, M. Fanelli<sup>1</sup>, A. Minutolo<sup>1</sup>, M. Iannetta<sup>2,3</sup>, V. Malagnino<sup>2,3</sup>, M. Zordan<sup>2,3</sup>, P. Vitale<sup>3</sup>, B. Charvet<sup>4,5</sup>, B. Horvat<sup>4</sup>, S. Bernardini<sup>1</sup>, E. Garaci<sup>6</sup>, P. Di Francesco<sup>1</sup>, P. Sinibaldi Vallebona<sup>1,7</sup>, L. Sarmati<sup>2,3</sup>, M. Andreoni<sup>2,3</sup>, H. Perron<sup>5,8</sup>, S. Grell<sup>1,9</sup>, E. Balestrieri<sup>1</sup>, C. Matteucci<sup>1</sup>

<sup>1</sup>Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy, <sup>2</sup>Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy, <sup>3</sup>Infectious Diseases Clinic, Policlinic of Tor Vergata, Rome, Italy, <sup>4</sup>International Center for Infectology Research (ICIR), Ecole Normale Supérieure de Lyon, University of Lyon, Lyon-France, <sup>5</sup>Geneuro - Innovation, Lyon-France, <sup>6</sup>IRCCS San Raffaele Pisana, Rome, Italy,

<sup>7</sup>Institute of Translational Pharmacology, National Research Council, Rome, Italy, <sup>8</sup>University of Lyon, Lyon, France, <sup>9</sup>Virology Unit, Policlinic of Tor Vergata, Rome, Italy

#### P 71 Immunological parameters and microbiological findings in mechanically ventilated COVID-19 patients with suspected ventilator - associated pneumonia

D. Mangioni<sup>1,2</sup>, M. Panigada<sup>3</sup>, E. Trombetta<sup>4</sup>, A. Lombardi<sup>1,5</sup>, L. Alagna<sup>1</sup>, A. Muscatello<sup>1</sup>, C.A. Peri<sup>1</sup>, A. Meli<sup>3</sup>, J. Fumagalli<sup>3</sup>, A. Guzzardella<sup>3</sup>, C. Martinato<sup>6</sup>, D. Prati<sup>7</sup>, F. Ceriotti<sup>8</sup>, A. Pesenti<sup>3,5</sup>, A. Gori<sup>1,5</sup>, L. Porretti<sup>4</sup>, G. Grasselli<sup>3,5</sup>, A. Bandera<sup>1,5</sup>

<sup>1</sup>Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, <sup>2</sup>Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy, <sup>3</sup>Department of Anaesthesia, Critical care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, <sup>4</sup>Flow Cytometry and Cell Sorting Laboratory, Clinical Laboratory, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, <sup>5</sup>Department of Pathophysiology and Transplantation, University of Milano, Milano, Italy, <sup>6</sup>Microbiology Laboratory, Clinical Laboratory, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, <sup>7</sup>Precision Medicine, Department of Transfusion Medicine and Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, <sup>8</sup>Clinical Laboratory, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy

#### P 72 SARS-CoV2 positivity at oropharyngeal swab after recovery: persistence of infection, reactivation or reinfection?

A. Rossati, O. Bargiacchi, A. Barco, F. Rinaldi, C. Nebbiolo, M. Sciarra, D. Brustia

Infectious Diseases Unit, Maggiore della Carità Hospital, Novara

### HIV CURE

#### P 73 An in vitro model of reversible proviral latency in primary human monocyte-derived macrophages polarized by pro-inflammatory M1-cytokines

P. Demela<sup>1</sup>, S. Ghezzi<sup>2</sup>, E. Vicenzi<sup>2</sup>, G. Poli<sup>1,3</sup>

<sup>1</sup>Human Immuno-Virology (H.I.V.) and <sup>2</sup>Viral Pathogenesis and Biosafety Groups, San Raffaele Scientific Institute, Milano, <sup>3</sup>Vita-Salute San Raffaele University School of Medicine, Milano

#### P 74 Transient increase of plasma HIV RNA after COVID-19 vaccination with mRNA-1272

G. Bozzi<sup>1</sup>, A. Lombardi<sup>1,2</sup>, S. Ludovisi<sup>1</sup>, A. Muscatello<sup>1</sup>, P. Saltini<sup>1</sup>, L. Manganaro<sup>1,3</sup>, D. Cattaneo<sup>4</sup>, A. Gori<sup>1,2</sup>, A. Bandera<sup>1,2</sup>

<sup>1</sup>Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, <sup>2</sup>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, <sup>3</sup>Romeo ed Enrica Invernizzi, Istituto Nazionale di Genetica Molecolare (INGM), Milan, Italy, <sup>4</sup>Unit of Clinical Pharmacology, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy







re-search, for re-start  
together Riccione 21-23 Ottobre 2021

## HIV IMMUNOLOGY AND IMMUNE-BASED THERAPIES

### P 75 Evaluation of 4-integrin on T-lymphocytes in HIV+ patients under effective antiretroviral treatment and chronic immune activation

M.A. Zingaropoli<sup>1</sup>, P. Pasculli<sup>1</sup>, M. Iannetta<sup>2</sup>, G. De Girolamo<sup>1</sup>, G. d'Ettoire<sup>1</sup>, M.R. Ciardi<sup>1</sup>, C.M. Mastroianni<sup>1</sup>

<sup>1</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, <sup>2</sup>Department of System Medicine, Tor Vergata University of Rome

### P 76 Virologically suppressed immunological non-responders

B. Nuti, L. Calza, P. Viale

Polidinicò Sant'Orsola, Bologna

## HIV PATHOGENESIS

### P 77 The progestin medroxyprogesterone acetate affects HIV-1 production in human lymphoid tissue explants in a dose-dependent and glucocorticoid-like fashion

C. Vanpouille<sup>1</sup>, G. Günaydin<sup>2</sup>, M. Clerici<sup>3,4</sup>, L. Margolis<sup>1</sup>, K. Broliden<sup>2</sup>, A. Introini<sup>2,5</sup>

<sup>1</sup>Section on Intercellular Interaction, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda MD, USA, <sup>2</sup>Center for Molecular Medicine, Department of Medicine Solna, Division of Infectious Diseases, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, <sup>3</sup>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, <sup>4</sup>IRCCS Fondazione Don Carlo Gnocchi, Milan, Italy, <sup>5</sup>Department of Biomedical and Clinical Sciences L. Sacco, University of Milan, Milan, Italy

### P 78 Thrombospondin receptor pathway can regulate HIV mucosal transmission in semen from HIV seropositive subjects

A. Andolfo<sup>1</sup>, C. Magagnotti<sup>1</sup>, C. Pastori<sup>2</sup>, Y. Ganor<sup>3</sup>, G. Siracusano<sup>2</sup>, J.P. Wolf<sup>3,4</sup>, M. Bomse<sup>3</sup>, L. Lopalco<sup>2</sup>

<sup>1</sup>ProMeFa, San Raffaele Scientific Institute, Milan, Italy, <sup>2</sup>DITID, San Raffaele Scientific Institute, Milan, Italy, <sup>3</sup>Université de Paris, Institut Cochin, INSERM, CNRS, Paris France, <sup>4</sup>Reproductive Biology, Cochin Hospital AP-HP, Paris France

## Social science, Epidemiology and Prevention

### GENDER ISSUES

### P 79 Sex and the women: test in a community-based site in Covid-19 time

A. Bianchi<sup>1</sup>, A. Antonino<sup>1</sup>, G. Fracca<sup>1</sup>, M. Lanza<sup>1</sup>, F. Rossi<sup>1</sup>, R. Repossi<sup>1</sup>, P. Testoni<sup>1</sup>, L. Chiametti<sup>1</sup>, D. Zagato<sup>1</sup>, M. Cernuschi<sup>1,2</sup>

<sup>1</sup>ASA, Associazione Solidarietà AIDS Onlus, Milan, Italy, <sup>2</sup>San Raffaele Hospital, Milan, Italy

### P 80 Unexpected women

A. Infante, L. Caponera, A. Rossi

Polidinicò Tor Vergata, Roma

## HIV EPIDEMIOLOGY AND RETENTION IN CARE

### P 81 Immune recovery in new HIV diagnoses in Over 50s

N. Leoni, G. Angioni

Infectious Disease Department, Cagliari

### P 82 Is EXTERNA service still meaningful in the time of COVID-19? Reflection

A. Antonino<sup>1</sup>, A. Bianchi<sup>1</sup>, F. Rossi<sup>1</sup>, M. Lanza<sup>1</sup>, M. Cernuschi<sup>1</sup>, A. Castagna<sup>2</sup>, N. Gianotti<sup>2</sup>

<sup>1</sup>ASA, Associazione Solidarietà AIDS Onlus, Milan, <sup>2</sup>San Raffaele Hospital, Milan

## HIV PREVENTION (PREP AND PEP)

### P 83 Change and decrease of Pre and Post Exposure assistance activities (PrEP and PEP) caused by the COVID-19 pandemic

A. Franco<sup>1</sup>, A. Bianchi<sup>2</sup>, R.M. Franco<sup>1</sup>, V. Iodice<sup>2</sup>, L. Izzo<sup>2</sup>, I. Manzillo<sup>2</sup>, A. Marocco<sup>2</sup>, M. Sardo<sup>2</sup>, E. Manzillo<sup>2</sup>

<sup>1</sup>UOSD di "Sorveglianza e Profilassi post-esposizione" AORN "Ospedali dei Colli", Napoli, <sup>2</sup>UOC di "Immunodeficienze e Malattie dell'Emigrazione" - AORN "Ospedali dei Colli" - Napoli



68

Poster Exhibition

13<sup>o</sup> CONGRESSO NAZIONALE Italian Conference on AIDS and Antiviral Research





## IMPACT OF COVID-19 ON HIV CARE

### P 84 The experience of the ANLAIDS forum during the SARS-CoV-2 pandemic

A. Venturelli, C. Balotta, R. Galipò, G.V. Calvino, B. Marchini  
Anlaids Onlus, Rome, Italy

### P 85 Increased risk of HIV viral blips during COVID-19 pandemic: a single center retrospective study

O. Bargiacchi, A. Barco, A. Rossati, F. Rinaldi, M. Sciarra, C. Nebbiolo, D. Brustia  
Infectious Diseases Unit, Maggiore della Carità Hospital, Novara, Italy

### P 86 The challenge of late presenters patients with AIDS-defining diseases during the COVID-19 pandemic

P. Brugnaro, E. Morelli, F. Cattelan, A. Petrucci, S. Caputo, F. Colombo, N. Geremia, S. Panese  
Infectious Diseases, Ospedale Civile "SS Giovanni e Paolo", Venezia

### P 87 Decrease in new diagnosis of HIV/AIDS in the two years period 2019-2020: impact of COVID-19 pandemic

M. Degli Antoni, I. Izzo, C. Carriero, S. Storti, G. Tiecco, G. Gardini, F. Castelli, E. Focà, E. Quiros-Roldan  
Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali di Brescia, Italy

### P 88 Impact of Covid19 on people living with HIV: an analysis of Gaetano Martino hospital in Messina

C. Micali<sup>1</sup>, Y. Russo<sup>1</sup>, L. Marletta<sup>1</sup>, V. Calabrese<sup>2</sup>, E. Venanzi Rullo<sup>1</sup>, G.F. Pellicano<sup>1</sup>, G. Nunnari<sup>1</sup>

<sup>1</sup>Dipartimento di medicina clinica e sperimentale, U.O.C. Malattie Infettive, Università di Messina, <sup>2</sup>Dipartimento di medicina clinica e sperimentale, U.O. Nefrologia, Università di Messina

## SARS-COV-2 EPIDEMIOLOGY

### P 89 Prevalence of COVID-19 and/or SARS-CoV-2 infection in individuals with opioid use disorder: Fondazione Villa Maraini's experience

G.F.M. Drenzo<sup>1</sup>, F.M. Forestiero<sup>2</sup>, F. Mondera<sup>2</sup>, F. Pirelli<sup>1,3</sup>, F. Turatto<sup>2</sup>, D. Masci<sup>1</sup>, P. Sammarco<sup>1</sup>, T. Di Giovanni<sup>1</sup>, E. Rossi<sup>1</sup>, M. Barra<sup>1</sup>, P. Villari<sup>2</sup>, A. Badiani<sup>1,3</sup>

<sup>1</sup>Fondazione Villa Maraini, Rome, Italy, <sup>2</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy, <sup>3</sup>Department of Physiology and Pharmacology, Sapienza University of Rome, Italy

### P 90 Epidemiology and clinical factors associated with death in COVID-19 patients managed outside the intensive care units

L. Alagna<sup>1</sup>, A. Muscatello<sup>1</sup>, R. Gualtierotti<sup>2</sup>, F. Blasi<sup>2,3</sup>, C. Canetta<sup>3</sup>, G. Costantino<sup>5</sup>, A.L. Fracanzani<sup>3,6</sup>, A. Gori<sup>1,3</sup>, C. Hu<sup>7</sup>, T. Lucchi<sup>8</sup>, N. Montano<sup>3,9</sup>, A. Nobili<sup>10</sup>, F. Peyvandi<sup>3,11</sup>, L. Valenti<sup>12</sup>, G. Harari<sup>13</sup>, E. Crisafulli<sup>14</sup>, F. Cipollone<sup>15</sup>, S. Bosari<sup>3,16</sup>, A. Bandera<sup>1,3</sup> for the COVID-19 Network

<sup>1</sup>Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, <sup>2</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Respiratory Unit and Cystic Fibrosis Adult Centre, Internal Medicine Department, Milan, Italy, <sup>3</sup>University of Milan, Department of Pathophysiology and Transplantation, Milan, Italy, <sup>4</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Acute Medical Unit, Milan, Italy, <sup>5</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Anesthesia, Critical Care and Emergency, Milan, Italy, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, <sup>6</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Internal Medicine and Metabolic Diseases Unit, Milan, Italy, <sup>7</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Internal Medicine, Italy, <sup>8</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Geriatric Unit, Italy, <sup>9</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Internal Medicine, Immunology and Allergology Unit, Milan, Italy, <sup>10</sup>Institute for Pharmacological Research Mario Negri IRCCS, Milan, Italy, <sup>11</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Internal Medicine and Hemostasis and Thrombosis Unit, Milan, Italy, <sup>12</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Transfusion Medicine and Hematology, Milan, Italy, <sup>13</sup>San Giuseppe Hospital MultiMedica IRCCS, Milan, Italy, <sup>14</sup>Department of Medicine, Internal Medicine Section D, University of Verona, Verona, Italy, <sup>15</sup>Department of Medicine and Science of Aging, Medical Clinic, "G. D'Annunzio", University of Chieti, Chieti, Italy, <sup>16</sup>Division of Pathology, IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

### P 91 Clinical characteristics and predictors of death among hospitalized patients infected with SARS-CoV-2 in Sicily, Italy: a retrospective observational study

F. Cosentino<sup>1</sup>, V. Mascatt<sup>1</sup>, A. Marino<sup>1</sup>, A. Pampaloni<sup>1</sup>, D. Scuderi<sup>1</sup>, M. Ceccarelli<sup>1</sup>, F. Benanti<sup>1</sup>, M. Gussio<sup>1</sup>, L. Larocca<sup>1</sup>, V. Boscia<sup>1</sup>, G. Vinci<sup>1</sup>, A. Zagami<sup>1</sup>, A. Onorante<sup>1</sup>, G. Lupo<sup>1</sup>, R. Bruno<sup>1</sup>, C. Iacobello<sup>3</sup>, S. Bonfante<sup>4</sup>, L. Guarneri<sup>5</sup>, A. Cascio<sup>6</sup>, A. Franco<sup>7</sup>, R. Fontana Del Vecchio<sup>7</sup>, M.A. Di Rosolini<sup>8</sup>, A. Pulvirenti<sup>9</sup>, D. Larnè<sup>2</sup>, G. Nunnari<sup>2</sup>, B.M. Cesia<sup>1</sup>, B. Cacopardo<sup>1</sup>

<sup>1</sup>Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, ARNAS Garibaldi Nesima Hospital, University of Catania, Catania, Italy, <sup>2</sup>Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy, <sup>3</sup>Infectious Disease Unit, Cannizzaro Hospital, Catania, Italy, <sup>4</sup>Infectious Diseases Unit, Gravina Hospital, Caltagirone, Catania, Italy, <sup>5</sup>Infectious Diseases Unit, Enna Hospital, Enna, Italy, <sup>6</sup>Infectious and Tropical Diseases Unit, Department of Health Promotion Sciences Maternal and Infantile Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, Italy, <sup>7</sup>Infectious Diseases Unit, Siracusa Hospital, Siracusa, Italy, <sup>8</sup>Infectious and Tropical Diseases Unit, Modica Hospital, Ragusa, Italy, <sup>9</sup>Bioinformatics Section, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy





re-search, for re-start  
together Riccione 21-23 Ottobre 2021

## SOCIAL AND BEHAVIOURAL SCIENCE, MARGINALIZED GROUPS, COMMUNITY ASPECTS AND COMMUNITY SURVEYS

### P 92 Re-framing communication: visual metaphors in COVID-19 Italian information campaigns

A. Castellano<sup>1</sup>, M. Rossi<sup>2</sup>

<sup>1</sup>Anlaids Liguria-Università degli Studi di Genova, Genova, <sup>2</sup>Università degli Studi di Genova, Genova

### P 93 Health and wellbeing as perceived by older gay males living with HIV in England. A qualitative investigation of the intersection between sexual orientation, HIV status, age and geographical location

S. Licchelli

University of Surrey, School of Psychology, Guildford

### P 94 Low-wage agricultural migrant workers in Apulian Ghettos, Italy: general health conditions assessment and HIV screening

F. Di Gennaro<sup>1,2</sup>, R. Lattanzio<sup>1,2</sup>, C. Falanga<sup>3</sup>, D. Mainieri<sup>3</sup>, S. Negri<sup>3</sup>, R. Papagni<sup>1</sup>, R. Novara<sup>1</sup>, G. Panico<sup>1</sup>, M. Poliseo<sup>1</sup>, D. Bavaro<sup>1</sup>, L. Raho<sup>2</sup>, R. Laforgia<sup>2</sup>, S. Lo Caputo<sup>4</sup>, G. Putoto<sup>2</sup>, A. Saracino<sup>1</sup>

<sup>1</sup>Clinic of Infectious Diseases, University of Bari, University Hospital Policlinico, Bari, Italy, <sup>2</sup>Operational Research Unit, Doctors with Africa CUAMM, Padua, Italy, <sup>3</sup>ANLAIDS Sezione Lombarda, <sup>4</sup>Department of Clinical and Experimental Medicine, Infectious Diseases Unit, A.O.U. "Policlinico Riuniti", Foggia, Italy

### P 95 Third Year of Mono-symptomatic therapeutical group for Chemsex users

G. Fracca, M. Manfredini, M. Lanza, M. Cernuschi, D. Zagato, D. Calzavara

A.S.A. Associazione Solidarietà Aids, Milano

### P 96 A Delayed fatal diagnosis due to stigma in a HIV-positive women

M. Brundu, C. Putaggio, S. Lo Menzo, D. Leoni, S. Marinello, F. Raumer, L. Sasset, A. Ferrari, M. Trevenzoli, A.M. Cattelan

Malattie Infettive, Azienda Ospedale Università di Padova, Padova

### P 97 Are changing models of communication easy in the 4th decade?

F. von Schlösser, A. Bove, D. Osorio

Nadir onlus

## Virology and Pharmacology

### HIV VIROLOGY

### P 98 Analysis of HIV quasispecies and monitoring of viral reactivations in an HIV D+ /R+ kidney-liver transplantation

G. Rozera<sup>1</sup>, U. Visco-Comandini<sup>2</sup>, E. Giombini<sup>1</sup>, F. Santini<sup>1</sup>, F. Forbici<sup>1</sup>, G. Berno<sup>1</sup>, C. Gruber<sup>1</sup>, P. De Paolis<sup>3</sup>, R. Colonnelli<sup>3</sup>, G. D'Offizi<sup>2</sup>, G.M. Ettorre<sup>4</sup>, P. Grossi<sup>5</sup>, M.R. Capobianchi<sup>1</sup>, G. Ippolito<sup>6</sup>, I. Abbate<sup>1</sup>

<sup>1</sup>Virology Unit, National Institute for Infectious Diseases, I.R.C.C.S. L.Spallanzani, Rome, Italy, <sup>2</sup>Hepatology Unit, P.O.I.T. San Camillo-Spallanzani, Rome, Italy, <sup>3</sup>Nephrology Unit, P.O.I.T. San Camillo-Spallanzani, Rome, Italy, <sup>4</sup>Surgical Unit, P.O.I.T. San Camillo-Spallanzani, Rome, Italy, <sup>5</sup>Insubria University, Varese, Italy, <sup>6</sup>Scientific Direction National Institute for Infectious Diseases, I.R.C.C.S. L.Spallanzani, Rome, Italy

### P 99 Setting up of a novel ultrasensitive RT-qPCR assay for evaluating the HIV reverse transcriptase activity

F. Marino-Merlo<sup>1</sup>, V. Stefanizzi<sup>2</sup>, A. Ragno<sup>1</sup>, B. Macchi<sup>2</sup>, A. Mastino<sup>3</sup>

<sup>1</sup>Dept of Chemical, Biological, Pharmaceutical, and Environmental Sciences, University of Messina, Messina, Italy, <sup>2</sup>Dept of Chemical Science and Technology, University of Rome "Tor Vergata", Rome, Italy, <sup>3</sup>The Institute of Translational Pharmacology, CNR, Rome, Italy

### P 100 Performance of the AD-SEQ HIV-1 Solution a next-generation sequencing commercial kit for HIV drug resistance analysis

T. Alice, M.G. Milia, E. Burdino, G. Gregori, F. Cerutti, A. Bottoni, M. Cazzadore, P. Tremante, B. Simoncelli, D. Fiorito, E. Scuccimarra, V. Ghisetti

Laboratory of Microbiology and Virology, ASL Città di Torino, Torino, Italy



70

Poster Exhibition

13<sup>o</sup> CONGRESSO NAZIONALE Italian Conference on AIDS and Antiviral Research



## PHARMACOLOGY, PHARMACOGENOMICS AND DRUG INTERACTIONS

### P 101 Dolutegravir plasma and intracellular pharmacokinetics according to drug companion in the clinical setting

M. Ferrara<sup>1</sup>, E. Salvador<sup>1</sup>, A. Di Stefano<sup>1</sup>, C. Alcantarini<sup>1</sup>, A. Trentalange<sup>1</sup>, S. Biffi<sup>1</sup>, M. Tettoni<sup>1</sup>, E. De Vivo<sup>2</sup>, J. Mula<sup>2</sup>, A. Ianniello<sup>2</sup>, A. De Nicolò<sup>2</sup>, A. D'Avolio<sup>2</sup>, G. Di Perri<sup>1</sup>, A. Calcagno<sup>1</sup>, S. Bonora<sup>1</sup>

<sup>1</sup>Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, <sup>2</sup>Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Torino, Torino

### P 102 Cyclosporine a inhibits viral infection and release as well as cytokine production in lung cells by three different SARS-CoV-2 variants

C. Fenizia<sup>1,2</sup>, S. Galbiati<sup>3</sup>, C. Vanetti<sup>1,2</sup>, R. Vago<sup>4,5</sup>, M. Clerici<sup>1,6</sup>, C. Tacchetti<sup>5,7</sup>, T. Daniele<sup>7</sup>

<sup>1</sup>Department of Pathophysiology and Transplantation, Milano University Medical School, <sup>2</sup>Department of Biomedical and Clinical Sciences "L. Sacco", Milano University Medical School, <sup>3</sup>Complication of Diabetes Unit, Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, <sup>4</sup>Urological Research Institute, IRCCS San Raffaele Scientific Institute, <sup>5</sup>Vita-Salute San Raffaele University, <sup>6</sup>IRCCS Don Carlo Gnocchi Foundation, <sup>7</sup>Cancer Imaging Unit, Experimental Imaging Centre, IRCCS San Raffaele Scientific Institute

## SARS-COV-2 VIROLOGY

### P 103 Antiviral activity of amphibian skin peptides against HIV and SARS-CoV-2

A. Chianese<sup>1</sup>, F. Dell'Annunziata<sup>1</sup>, A. Ambrosino<sup>1</sup>, M.V. Morone<sup>1</sup>, D. Stelitano<sup>1</sup>, G. Franci<sup>2</sup>, M. Galdiero<sup>1</sup>

<sup>1</sup>Department of Experimental Medicine, section of Virology and Microbiology, University of Campania "Luigi Vanvitelli", Naples, Italy, <sup>2</sup>Department of Medicine, Surgery and Dentistry Scuola Medica Salernitana, University of Salerno, Salerno, Italy

## VACCINES

### P 104 Development of SARS-CoV-2 IgG antibodies in an elderly population after m-RNA vaccination: a real-life experience

B. Zauli, A. De Vito, A. Colpani, A. Puggioni, E. Princic, C. Fanelli, L. Firino, S. Rubino, S. Babudieri, S. Uzzau, G. Madeddu

Unit of Infectious Diseases, Department of Medical, Surgical, and Experimental Sciences, University of Sassari, Sassari, Italy, Microbiology Division, Department of Biomedical Sciences, University of Sassari, Sassari, Italy

### P 105 Vaccination against sexually transmitted infections in a STI clinic

R. Rosso<sup>1,2</sup>, C. Baiguera<sup>1</sup>, M.C. Moiola<sup>1</sup>, D. Calzavara<sup>2</sup>, C. Rogati<sup>1</sup>, P. Vinti<sup>2</sup>, L. Brunelli<sup>1</sup>, L. Rezzonico<sup>1</sup>, M. Cernuschi<sup>2,3</sup>, M. Puoti<sup>1</sup>

<sup>1</sup>ASST Grande Ospedale Metropolitano Niguarda, Milan, <sup>2</sup>Milano Checkpoint, Milan, <sup>3</sup>IRCCS San Raffaele Scientific Institute, Milan

### P 106 Sero-survey on long-term care facility residents reveals risk factors of sub-optimal antibody response to BNT162B2: implications for breakthrough prevention

M. Franzetti<sup>1</sup>, B. Caimi<sup>2</sup>, R. Velleca<sup>3</sup>, A. Lai<sup>3</sup>, A. Gatti<sup>2</sup>, P.L. Rossi<sup>2</sup>, M. D'Orso<sup>4</sup>, F. Pregliasco<sup>5</sup>, C. Balotta<sup>2</sup>, G. Calicchio<sup>2</sup>

<sup>1</sup>Infectious Diseases Unit, Legnano General Hospital, ASST Ovest Milanese, Legnano, Milan, Italy, <sup>2</sup>Azienda Servizi alla Persona, Istituti Milanese Mariniotti e Stelline e Pio Albergo Trivulzio, Milan, Italy, <sup>3</sup>Department of Biomedical and Clinical Sciences L. Sacco, University of Milan, Milan, Italy, <sup>4</sup>Department of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy, <sup>5</sup>Department of Biomedical Sciences, University of Milan and IRCCS Istituto Ortopedico Galeazzi, Milan, Italy

### P 107 A case of meningitis and cerebral venous thrombosis a week after BNT162b2

R. Valvason<sup>1</sup>, C. Putaggio<sup>2</sup>, S. Marinello<sup>2</sup>, A. Ferrari<sup>2</sup>, S. Lo Menzo<sup>2</sup>, G. Castelli<sup>1</sup>, M.E. Schirinz<sup>3</sup>, A.M. Cattelan<sup>2</sup>

<sup>1</sup>Respiratory Disease Unit University hospital Padova, <sup>2</sup>Infectious Diseases Unit University Hospital Padova, <sup>3</sup>Nephrology Unit University Hospital Padova

### P 108 Adherence to vaccination in people with HIV infection in s SARS-CoV2 pandemic era

G.C. Orofino<sup>1</sup>, M. Guastavigna<sup>1</sup>, M. Farenga<sup>1</sup>, G.D. Greco<sup>2</sup>, G. Calleri<sup>1</sup>

<sup>1</sup>Divisione A di Malattie Infettive e Tropicali, Ospedale Amedeo di Savoia, Torino, <sup>2</sup>SSD SISP Emergenze Infettive e Prevenzione, Asl Città di Torino, Torino

### P 109 Antibody development against SARS-CoV-2 following Comirnaty vaccine: comparison between healthy and frail patients

R. Campagna<sup>1</sup>, L. Mazzuti<sup>1</sup>, G. Guerrizio<sup>1</sup>, C. Nonne<sup>1</sup>, V. Pistolesi<sup>2</sup>, S. Chiaretti<sup>3</sup>, C. Fimiani<sup>4</sup>, I. Mezzaroma<sup>3</sup>, S. Morabito<sup>2</sup>, G. Antonelli<sup>1</sup>, O. Turriziani<sup>1</sup>

<sup>1</sup>Department of Molecular Medicine Sapienza University, Rome, <sup>2</sup>Department of Internal Medicine and Medical Specialties Sapienza University, Rome, <sup>3</sup>Department of Translational and Precision Medicine Sapienza University, Rome, <sup>4</sup>Department of Infectious Diseases, Umberto I University Hospital, Rome



*re-search for re-start together*

Riccione 21-23 Ottobre 2021



**13° CONGRESSO NAZIONALE Italian Conference on AIDS and Antiviral Research**

Presidenza del Congresso:  
**G. V. Calvino, M. R. Capobianchi, A. M. Cattelan, C. Mussini**

GENERAL  
INFORMATION



# General Information



*re-search, for re-start*  
*together* Riccione 21-23 Ottobre 2021

## Conference Venue

### Palazzo dei Congressi

Via Virgilio, 17

47838 Riccione RN

[www.palariccione.com](http://www.palariccione.com)



## How to reach the Conference Venue



### Railway Station

Riccione: 600 m from station

Rimini: 11 Km from station



### Bologna Airport

131 Km from the airport - 1 hour and 15 minutes by car



### Car

Large pay parking facility available at the Conference Venue



74

General Information



## Conference registration

It is possible to attend the conference in both **residential** and **webinar** mode.

For both of them, participants must submit the registration form through the website [www.icar2021.it](http://www.icar2021.it).

After completing the form, you will receive an email with a link to confirm the activation of your account; you will receive a message with the instructions to access the congress live streaming or you will be contacted by the Organizing Secretariat for your participation.

## Official languages

Italian and English. No simultaneous translation provided.

## Pre-conference advanced Courses and Congress dates

**Pre-conference advanced courses: Thursday, October 21 from 13:30 to 16:00**

**Conference: from Thursday, October 21 h. 16:30 to Saturday, October 23 h 16:40**

## Conference Secretariat opening times

- **Thursday, October 21** from 10:30 to 20:00
- **Friday, October 22** from 08:00 to 18:30
- **Saturday, October 23** from 08:00 to 17:00

## Exhibition Area opening times

- **Thursday, October 21** from 13:30 to 20:00
- **Friday, October 22** from 08:30 to 18:30
- **Saturday, October 23** from 08:30 to 16:40







## General Information



*re-search, for re-start  
together* Riccione 21-23 Ottobre 2021

### Instructions for Speakers

It is not possible to bring presentations directly to the lecture hall. All presentations have to be handed over at the Slide Center Room at least **2 hours before the session**. At the Slide Center Room, Speakers will have the possibility of:

- Reviewing power point presentations
- Last minute changes of power point presentations
- Being supported by technical staff
- Uploading power point presentation in the dedicated session conference room

**All Speakers are requested to start their presentations with a Disclosure of Potential Conflicts of Interest slide. For more information: <http://www.icmje.org/disclosure-of-interest/>**

### Oral Communication Sessions

Selected abstracts will be presented in Oral Communication Sessions. Authors of the selected abstract are requested to attend their sessions and **provide max 8/10 (power point) slides** resuming their abstract. Time allowed for **presentation: 10 minutes followed by 2 minutes for discussion.**

**All Speakers are requested to start their presentations with a Disclosure of Potential Conflicts of Interest slide.**

### Oral Poster

Selected abstracts will be presented in Oral Poster Sessions in the dedicated area at Foyer Auditorium. Authors of the selected abstract are requested to attend their sessions and **provide max 5 (power point) slides resuming their abstract.** Time allowed for **presentation: 5 minutes followed by 2 minutes for discussion.**

**All Speakers are requested to start their presentations with a Disclosure of Potential Conflicts of Interest slide.**

### Poster Exhibition

Due to COVID-19 issues, it is not possible to display posters. All the posters can be viewed through the touch monitors located in the dedicated area at Foyer Auditorium.



76

General Information



**MI AMO, VI AMO, FACCIAMO IL TEST**

**GRATUITO, ANONIMO, AFFIDABILE E RICHIEDE POCHI MINUTI**  
**TEST RAPIDO HIV e HCV**

**RICCIONE** PIAZZALE CECCARINI, ANGOLO VIALE DANTE  
VICINO AL PALAZZO DEL TURISMO

GIOVEDÌ 21 OTTOBRE h. 15.00-19.00  
VENERDÌ 22 OTTOBRE h. 11.00-13.00 e h. 15.00-19.00  
SABATO 23 OTTOBRE h. 11.00-13.00 e h. 15.00-19.00

Con il Patrocinio del  
COMUNE DI  
RICCIONE

Con la sponsorizzazione non condizionante di  
**GILEAD**

13° CONGRESSO NAZIONALE  
**Italian Conference on AIDS  
and Antiviral Research**  
11-13 OTTOBRE 2021  
PALAZZO DEI CONGRESSI DI RICCIONE

In collaborazione con  
**meridian** biosciences

## Quick test for HIV and HCV

In Piazzale Ceccarini, at the corner of Viale Dante near Palazzo del Turismo:

- **Thursday, October 21** from 15:00 to 19:00
- **Friday, October 22** from 11:00 to 13:00 and from 15:00 to 19:00
- **Saturday, October 23** from 11:00 to 13:00 and from 15:00 to 19:00

Healthcare personnel will perform free rapid testing for HIV and HCV at the request of citizens in a confidential and anonymous way. The test is non-invasive, requires few minutes and is highly reliable.

Grazie al supporto di: Azienda Ospedaliero-Universitaria di Ferrara, Bergamo Fast-Track City e Fondazione Villa Maraini.

Con la sponsorizzazione non condizionante di Gilead Sciences  
In collaborazione con Meridian Biosciences

SETTIMO CONCURSO ARTISTICO

# RACCONTART

**#HIV** HIV, Infezioni Sessualmente Trasmissibili e Covid-19

Riccione 21-23 Ottobre 2021  
Palazzo dei Congressi

13° CONGRESSO NAZIONALE **Italian Conference on AIDS and Antiviral Research**  
www.icar2021.it

## RaccontART HIV

- **Thursday, October 21** Conference venue

**Auditorium Concordia, from 13:30 to 16:00**

Presentation of the finalist works

**Auditorium Concordia, from 17:40 to 18:00**

Winners' Awards

The art competition launched by ICAR to students invited to present their views on HIV/AIDS, COVID-19 and STIs through various forms of expression. During the Conference Opening Session the winners will be awarded by the Jury composed of leading representatives of the national cultural world, ICAR Faculty Members and Community Representatives.





## Special Awards



*re-search, for re-start*  
*together* Riccione 21-23 Ottobre 2021

The work of young researchers and community representatives continues to be widely recognized by ICAR, not only through Scholarships, but also with special prizes. The 13rd edition of ICAR awards as follows:



### ICAR-CROI Awards 2021

The absolute winners among the young Italian investigators who presented their works at CROI 2021

- **N. 1 Award** of € 1.000,00 for the best work in **Clinical**
- **N. 1 Award** of € 1.000,00 for the best work in **Basic Sciences**

**Winners will be announced during the ICAR-CROI Awards 2021 session in Auditorium Concordia on Saturday October 23 from 16:20 to 16:40.**



### ICAR 2021 Scientific Committee Awards

The 13rd ICAR Chairs and Scientific Secretariat will recognize the "Scientific Committee Awards": the ICAR awards to the best abstracts

- **N. 3 Awards** of € 1.000,00 each: **Clinical (1 Award), Basic Science (1 Award) and Social Science (1 Award).**

**Winners will be announced during the ICAR 2021 Scientific Committee Awards in Auditorium Concordia on Saturday October 23 from 16:20 to 16:40.**



### SIMIT Special Awards

The 13rd ICAR Chairs and Scientific Secretariat wish to thank SIMIT for the Special Awards addressed to Young Investigators:

- **N. 5 Awards** of € 2.000,00 each for the best abstracts accepted as Oral Communications in:
  - 1. Clinical HIV**
  - 2. Clinical Hepatitis Virus**
  - 3. Clinical SARS-CoV-2**
  - 4. Virology and Immunopathogenesis**
  - 5. Epidemiology and Social Science**

Presented by young Investigators (under 45 years), regularly registered to SIMIT for years 2020 and 2021.

**Abstracts will be selected at the Congress Venue by a dedicated SIMIT Commission and winners will be announced during the ICAR 2021 Special Awards Session in Auditorium Concordia on Saturday October 23 from 16:20 to 16:40.**





## ICAR 2021 App

Designed to facilitate participation in ICAR 2021 and to respond to request for effective and high performance digital tools and supports. Two simple steps to access:

- **Download the ICAR App for free** from the main markets (Apple Store and Google Play) "Minimum system requirements required for the App: Android 7.0 and iOS 10"
- **Login App:** enter your personal login credentials (username and password) sent to you by the Organizing Secretariat Effetti.



## Menu Functions

**HOME:** Simple and immediate with a usability designed specifically for the Conference. Each menu item corresponds to a precise and useful feature

**PROGRAMMA SCIENTIFICO:** Complete Scientific Programme day by day with detailed information about each session (title, speaker, time, room). Users can also select favorite Lectures, clicking on the calendar icon: those will be saved in My Agenda

**MY AGENDA:** User can customize their own Agenda using this function. ICAR 2021 App will create the list of favorite selected sessions in a chronological order

**PROGRAMME AT A GLANCE:** To discover the Programme, rooms and timetable quickly

**RACCONTART:** To access the Art Contest, consult the works in competition, learn about participating schools, and much more

**ABSTRACT:** All abstracts accepted, broken down by type of presentation (Oral, Oral poster, Poster) and the Abstract Reviewers. From October 21, the Abstract Repository at your fingertips with keyword search, Authors names, Abstract IDs

**ICAR-CROI AWARDS:** The winners of the ICAR-CROI Awards 2021 with their Mentors

**SPECIAL AWARDS:** The official rewards that ICAR assign to young investigators and Community ambassadors

**WORDCLOUD:** Allows to select the key-words that represent the Congress main concept, creating a "cloud" that will highlight the most selected words

**TEST RAPIDO HIV-HCV:** Where, when and at what times: all the appointments of the Quick test for HIV and HCV

**ICAR SOCIAL:** Direct links to ICAR 2021 Social. Stay connect #ICAR2021

**INFORMAZIONI GENERALI:** A menu item for the most useful and important links: Congress Venue, Transportation and much more...

Con la sponsorizzazione non condizionante di Janssen Cilag





# ICAR for Participants



re-search, for re-start  
together Riccione 21-23 Ottobre 2021



## Community Village

A specific area of the Congress Venue dedicated to the Community Village: a meeting point for all the participants to visit the booths of patient associations and meet the Community activists.



## Nice to ICAR you

The Secretary Meeting point where all registered participants can ask for ICAR T-shirt, Water Thermos and Abstract USB pendrive.



## Poster 4 you

A free service for selected posters' Authors to create their own posters and record their own comments. **ICAR Poster-4-you USB pendrive** can be requested showing the coupon at the Gilead Sciences booth.

*Con la sponsorizzazione non condizionante di Gilead Sciences*



## ICAR Journal

Three special editions of ICAR Daily Journal, the real-time newspaper of the Congress (from Thursday to Saturday), in the form of articles, interviews and highlights from the different sessions and from the voice of Opinion Leaders. It's published daily in digital version on the Congress portal [www.icar2021.it](http://www.icar2021.it) and notified to all participants.

*Con la sponsorizzazione non condizionante di Gilead Sciences*



## Abstract USB Pendrive

All registered participants can ask for the **ICAR Abstract USB pendrive** showing the coupon at Nice to ICAR you booth: it contains all accepted abstract.

*Con la sponsorizzazione non condizionante di ViiV Healthcare*



## ICAR On-Demand and Web Repository

After the congress, the ICAR official website ([www.icar2021.it](http://www.icar2021.it)) will publish the ICAR 2021 web repository with abstracts, presentations, oral communications, accepted posters, podcasts and photo gallery.

*Con la sponsorizzazione non condizionante di ViiV Healthcare*



## Social Media

[www.instagram.com/icarcongress](https://www.instagram.com/icarcongress)  
[www.twitter.com/ICARcongress](https://www.twitter.com/ICARcongress)  
[www.facebook.com/ICARcongress](https://www.facebook.com/ICARcongress)





## Conference

The 13° ICAR Conference has been accredited to the Italian Ministry of Health for 14 CME Credits.

Every single day has been accredited for the following professionals:

ID ECM Number	Credits	Professionals
<b>Thursday, October 21</b> 150-329181	<b>2,1</b>	<b>Medical Doctor</b> (all disciplines)
<b>Friday, October 22</b> 150-329186	<b>6,3</b>	<b>Healthcare Assistant, Biologist, Hospital Pharmacist, Nurse, Medical laboratory technician, Phychologist, Psychotherapist, Professional Educator</b>
<b>Saturday, October 23</b> 150-329189	<b>5,6</b>	

## Pre-conference advanced Courses

The 13° ICAR advanced Courses have been accredited to the Italian Ministry of Health for each single course:

ID ECM Number	Credits	Professionals
<b>Focus on molecular surveillance of epidemic/pandemic viral infections</b> 150-329154	<b>3</b>	<b>Medical Doctor</b> Allergology and Clinical Immunology; Hygiene, Epidemiology and Public Health; Gastroenterology; Infectious and Tropical Diseases; Internal Medicine; Microbiology and Virology; Clinical Pathology; <b>Biologist; Medical Laboratory Technician</b>
<b>New opportunities in HIV and prevention: towards achieving controlled risk</b> 150-329175	<b>3</b>	<b>Medical Doctor</b> Allergology and Clinical Immunology; Hygiene, Epidemiology and Public Health; Gastroenterology; Infectious and Tropical Diseases; Internal Medicine; Microbiology and Virology; Clinical Pathology; Dermatology and Venereology; Neurology; Pharmacology and Clinical Toxicology; <b>Healthcare Assistant, Biologist, Hospital Pharmacist, Professional educator, Psychologist</b>
<b>Long-acting therapies in HIV and bacterial infections: the nurse role</b> 150-329177	<b>3</b>	<b>Medical Doctor</b> Allergology and Clinical Immunology; Hygiene, Epidemiology and Public Health; Continuity Care; Gastroenterology; Infectious and Tropical Diseases; Internal Medicine; Geriatrics; Neurology; Oncology; Psichiatria; Psychoterapy, Hematology; Epidemiology; <b>Healthcare Assistant, Nurse, Professional Educator, Psychologist</b>







CME  
Accreditation

*re-search, for re-start*  
*together* Riccione 21-23 Ottobre 2021

## Obtaining credits

### Participants

To obtain credits, registered participants are required to:

- Wear the identification badge during working sessions
- Provide their signature and write entrance/exit times before and after attending working sessions
- Complete assessment and satisfaction questionnaires for each day on the official website [www.icar2021.it](http://www.icar2021.it) (from Monday 25 to Thursday 28 October)

### Speakers

Speakers will be given 1 credit for each half-hour of consecutive teaching.

Speakers, moderators and discussants can decide to obtain credits as participants (see participants).

### Attendance Tracking

Attendance will be tracked through participants' signature at the start/end of each day, and through assessment and satisfaction questionnaires.

### CME certification

Credits will be given only if a participant attends 90% of the working sessions and provides correct answers to at least 75% of the questions included in the final assessment questionnaire. The Provider will send CME certificates to the participants after the Conference.

### SVC Assobiomedica

The pre-conference courses and the Congress were assessed as compliant with the Ethics' Code by the Assobiomedica Conference Evaluation System (SVC).



82

General Information



## Pre-conference advanced Courses

**Free of charge** (registrations available on a “first come, first served” basis).

## Conference

### Conference registration fees (22% VAT not included)

Physicians	€ 700,00
Physicians < 35 years of age, Biologist, Biotechnologist, Pharmacist, Nurse, Psychologist	€ 310,00
Students/PhD and Post-graduate medical trainees	Free
Members of HIV/AIDS Community	Free

**The registration fee includes:** congress kit (delegate bag, badge, certificate of attendance), Opening Session and Welcome Cocktail on October 21, coffee breaks and lunches on October 22 and 23, CME registration, Conference USB/abstract and poster.

### Daily Conference registration fees (22% VAT not included)

Physicians	€ 300,00
Physicians < 35 years of age, Biologist, Biotechnologist, Pharmacist, Nurse, Psychologist	€150,00
Students/PhD and Post-graduate medical trainees	Free
Members of HIV/AIDS Community	Free

**The registration fee includes:** congress kit (delegate bag, badge, certificate of attendance to the sessions of the day), coffee break and lunch for the day, CME registration, Conference USB/abstract and poster.



*re-search for re-start together*

Riccione 21-23 Ottobre 2021



**13° CONGRESSO NAZIONALE Italian Conference on AIDS and Antiviral Research**

Presidenza del Congresso:  
**G. V. Calvino, M. R. Capobianchi, A. M. Cattelan, C. Mussini**


CONGRESS  
MAP



# Congress Map FLOOR 1

*re-search, for re-start  
together* Riccione 21-23 Ottobre 2021





## Floor 1

- Entrata
- Segreteria Organizzativa
- Nice to ICAR you
- Torri Led
- Area Relax
- Area Recharge
- Villaggio Community
- Ufficio stampa

### TORRE LED

- A GILEAD
- B ANGELINI
- C VIATRIS

### AREA RELAX E RECHARGE

- 16 GILEAD


### VILLAGGIO COMMUNITY

- |   |    |
|---|----|
| 1 | 8  |
| 2 | 9  |
| 3 | 10 |
| 4 | 11 |
| 5 | 12 |
| 6 | 13 |
| 7 |    |



# Congress Map FLOOR 3

*re-search, for re-start*  
together Riccione 21-23 Ottobre 2021



STAND	
1	<b>Janssen</b> <small>CONSIGLIO D'AMMINISTRAZIONE di Johnson &amp; Johnson</small>
2	<b>GILEAD</b>
3	<b>ViiV</b> Healthcare
4	<b>ReAdfiles</b> <small>RESEARCH AND ANALYTICS</small>
5	<b>sobi</b> rare strength
6	<b>gsk</b>
7	<b>THERA</b> technologies


TORRE LED	
D	<b>ViiV</b> Healthcare
E	<b>ANGELINI</b> PHARMA
F	<b>Janssen</b> <small>CONSIGLIO D'AMMINISTRAZIONE di Johnson &amp; Johnson</small>

POP UP	
8	<b>Abbott</b>
9	<b>abbvie</b>
10	<b>Agilent</b>

ICAR ACTIVE ZONE	
12	<b>ViiV</b> Healthcare







## Floor 3

### Area espositiva

### ICAR active zone - Foyer Auditorium:

- Area Oral Poster
- Area Poster Exhibition

### Auditorium Concordia

### Torri Led


### Virtual Set



# Congress Map FLOOR 4



*re-search, for re-start  
together* Riccione 21-23 Ottobre 2021



AREA RELAX E RECHARGE

15  MSD

TORRE LED

  MSD

HOSPITALITY SUITE

13 

14  GILEAD

## Floor 4

Polissena A Hall

Polissena B Hall

Centro slide "Costanza"

Hospitality Suite

Area Relax


Area Recharge

Torri Led




90

Congress Map



Congress Map  
FLOOR 5

Room 3





## THANKS TO THE SPONSORS

The Chairs, the Scientific Secretariat and CME Provider wish to thank the following Companies for the support given to the Congress, as unrestricted educational grants:

### *Platinum*



### *Gold*



### *Silver*



### *Other*

